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Abstract 
Osteoarthritis (OA) is a debilitating disease suffered by millions of people around the 
world. It affects the whole joint but is defined in part by a degradation of cartilage 
which becomes more pronounced as the disease progresses. The initiation and 
progression of OA is still not fully characterised. 
MicroRNAs are small, non-coding RNA molecules which are known to regulate gene 
expression, however, at the moment it is unclear exactly how many may be expressed in 
cartilage or how their expression may alter during osteoarthritis. 
Using human OA cartilage and cells derived from it, we have optimised small RNA 
purification and have shown that there is a clear difference between microRNA 
expression in cartilage compared with cell isolates, with miR-140 most highly 
expressed in cells immediately after digestion.  This may suggest a stress-type response.  
RNA purified from chondrocytes immediately after digestion from cartilage was 
utilised for Illumina GIIX deep sequencing in an attempt to identify novel microRNAs 
in addition to expressed known microRNAs. 990 previously documented and 1621 
potential novel microRNAs were discovered and 16 novel candidates were chosen for 
further validation. 
Validation was carried out using northern blotting and qRT-PCR on a number of 
samples and tissue types. In addition, the selected candidates were also examined in 
chondrogenesis models, and one candidate was probed in mouse embryo in situ 
hybridisation in an attempt to localise the candidate to cartilage tissue. 
Three of the candidates with the most promising validation results were analysed for 
function using a whole genome microarray combined with computational target search 
analysis. A number of likely targets obtained from the array were further validated by 
subcloning and luciferase assays, resulting in the discovery of ITGA5 as a target of 
candidate novel 11. 
The outcomes from this research provide us with an increased understanding of the 
miRNome of human OA cartilage and could impact upon future drug development and 
the use of microRNAs as biomarkers. 
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1.1 - Articular Cartilage And Its Properties 
Osteoarthritis (OA) is a painful, degenerative disease which can affect all synovial 
joints within the body.  All joint tissues are involved and affected during OA, however 
the main structural change which generally characterises OA is the breakdown and 
degradation of articular cartilage at moving joints such as the knee and hip, common 
locations of osteoarthritis (Goldring and Goldring, 2006). 
As we become an increasingly ageing population with people living much longer, the 
incidence of OA is rising. Arthritis Care reported in 2012 that around 8.5 million people 
in the UK currently suffer from osteoarthritis, with 70% of those in constant pain and 
they predicted that by 2030, the number of people diagnosed with OA will have risen to 
over 17 million (Arthritis-Care, 2012). The peak health of joints is thought to be 
reached by the age of 30, specifically the tensile strength apparent in the superficial 
zone, whilst the tensile strength of cartilage in the deep zone decreases progressively 
with age (Kempson, 1982), this may explain the common occurrence of OA within the 
elderly, however this is still not well understood. It is also thought that the risks 
associated with age and osteoarthritis are due to changes in TGFβ signalling resulting in 
reduced proteoglycan synthesis (van der Kraan et al., 2010). 
 
There are three main types of cartilage (one of many connective tissues) within the 
human body. The first is elastic cartilage, found in the outer ear, the eustachian tube of 
the ear and the epiglottis at the back of the throat. This type of cartilage is composed of 
elastin proteins and collagen fibres, and is therefore more flexible than the other forms 
of cartilage. Fibrocartilage is present in the meniscus of the knee and between the 
vertebral discs. Fibrocartilage functions to withstand shear stress and appears to be 
similar in structure to both hyaline cartilage and dense fibrous tissue (Hu et al., 2001). It 
contains aggrecan in addition to type I collagen and type II collagen, however, the 
proportions of type II collagen and aggrecan present are substantially lower than in 
hyaline cartilage. The cells within fibrocartilage resemble chondrocytes, however, they 
are more spread out and fewer in number than those found in hyaline cartilage 
(Freemont and Hoyland, 2006). Finally there is hyaline cartilage, also known as 
articular cartilage. This type of cartilage appears between ribs and sternum, in the 
trachea and at the ends of long bones at moving joints such as the knee and the hip 
(Bhosale and Richardson, 2008; Carter, 2007). Hyaline, or articular, cartilage is the 
most common form of cartilage found in the body (Umlauf et al., 2010). 
17 
 
Articular cartilage develops through a process called chondrogenesis, where 
mesenchymal stem cells (MSC) progress through differentiation into the chondrocyte 
cells found in cartilage. This process is a vital part of endochondral ossification and the 
development of the long bones of the body. 
Chondrogenesis begins with mesenchymal stem cells (originating from neural crest 
cells) migrating, proliferating and condensing as chondroprogenitor cells to form the 
cartilage anlagen scaffold. This involves cell-cell and cell-matrix interactions, and the 
production of type I and II collagen as well as hyaluronan (Olsen et al., 2000; Sandell et 
al., 1994). These chondroprogenitor cells develop, first into chondroblasts (small, flat, 
immature cartilage cells) and then finally to chondrocytes (mature cells) which are 
larger and more round in morphology than their immature counterparts. Chondrocytes 
progress through multiple differentiation events, sequentially: proliferation, hypertrophy 
and terminal differentiation. This is followed by mineralisation of the matrix, 
programmed cell death, and finally the invasion of osteoblasts and the formation of the 
long bone structures (Carter, 2007; Goldring et al., 2006; Umlauf et al., 2010).  
During chondrogenesis, chondrocytes produce increasing amounts of extracellular 
matrix (ECM) molecules such as type II collagen and aggrecan (Carter, 2007). The 
chondrogenesis process can be defined specifically by the expression patterns of a 
number of ECM components. Firstly, type I collagen decreases as chondrogenesis 
progresses, whilst the expression of collagens II, IX and XI by chondrocytes begins to 
increase. Levels of other ECM components such as aggrecan, Gla protein (Luo et al., 
1995) and link protein are also increased. Link protein is known to play a role in cross 
linkage and stabilisation between key ECM components of cartilage tissue. 
Furthermore, a fragment of link protein, known as LPP (Link protein N-terminal 
peptide) has been found to up-regulate the expression of the transcription factor SOX9 
as well as cartilage components such as aggrecan and collagen type II in the matrix of 
cultured invertebral discs (Wang et al., 2013). 
A number of signalling molecules and pathways regulate chondrogenesis and 
endochondral ossification (Fig 1.1). Bone morphogenetic proteins (BMPs) and 
fibroblast growth factors (FGFs) have been linked to the control of chondrocyte 
proliferation during chondrogenesis (Minina et al., 2002). A number of Sox genes are 
also involved in chondrogenesis regulation. Sox9 is responsible for the expression of 
type II collagen, in addition to type XI collagen and cartilage-derived retinoic-acid-
18 
 
sensitive protein (CD-RAP) by chondroprogenitor cells (Goldring et al., 2006). L-Sox5, 
Sox5 and Sox6 are further expressed alongside Sox9 during chondrocyte differentiation 
and regulate the production of aggrecan, type IX collagen, type II collagen and link 
protein (Ikeda et al., 2004; Smits et al., 2001). Pax1 and Pax9 (paired-box gene -1 and -
9) are also involved in the induction of chondrogenesis, in part via their activation of 
Bapx1 [also known as NKX3-2 (NK3 Homeobox 2)] which in turn has been found to 
repress Runx2 (Runt-related transcription factor 2) and therefore enhance differentiation 
of chondrocytes (Lengner et al., 2005; Rodrigo et al., 2003). HDAC4 (Histone 
deacetylase 4) is also involved in the inhibition of Runx2 and subsequent prevention of 
chondrocyte hypertrophy (Vega et al., 2004). 
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Figure 1.1 Transcriptional regulation during chondrogenesis. The regulation of a 
number of important transcription factors during chondrogenesis starting from a 
mesenchymal precursor cell. Green arrows represent positive factors, whilst red lines 
indicate negative factors. Diagram adapted from Hartmann (Hartmann, 2009). 
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During endochondral ossification (Fig. 1.2), cartilage tissue formed through 
chondrogenesis is replaced with bone tissue by osteoblasts. Mature chondrocytes firstly 
undergo hypertrophy in the centre of the prospective bone, and ossification is initiated 
by osteoblasts depositing a periosteal bone collar. Expression of Indian hedgehog (Ihh) 
is vital to the bone formation and is produced by chondrocytes prior to their 
hypertrophy (St-Jacques et al., 1999) along with Runx2 which is an important factor in 
regulating chondrocyte hypertrophy (Enomoto et al., 2000). Komari et al (Komori et al., 
1997) show that the absence of Runx2 in mice results in the absence of chondrocyte 
hypertrophy. 
The tissue is subsequently invaded by blood vessels, osteoclasts, osteoblasts and bone 
marrow precursor cells. Osteoclasts resorb the ECM of the cartilage tissue and bone 
tissue is deposited by osteoblasts in its place. Working in this manner, the expanse of 
bone tissue gradually grows outwards towards the ends of the cartilage model. In long 
bones, a growth plate of cartilage tissue can be seen between secondary ossification 
centres forming at the ends of the model. Within the growth plate, expression of 
Fibroblast growth factor receptor 3 (FGFR3) binding to the ligand FGF-18 is involved 
in inhibition of chondrocyte proliferation via the phosphorylation of Stat1, this results in 
an increase in p21 expression (Liu et al., 2002; Sahni et al., 1999). 
The chondrocytes at the ends of long bones and their corresponding ECM remain, 
prevented from entering hypertrophy due to the induction of chondrocyte proliferation 
markers and repression of chondrocyte differentiation by Ihh (Indian hedgehog) and 
PTHrP (Parathyroid hormone-related protein) (Goldring et al., 2006). These 
chondrocytes form a layer of articular cartilage which is maintained by the chondrocytes 
themselves in a balance of production and degradation of ECM components (Carter, 
2007; Mackie et al., 2011). The composition of the ECM in the areas of the model to be 
replaced by bone also changes; specifically as chondrocytes undergo hypertrophy, type 
X collagen is expressed (Umlauf et al., 2010). 
The SMAD pathway (specifically SMAD3) is also responsible for maintaining the 
articular cartilage layer at the ends of long bones. Both TGFβ and SMAD3 inhibit the 
terminal hypertrophic differentiation of chondrocytes within the cartilage layer, 
therefore maintaining the tissue in its current state (Yang et al., 2001). 
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Figure 1.2 Endochondral ossification. Overview of endochondral ossification 
resulting in bone formation. (A) The cartilage model of future bone, (B) A periosteal 
bone collar forms and the primary centre of ossification begins to form, (C) The primary 
centre of ossification begins to expand towards the ends of the cartilage model. (D) The 
secondary centres of ossification form at each end of the bone, this leaves a 
cartilaginous growth plate between the primary and secondary ossification centres. (E) 
The mature bone has formed, with the growth plate cartilage being fully replaced by 
bone. The only cartilage which remains is a layer of articular cartilage at either end of 
the bone. (Mackie et al., 2011). 
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Articular cartilage as a tissue contains no nerve fibres or lymphatic vessels and is 
avascular. It uses very little oxygen for energy synthesis, the oxygen within the tissue 
ranges from <1% in the deeper zones to ~10% at the cartilage surface (Grimshaw and 
Mason, 2000). Instead articular cartilage relies on the Embden-Meyerhof-Parnas 
pathway of glycolysis to provide energy (Lee and Urban, 1997; Otte, 1991) via the 
proteins GLUT3 (Glucose transporter, type 3) and GLUT8 (Glucose transporter, type 8) 
(Mobasheri et al., 2005).  However, the presence of oxygen does appear to have a role 
within chondrocytes, with abnormal matrix production resulting from too little O2 
(Grimshaw and Mason, 2000; Zhou et al., 2004). It has been found in in vitro 
chondrocyte culture, that HIF-1α (Hypoxia inducible factor 1 alpha) is up-regulated 
resulting in the induction in expression of numerous GLUT genes in response to the low 
oxygen levels. (Mobasheri et al., 2005). 
Articular cartilage is composed of four main zones (Fig. 1.3) and is made up of a 
combination of collagens (predominantly type II collagen, but also includes types I, III, 
VI, IX, X XI, XII, XIV and XXVII collagens), proteoglycans, specifically aggrecan; a 
large chondroitin sulphate proteoglycan, but also hyaluronan, syndecans, glypican, 
perlecan, epiphycan, decorin, lumican, fibromodulin, and biglycan. The glycoprotein 
lubricin is also found in cartilage, specifically the superficial zone and synovial fluid 
where it acts as a lubricant and functions to protect cartilage from friction-induced wear. 
The last component of cartilage is water (French, 2003; Rhee et al., 2005; Umlauf et al., 
2010; Wardale and Duance, 1994).  
The first zone of cartilage is the ‘surface’ or ‘superficial’ zone and is the thinnest of the 
four layers.  It is in contact with the synovial fluid, and consists of fine collagen fibrils 
with chondrocytes aligned in parallel with the surface of the tissue (Martel-Pelletier et 
al., 2008); there is a low abundance of aggrecan at this level (Goldring and Marcu, 
2009).  The specific orientation of the collagen fibrils results in the tissue being able to 
withstand shearing forces placed on the joint by movement (French, 2003; Guilak et al., 
1994).  The centre layer is the ‘middle zone’ also known as the transitional zone.  This 
thick zone consists of high concentrations of proteoglycans, such as aggrecan, and thick 
collagen fibres which are usually organised into layers or radial bundles.  The 
chondrocytes at this level, unlike those at the surface layer, are more rounded and are 
present at lower concentration (Martel-Pelletier et al., 2008).  The third layer is the deep 
zone (the radial zone) and this is closest to the bone layer. Out of the 3 zones, the deep 
zone contains the highest concentration of collagen fibres but less proteoglycans within 
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its extracellular matrix than the previous zone.  The chondrocytes here are aligned 
perpendicularly to the surface layer, at a similar concentration to the middle layer 
(Martel-Pelletier et al., 2008; Umlauf et al., 2010). The very final zone, found 
immediately below the radial zone, is the calcified cartilage zone and is the area where 
the cartilage matrix interacts with the subchondral bone (Umlauf et al., 2010). It remains 
beyond the final closure of the growth plate and acts as a buffer between the bone and 
articular cartilage layers (Goldring and Marcu, 2009). All of the  layers have distinctly 
different gene expression (Dunn et al., 2009). 
Healthy articular cartilage functions to absorb impact to the joint, and cope with 
mechanical stresses such as shearing forces.  The surface; or ‘superficial’ zone of 
cartilage is the area most responsible for managing mechanical strain and tensile forces 
placed upon the joint.  The structure of the extracellular matrix (ECM) is in part the 
basis for the properties of articular cartilage in how it is able to withstand loads, and 
enable free movement of the joint, and consists mainly of aggrecan, collagen (in fibril 
form) and water. The degradation of articular cartilage ECM that occurs during 
osteoarthritis results in a loss of these functions and the development and progression of 
the disease (Martel-Pelletier et al., 2008).  
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Figure 1.3 The zones of articular cartilage. The superficial zone is the first zone 
beneath the articular surface and consists of fine collagen fibrils with chondrocytes 
aligned in parallel with the surface of the tissue. The centre layer is the transitional zone 
and contains thick collagen fibres which are usually organised into layers or radial 
bundles.  The chondrocytes at this level are more rounded and are present at lower 
concentrations. The third layer is the radial zone and contains the highest concentration 
of collagen fibres. The chondrocytes here are aligned perpendicularly to the surface 
layer, at a similar concentration to the middle layer. The final zone, found immediately 
below the radial zone, is the calcified cartilage zone and interacts with the subchondral 
bone. Diagram adapted from Wiesler et al. (Martel-Pelletier et al., 2008; Umlauf et al., 
2010; Wiesler et al., 2007). 
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The only cell type present in cartilage, sparsely distributed, is the chondrocyte. 
Chondrocytes are found within chondrons, which are defined as the cell itself as well as 
the 1-5µm surrounding PCM (pericellular matrix). This in turn is surrounded by a 
fibrillar pericellular capsule (Poole, 1997). Chondrons are the mechanical units of 
hyaline cartilage and the pericellular matrix has been found to have an impact upon the 
mechanical properties of the chondrocyte, with chondrons thought to be responsible for 
absorbing mechanical load due to their ability to vertically compress when under strain 
and recover when unloaded (Nguyen et al., 2010; Poole, 1997). 
Chondrocytes are dispersed in varying percentages between the zones of cartilage and 
often differ slightly in morphology between the layers. This is thought to be partially 
due to the mechanical environs found within each zone (Poole et al., 2007). It is these 
cells which (although they do not usually divide) produce extracellular matrix 
components such as collagens and proteoglycans and are responsible for maintaining 
this environment.  Most matrix components are produced by early stage chondrocytes, 
with the main role of the mature cells being to maintain the homeostasis of this 
environment by interactions with integrin-mediated attachments (French, 2003). The 
matrix is also responsible for maintaining the phenotype of its surrounding 
chondrocytes (Aigner et al., 2006).   The extracellular matrix, whilst mainly composed 
of collagen fibrils and proteoglycans, also contains a number of other molecules 
including cartilage oligomeric matrix protein (COMP) which acts as a catalyst in the 
formation of the fine collagen fibrils (fibrillogenesis) found in the matrix (Halasz et al., 
2007) aided by perlecan (Kvist et al., 2006). Other components of the matrix include 
decorin, fibromodulin, biglycan and a number of matrilins (Goldring and Marcu, 2009). 
It is known that the maintenance and actual formation of articular cartilage matrix is 
greatly influenced by the interactions between these molecules, specifically type IX 
collagen, COMP and matrilin-3 (Leighton et al., 2007). These additional matrix 
components are also responsible for connecting different collagen types (such as VI and 
II) to each other and aggrecan (Wiberg et al., 2003). 
The extracellular matrix is split into three matrices arranged in a specific order 
surrounding chondrocytes within the three main zones of cartilage.  These are, in order 
of least distance from the chondrocytes: pericellular, territorial and interterritorial 
matrices (Fig. 1.4) (Heinegard and Saxne, 2011). Type II collagen, along with aggrecan, 
makes up the majority of the extracellular matrix of adult articular cartilage (Table 1.1) 
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and is involved in providing the tensile strength of the tissue as part of the 
interterritorial matrix (Martel-Pelletier et al., 2008).  Specifically, compressive 
resistance is provided by aggrecan, a proteoglycan with a half-life of between 3 and 24 
years (Goldring and Marcu, 2009). Type II collagen forms a framework for aggrecan 
which swells with water due to its negatively charged glycosaminoglycan side chains, 
creating large hydrodynamic domains. This combination of pressure restrained by a 
collagen grid gives cartilage its shape, tensile strength (Fosang and Beier, 2011) and 
elasticity (Aigner et al., 2006), and the proteoglycan network in turn protects the 
collagen network within the matrix. Collagen is known to have a half-life of over 100 
years in cartilage if not exposed to deleterious conditions (Goldring and Marcu, 2009). 
The combination of the collagenous network and aggrecan is key to avoiding damage to 
cartilage during loading. They are able to dissipate the mechanical pressure resulting 
from loading and distribute it across a larger area (Aigner et al., 2006). 
Type IX collagen is found at intersections within collagen fibrils and co-localizes with 
type II at the surface, it provides stability to the collagen fibrils (Muller-Glauser et al., 
1986).  Type XI collagen is also found throughout collagen fibrils however, unlike type 
II and IX, it cannot be detected by antibodies on intact fibrils, only at areas where fibril 
structure is incomplete or has been disrupted (Mendler et al., 1989).  This is due to its 
function as a template for the fibril (Table 1.1).  Both collagens type IX and XI are vital 
in disease processes, as mutations in either can result in chondrodysplasia (Eyre et al., 
2006). All three collagens (II, IX and XI) are heavily involved in cartilage formation 
and form what is known as a heteropolymeric template (Eyre et al., 2006). In contrast to 
the interterritorial zone, the territorial matrix contains collagen type VI but very little 
fibrillar collagen, and is located closer to the chondrocyte cells. Collagen XXVII is also 
a member of the fibrillar collagen family and has a role in maintaining stability within 
the matrix (Goldring and Marcu, 2009). More recently it has been found that type 
XXVII Collagen plays a vital role in the structure of the pericellular extracellular matrix 
of the growth plate and is also necessary for the organisation of the proliferative zone of 
cartilage (Plumb et al., 2011). 
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Figure 1.4 Matrices formation within cartilage. Diagram of the placement of 
matrices within cartilage in relation to the chondrocyte [figure from (Heinegard and 
Saxne, 2011)]. Pericellular is adjacent to the cell and is primarily the location where cell 
signalling with cell surface receptors occurs, one example of this is of the 
glycosaminoglycan hyaluronan binding to the CD44 receptor. The subsequent matrix 
zone (territorial) is comprised predominantly of aggrecan HA (hyaluronan) complexes 
and collagen VI whilst the zone furthest from the cell surface (interterritorial) contains 
mainly types II and XI collagen.  Abbreviations: CILP-1 (cartilage intermediate layer 
protein 1), COMP (cartilage oligomeric matrix protein), and KS (keratan sulphate) 
(Heinegard and Saxne, 2011). 
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Collagen 
Type 
Percentage of total collagen 
Type I Present in adult articular surface and pericellular 
Type II 75% foetal, >90% adult 
Type III >10% in adult human articular cartilage 
Type IX Covalently fibril-associated collagen 10% foetal, 3% adult 
Type X Hypertrophic cartilage only 
Type XI Fibril template 10% foetal, 3% adult 
Type VI Chondron basket, microfilaments <1% 
Type XII/XIV Non-covalently fibril-associated collagens 
Type XIII Transmembrane 
Type XXVII Fibrillar collagen, role in maintaining stability 
 
Table 1.1 Collagen types in Cartilage Matrix [table adapted from (Eyre et al., 2006; 
Plumb et al., 2011; Wardale and Duance, 1994)]. 
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In healthy cartilage, equilibrium between the production and destruction of ECM 
components is maintained by the chondrocytes present and involves a number of both 
anabolic and catabolic factors (Fig. 1.5). Those involved in maintaining and producing 
ECM components include TIMPs, IGF-1 and members of the TGF-beta family. Whilst 
from the catabolic side, inflammatory cytokines, MMPs and aggrecanases are 
responsible for ECM breakdown (Aigner et al., 2006). If the balance between ECM 
synthesis and degradation becomes disrupted and begins to fall more on the catabolic 
side, as in OA, then the cartilage begins to degrade (Martel-Pelletier et al., 2008).   
The release of proteins and other products from the breakdown of cartilage can further 
induce enzyme release from the surrounding macrophages and synovial cells via TLR 
(Toll-like receptor) activation; it can also result in other inflammatory events such as 
vascular hyperplasia in the neighbouring synovial membrane and invasion of immune 
cells such as B lymphocytes (Da et al., 2007).  These processes can ultimately lead to 
positive feedback, with molecules such as tumour necrosis factor α and interleukin-1β 
becoming induced and subsequently accentuating the degradation effect (Da et al., 
2007).  
Physical trauma can also result in inflammation in the early stages of OA, a symptom 
which was once thought to be a feature solely of rheumatoid arthritis (Saxne et al., 
2003). Inflammation, through the production of cytokines can result in a switch to more 
catabolic processes by chondrocytes and other cells within the affected joint.  As 
mentioned earlier this can cause more tissue damage and follow the increasing cycle of 
degradation, as well as meaning an increase in sensitivity of the joint to mechanical 
loading.  Inflammation is also thought to be an important factor in the debilitating pain 
that most if not all patients of OA suffer (Heinegard and Saxne, 2011; Sellam and 
Berenbaum, 2010). However, the use of anti-inflammatory drugs often does not give the 
patient long-term respite against the pain, suggesting that OA may not be inflammatory 
in quite the same way as rheumatoid arthritis (Lin et al., 2004). 
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Figure 1.5 The balance of anabolic and catabolic factors in healthy cartilage. In 
healthy tissue, anabolic and catabolic factors are in balance. All these factors are 
primarily produced by chondrocytes during autocrine and paracrine signalling. And it is 
when these factors become imbalanced that osteoarthritis occurs. (BMP: bone 
morphogenetic protein; IGF: insulin-like growth factor; Il-1ß: interleukin 1ß; TNF: 
tumour necrosis factor). [Image adapted from (Aigner et al., 2006)]. 
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1.2 - Osteoarthritis 
Osteoarthritis is not just a disease of the cartilage, although this is usually the major area 
affected, and is used clinically to diagnose the disease. It is a disease encompassing the 
whole joint including the synovial tissue, tendons and surrounding bone. Specifically in 
OA there is a tendency for an increase in the thickness and remodelling of the 
subchondral plate beneath joint cartilage to occur.  Symptoms also include other 
structural changes such as the overgrowth of bone (osteophytes) at the joint, which can 
press on nerve endings (Martel-Pelletier et al., 2008).  The growth of osteophytes is 
thought by some to be an attempt by the body to repair the damage to the worn joint, but 
in effect it seems to lead to a misshapen joint and result in increased pain as well as 
adversely affecting mobility (Swales, 2010).   
 
Although some attempt is seen by chondrocytes to repair cartilage matrix in early stage 
OA with an initial increased expression of type II collagen and aggrecan, this is also 
paired with increased production of matrix degrading enzymes (Goldring, 2000). The 
overall reason behind the poor ability of cartilage to repair itself may be the slow 
turnover of new cartilage due to mature chondrocytes functioning more to maintain the 
articular cartilage tissue rather than rapidly produce new matrix (Eyre et al., 2006). 
Cartilage tissue is also an avascular tissue and so has no ready access to a blood supply, 
hindering its repair (Oldershaw et al., 2010). Interestingly, it has been found that 
specific mouse models can rapidly repair damaged cartilage in vivo. Eltawil et al found 
that when DBA/1 and C57BL/6 mice underwent microsurgery in order to damage knee 
cartilage, mice of the DBA/1 strain showed a faster and more consistent repair of the 
tissue, whilst the C57BL/6 strain developed osteoarthritic characteristics. This shows a 
potential strain dependent outcome to induced osteoarthritis. Eltawil et al also showed 
this repair to be age dependent, with 8-week old DBA/1 mice showing more efficient 
repair than 8-month old DBA/1 which had undergone the same procedure (Eltawil et al., 
2009).   
 
Other symptoms, particularly of knee osteoarthritis, include, but are not limited to, 
structural changes within the menisci and cruciate ligaments (Englund et al., 2010).  
And at later stages of the disease, the structural changes increase further in severity, and 
chronic inflammation of the synovial membrane occurs (Martel-Pelletier et al., 2008). 
Some levels of synovitis are also thought to occur in early osteoarthritis but not to the 
same extensive degree; however Benito and colleagues saw an increase in inflammatory 
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markers at early stages of OA compared to the latter, advanced, stages (Benito et al., 
2005). An inflamed synovial membrane is characterised by hypertrophy and hyperplasia 
of the membrane as well as the occurrence of lymphocytes invading the sub-lining 
tissue of the synovium (Benito et al., 2005). This was also seen in studies by Rollin et al 
who studied the expression of CD5 and CD69 and found an influx of lymphocytes into 
the synovium, however, it was reduced when compared to lymphocyte invasion in RA 
tissue (Rollin et al., 2008).  The synovial inflammation triggers the release of more 
inflammatory mediators which further alters the homeostasis of the ECM in cartilage, 
accelerating degradation (Martel-Pelletier et al., 2008; Sellam and Berenbaum, 2010). 
 
One of the main obstacles to dissecting the aetiology of this disease is the lack of tissue 
readily available from early stages of osteoarthritis to study. This is due to the fact that 
the clinical symptoms that diagnose OA, such as radiographic changes in cartilage 
thickness, generally only appear in the latter stages (Heinegard and Saxne, 2011; 
Rousseau and Garnero, 2012). Also, the radiographic scores do not always correspond 
to what is classed as the predominant clinical representation of OA: patient defined joint 
pain (Thakur et al., 2013). Rarely are early stage human OA tissue samples available to 
study since joints are only removed at the end point of the disease. However, a large 
area of arthritis research now lies around early stage markers to better diagnose the 
disease (Rousseau and Garnero, 2012). In addition to the problems of attaining early 
stage osteoarthritic cartilage, samples used experimentally as controls usually originate 
from trauma patients with fractured neck of femur. Generally this tissue is sourced from 
the elderly or those already predisposed to fragile bones such as those with 
osteoporosis. This means that although the tissue is non-arthritic, it is far from ‘normal’. 
The ideal control would be tissue obtained via amputation, however obviously this 
tissue is harder to obtain and comes with its own problems, such as if the joint has been 
aberrantly loaded in its lifetime, and how long the joint has spent in an unloaded 
condition before the tissue is processed. 
 
The progression and initiation of OA is still not completely understood and is 
compounded by the growing theory that there are in fact many subtypes of osteoarthritis 
and not, as once thought, merely primary and secondary OA. These subtypes are being 
defined by a number of factors, for example, joint site, presence of inflammation, 
structural aspects and the threshold of pain suffered by a patient (Bierma-Zeinstra and 
Verhagen, 2011). 
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Osteoarthritis is thought to be the result of a combination of many different factors 
including mechanical stress and enzymatic feedback loops (Martel-Pelletier et al., 2008) 
as well as a combination of both environmental and genetic factors. It has also been 
shown that OA can be more prevalent in certain joints in women more than men and 
vice versa, with one example being knee OA more prevalent in females (Dieppe and 
Lohmander, 2005).  Most recently, initiation factors of OA are thought to include 
mutations within matrix proteins such as type II collagen (Jakkula et al., 2005; 
Kuivaniemi et al., 1997; Metsaranta et al., 1992), type IX collagen (Dreier et al., 2008; 
Fassler et al., 1994; Jakkula et al., 2005), and XI Collagen which correlate with an 
increased incidence of early onset primary osteoarthritis (Jakkula et al., 2005). 
 
There have been a number of genome-wide association studies (GWAS) carried out to 
investigate osteoarthritis genetically. Although not totally successful in finding a 
conclusive genetic cause of OA, they have suggested a number of interesting genes with 
possible links to osteoarthritis.  These include DVWA, a gene expressed specifically in 
cartilage (Miyamoto et al., 2008), and the IL-1 gene cluster at 2q13 which has been 
associated with susceptibility to knee osteoarthritis (Loughlin et al., 2002). Other 
GWAS studies [including arcOGEN (Zeggini et al., 2012) and the TREAT-OA 
consortium (Kerkhof et al., 2011)] have identified other potential common loci for 
susceptibility to osteoarthritis such as GLT8D1 (glycosyltransferase 8 domain 
containing 1), ASTN2 (Astrotactin 2), CHST1L and TP63. These studies focussed on 
those patients who had joints replaced due to osteoarthritis and so the loci were also 
considered to be linked to the pain of OA sufferers since pain is the major reason behind 
replacement surgery. Although a large number of genes were identified within each 
GWAS, each observed  only a small effect size, possibly suggesting a synergistic effect 
(Thakur et al., 2013). 
 
Those most at risk of OA are thought to be the elderly, overweight or obese, and 
patients of trauma incidents (Attur et al., 2010), with incidents of osteoporosis thought 
to increase the chance of OA (Bellido et al., 2010).  The link between osteoporosis 
leading to osteoarthritis, is however, refuted by a number of studies including one case 
study where patients with fractured hips were found to be at risk of getting hip OA in 
the same joint by one third compared to controls (Franklin et al., 2010).  
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The increased incidence, particularly seen in those overweight or obese patients, was 
traditionally thought to be due to the excess weight imposed upon the joints.  However, 
there has been literature published which suggests that it is not necessarily the added 
weight, but the fat tissue itself which is responsible, or more precisely, inflammatory 
factors such as adipokines released from the adipose tissue (Aspden, 2011; Hotamisligil, 
2006).  The influence of adipose tissue upon OA is shown in part by the fact that obese 
patients also exhibit increased OA in finger joints which would not be affected by a 
larger mechanical load (Aspden, 2011). This is supported by the location and structure 
of adipocytes in relation to immune cells in that they are situated close to macrophages 
and can provide interactions between the immune system and metabolic responses 
(Hotamisligil, 2006).  The infrapatellar fat pad is thought to be a potential source of 
adipokines in the knee and one study has suggested that cytokines, such as IL-6, 
produced from the infrapatellar fat pad in OA patients could be involved in 
inflammation in addition to being a factor in causing cartilage damage (Distel et al., 
2009).  
 
There is also thought to be a link between osteoarthritis and metabolic syndromes, to 
such an extent that metabolic osteoarthritis has now been described as a subtype of 
osteoarthritis. For example, hypertension has been linked to bone remodelling in OA 
due to its effect on the exchange of nutrients into articular cartilage, and dyslipidemia is 
thought to play a role in the initiation of OA by the dysregulation of lipid metabolism 
within the joint (Zhuo et al., 2012). Diabetes is also thought to be an additional 
independent risk factor of OA (Berenbaum, 2012), with those suffering from type 2 
diabetes found to be at a much higher risk of developing severe OA than their non-
diabetic counterparts (Schett et al., 2013). There has however been more recent research 
finding a more inconclusive link between OA and diabetes, suggesting that they are not 
causally related based on genetic risk scores for the diseases in a tested population 
(Hoeven et al., 2014). This could suggest instead that the link seen is due to common 
risk factors between the diseases such as increased weight and age. 
 
There is also the possibility of cartilage degradation being aggravated, and the disease 
progressed, by an autoimmune response to the cartilage components (Nishioka, 2004). 
The concentrated presence of immune cells within the synovial tissue are thought to be 
involved with disease progression and development with one study showing an 
infiltration of B lymphocytes in half of the OA knee samples tested associated with an 
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increase in synovial inflammation (Da et al., 2007). There has also been shown to be a 
T-cell immune response to aggrecan specific peptides in osteoarthritis and rheumatoid 
arthritis patients (de Jong et al., 2010; Sakkas and Platsoucas, 2007), associated with an 
up-regulation in the cytokines and tumour necrosis factors (particularly IL-β and TNF-α 
respectively) (Kobayashi et al., 2005; Malemud, 2010), and it is thought that these 
factors may have a role in the degradation of articular cartilage matrix proteins, as well 
as causing damage to subchondral bone. However this is still controversial as human 
trials utilising antagonists to these cytokines have so far proved unsuccessful (Malemud, 
2010). Additional research has suggested a role for the innate immune response in 
osteoarthritis, with a focus on TLR (Toll-like receptors) interacting with hyaluronan 
within the joint (Scanzello et al., 2008). 
 
Treatments for osteoarthritis are limited and are generally restricted to analgesics,  non-
steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid injections (Arroll and 
Goodyear-Smith, 2004), although trials have shown that both anti-inflammatories and 
injections have a limited effect on pain from OA (Lin et al., 2004). There are as yet no 
effective DMOADs (disease modifying osteoarthritis drugs) and the last resort for OA 
patients is surgery with either partial (uni-compartmental) or full joint replacements. A 
knee replacement, for example, can last up to 20 years, but must eventually be replaced, 
especially in a younger patient (NHS, accessed 03/04/14). Alternative treatments 
include attempts to alter a patient’s gait to treat the disease (Fregly, 2012). 
  
There have also been investigations into the use of the compounds glucosamine 
sulphate and chondroitin sulphate as treatments for OA to use as both pain relief and to 
treat the structural symptoms of cartilage destruction. There is however differing reports 
as to the effectiveness of these treatments, with some studies finding no physiologically 
significant effect (Sawitzke et al., 2010), and others showing a significant reduction in 
OA symptoms when treated with either chondroitin sulphate or glucosamine (Martin et 
al., 2012; Reginster et al., 2012; Wildi et al., 2011). 
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1.3 - Regulatory Mechanisms Of Osteoarthritis 
Although it is observed that there is unlikely to be one sole cause of OA, much 
investigation has gone into mapping the various changes that occur during the disease.  
Primarily osteoarthritis develops when there is some form of dysregulation in the 
balance between matrix production and degradation. 
 
Cartilage degradation is a key factor of osteoarthritis and usually begins with a loss of 
proteoglycans such as aggrecan due to the up-regulation of the aggrecanases; 
ADAMTS-4 and -5 (a disintegrin and metalloprotease domain with thrombospondin 
motifs).  In the past, studies have shown that the degradation also corresponds with an 
up-regulation of MMPs (matrix metalloproteinases) which cleave aggrecan, although at 
different sites to the ADAMTS family (Nagase and Kashiwagi, 2003; Umlauf et al., 
2010).  However, more recent publications have noted that ADAMTSs are much more 
efficient at aggrecan degradation, meaning MMPs may have a smaller role in in vivo 
aggrecan degradation than once thought (Durigova et al., 2011). This theory could 
however be explained by research employing the use of neoepitope antibodies against 
aggrecan cleavage by both MMPs and aggrecanases, showing that MMPs are 
responsible for aggrecan cleavage at later stages of the disease compared with 
aggrecanases which appear responsible for the early stage loss of the protein (Fosang et 
al., 2010).   
 
Aggrecan is responsible for the weight bearing properties of cartilage, and its 
progressive destruction results in structural instability of the ECM. There has been 
much research into which of the two aggrecanases: ADAMTS-4 and ADAMTS-5, is the 
key aggrecanase in osteoarthritis progression (Umlauf et al., 2010) and which 
specifically is most important in terms of that regulation. Although both are responsible 
for aggrecan degradation, ADAMTS-4 is stimulated by pro-inflammatory cytokines, 
and both ADAMTS-4 and 5 are expressed by chondrocytes. It is thought that 
ADAMTS-5 is the most active out of the two aggrecanases as seen from in vitro 
cartilage experiments, with activity 1000-fold higher than ADAMTS-4  (Gendron et al., 
2007; Troeberg and Nagase, 2012). In mouse studies, ADAMTS-5 also appears to have 
the greatest effect in osteoarthritis. This is shown by ADAMTS-4 knock-out mice with 
surgically induced joint instability, which showed no halt in OA progression (Glasson et 
al., 2004), whereas ADAMTS-5 null mice show an abrogation of cartilage destruction 
in an inflammatory arthritis mouse model (Stanton et al., 2005).  
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It has been found that degradation of collagen fibrils begins after the loss of aggrecan, 
due in part to the theory that the presence of aggrecan in the matrix protects the collagen 
fibrils (Pratta et al., 2003; Troeberg and Nagase, 2012) and so collagen degradation is 
prevented whilst aggrecan is still intact.  
 
Collagen degradation is due to the presence of collagenases such as MMP-13 which is 
known to be involved in maintaining the matrix equilibrium of cartilage as well as being 
implicated in chondrocyte differentiation (Goldring and Marcu, 2009; Troeberg and 
Nagase, 2012; Wu et al., 2002). Their involvement in osteoarthritis is shown by up-
regulated levels of collagenase matrix metalloproteinases 1, 8 and 13 cleaving type II 
collagen in OA human cartilage compared to normal cartilage tissue (Billinghurst et al., 
1997). This is combined with increased expression of MMP-3, MMP-10, MMP-11, 
MMP-2 and MMP-9 in osteoarthritic tissue (Umlauf et al., 2010). MMP-2 and MMP-14 
have also been found to cleave collagen, although MMP-13 appears to be the 
predominant MMP with the highest specific activity against collagen involved in 
osteoarthritis (Kevorkian et al., 2004). 
 
Collagen degradation can be partially inhibited by the introduction of MMP-8 and 13 
inhibitors (Dahlberg et al., 2000; Piecha et al., 2010; Poole et al., 2002). This is 
supported by data from an MMP-13 knock out mouse model surgically induced through 
osteoarthritis which was found to have reduced cartilage destruction compared to a wild 
type control, suggesting that MMP-13 is key in the progression of osteoarthritis (Little 
et al., 2009). In addition, there is also evidence showing the effectiveness of MMP-13 
inhibitors in the prevention of cartilage destruction in an osteoarthritic rat model 
(surgical induction of medial meniscus tear) (Baragi et al., 2009) as well as a decrease 
in collagen degradation recorded in articular cartilage from both human and bovine 
origins in response to MMP-13 inhibitors (Piecha et al., 2010). 
 
Other factors, in addition to the aforementioned collagenases and aggrecanases, are also 
known to influence chondrocyte function during osteoarthritis. Pro-inflammatory 
cytokines such as IL-1β (interleukin 1 beta) and TNF-α (tumour necrosis factor alpha) 
are heavily involved in altering chondrocyte metabolism (as well as their phenotype) 
and therefore have a role in affecting matrix production and structure by activating 
catabolic pathways.  They are known to induce the production of MMPs, including 
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MMP-1, MMP-3 and MMP-13, iNOS (inducible nitric oxide synthase) and COX-2 
(cyclooxygenase 2), in addition to inhibiting TIMP production which are known MMP 
inhibitors (Umlauf et al., 2010). Both IL-1β and TNF-α are also known to activate a 
number of signalling pathways within chondrocytes, including JNK (c-Jun N-terminal 
kinases), p38, MAPK (Mitogen-activated protein kinases) and NF-κB (Nuclear factor 
kappa-light-chain-enhancer of activated B cells) (Goldring et al., 2011). MAPK, p38 
and NF-κB  are known to have roles within chondrocyte differentiation, with p38 
showing expression in the growth plate of long bones (Bobick and Kulyk, 2008; Zhang 
et al., 2006b) and MAPK and NF-κB signalling implicated in MMP and ADAMTS  
induction (Goldring, 2012). The JNK pathway has been implicated in stress responses 
in chondrocytes and Kao et al describes its role in chondrocyte apoptosis after treatment 
with nitric oxide. They demonstrate a reduction in cell death with JNK inhibitor 
treatment (Kao et al., 2013). 
 
Further, TNF-α  has been implicated in disease as well as normal chondrocyte 
physiology, with research involving an inhibition of TNF-α showing a suppression in 
cartilage degradation in arthritis (Fernandes et al., 2002).  
 
Additional cytokines and chemokines implicated in osteoarthritis include LIF 
(Leukaemia inhibitory factor), IL-6, IL-8, IL-15, IL-17, IL-18 and IL-21 (Kapoor et al., 
2011). IL-6 has been found to up-regulate MMP-1 and MMP13 (Cawston et al., 1998; 
Rowan et al., 2001) and is detected in the synovial fluid of OA joints (Kaneko et al., 
2000). IL-15 and IL-21 have also been detected at increased levels in OA synovial fluid 
(Scanzello et al., 2009). IL-18 on the other hand is expressed at higher levels in 
osteoarthritic chondrocytes compared to non-diseased cells and also appears to up-
regulate the synthesis of MMPs as well as decrease expression of inhibitors of MMPs 
(Sandell and Aigner, 2001). IL-17 is a pro-inflammatory cytokine and has been found to 
down-regulate the levels of proteoglycans in OA (Lubberts et al., 2000), in addition to 
inducing the up-regulation of MMPs (Martel-Pelletier et al., 1999). The chemokine IL-8 
has shown increased expression in OA tissue and is also thought to be involved in 
proteoglycan degradation (Alaaeddine et al., 1999). Finally LIF is another cytokine 
linked to OA, and has been detected at elevated levels in the synovial membrane and 
fluid of osteoarthritic joints, as well as being implicated in proteoglycan degradation 
(Alaaeddine et al., 1999). 
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A review by Tchetina et al  comments on how some of the characteristic changes in OA 
that are shown by the cartilage cells themselves, resemble the changes that occur in 
development of the bone (endochondral ossification) (Tchetina, 2011).  These include, 
for example, the expression of genes related to differentiation such as type X collagen 
which was found to be expressed more highly by OA chondrocytes than within a 
control and is a marker of hypertrophy in normal cell physiology (Girkontaite et al., 
1996; von der Mark et al., 1992; Walker et al., 1995).   
 
On a cellular level it has been found that apoptosis of terminally differentiated 
chondrocytes is also found in OA (Blanco et al., 1998), with up-regulated expression of 
Fas and Caspase 8 in OA compared to normal cartilage tissue (Robertson et al., 2006).  
Another paper noted in an animal OA model, the presence of apoptosis in the early 
stages of OA in both the superficial and middle zones of cartilage. This is thought to be 
due to the ongoing mechanical damage occurring in the joint. At later stages of the 
disease chondrocytes appear to undergo autophagy as well as apoptosis in the same two 
zones, shown by high levels of caspase 3 and LC3III within the chondrocytes. In the 
deep zone, only apoptosis is apparent, thought to be because of ossification of the 
subchondral bone (Almonte-Becerril et al., 2010). 
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1.4 – Biosynthesis Of MicroRNAs 
MicroRNAs are small (20-22mer) double stranded RNAs. Other known small RNAs 
include repeat-associated short interfering RNAs (rasiRNAs), short interfering RNAs 
(siRNAs), piwi-interacting RNAs (piRNA), small nucleolar RNAs (snoRNA), transfer 
RNAs (T-RNAs), Y-RNAs, mirtrons, and endogenous short-hairpin RNAs (endo-
shRNAs) (Kato et al., 2009; Kim et al., 2009; Meister and Tuschl, 2004; Nicolas et al., 
2012).  
 
These short RNAs, along with RNA silencing machinery are responsible for the 
suppression of target gene activity.  In fact, the machinery involved was first discovered 
due to its role in the defence against RNA viruses (Waterhouse et al., 2001) as well as a 
preventative measure against the random integration of transposable elements into the 
genome.  
 
PiRNAs are thought to play a key role in transposon silencing in the germline via their 
interaction with Piwi proteins (part of the Argonaute protein family) (Girard et al., 
2006; Kato et al., 2009).  RasiRNA are also though to interact with Piwi proteins and 
are involved in the RNA interference pathway where they are responsible for silencing 
endogenous selfish genetic elements, for example repetitive sequences (Vagin et al., 
2006).  
 
siRNAs function in a similar manner to microRNAs, and they both undergo a similar 
biogenesis, however, whilst miRNAs are known to regulate endogenous genes, siRNAs 
are responsible for defending the genome against foreign nucleic acids, for instance 
viruses (Carthew and Sontheimer, 2009).  
 
SnoRNAs exist in one of two groups, and are known to modify ribosomal RNA or aid 
in rRNA processing. The groups are known as box C/D and box H/ACA. Box C/D 
snoRNAs are mainly involved in methylating the 2’-hydoxyl groups of target 
nucleotides whilst the box H/ACA snoRNAs are responsible for converting uridine to 
pseudouridine (Kiss, 2002; Ono et al., 2010). Some snoRNAs are also thought to act as 
precursors for microRNAs (Scott et al., 2009). The small RNAs known as T-RNAs are 
involved in protein synthesis via their association with the ribosome complex (Fischer 
et al., 2010). Recently, Haussecker et al have identified a new form of small RNA 
derived from tRNA now known as tsRNA (tRNA-derived small RNAs). It is thought 
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that tsRNAs are found within the cytoplasm, associated with Argonaute proteins, and 
are involved in small RNA silencing, potentially having a regulatory role upon 
microRNA function (Haussecker et al., 2010).  
 
Y-RNAs are involved in DNA replication. These Y-RNAs are longer, non-coding 
RNAs of around 100 nucleotides and have been linked to apoptosis, they bind to Ro60 
and La (Nicolas et al., 2012). Mirtrons, on the other hand are thought to be a type of 
microRNA, or more specifically a new form of microRNA precursor and are generally 
found within the spliced out introns of host genes. These small RNAs follow an 
alternate route of biogenesis, utilising splicing rather than cleavage by the Drosha 
enzyme found in microRNA synthesis (see below). They do however function as 
microRNAs by regulating the expression of target genes (Westholm and Lai, 2011). 
Endogenous short-hairpin RNAs (endo-shRNAs) are thought to be another potential 
form of precursor for microRNAs, forming from Dicer cleavage of long hairpins 
(Babiarz et al., 2008; Matera et al., 2007). 
 
MicroRNAs are responsible for the regulation of their target mRNA counterparts, and 
through this they are able to control gene expression. It is thought that they are involved 
in the translational regulation of at least 60% of all human genes (Akbari Moqadam et 
al., 2013; Ambros, 2004; Bartel, 2009; Friedman et al., 2009). There are over 2,500 
published mature microRNA sequences described on the online database miRBase in 
humans alone, with over 30,000 mature sequences arising from more than 24,000 
microRNA precursors across all species (Griffiths-Jones et al., 2006; Griffiths-Jones et 
al., 2008; Kozomara and Griffiths-Jones, 2011), proving that they are an important 
factor in genetics. There are many techniques utilised to establish microRNA function, 
including knock out mouse models, and to date there are around 50 published mouse 
lines of knockout microRNAs (Park et al., 2012). 
 
The microRNA synthesis process (Fig. 1.6) begins with the transcription of the miRNA 
gene by RNA polymerase II and III in the nucleus into a long primary transcript 
(Borchert et al., 2006). MicroRNAs are generally transcribed from introns within other 
genes and are known as intronic. They can be co-transcribed with that gene, although 
some also possess their own promoters, and it is thought that they can be processed 
from both pre- and post- spliced introns (Kim and Kim, 2007; Ozsolak et al., 2008). 
Other microRNAs however have been found between gene transcripts (more than 1kb 
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away from known or predicted gene sequences) and are transcribed independently from 
their own promoters (Ozsolak et al., 2008). These are known as intergenic. (Hon and 
Zhang, 2007; Kim, 2005). 
 
The RNase III enzyme Drosha combined with the double stranded RNA binding 
domain (dsRBD) protein DGCR8, cleaves the double stranded miRNA primary 
transcript (pri-miRNA) resulting in a stem loop precursor miRNA (pre-miRNA) 
(Gregory et al., 2004; Lee et al., 2003) with two overhangs, at the 5’ end; a phosphate, 
and at the 3’ end; a 2 nucleotide long segment (Borchert et al., 2006). It is known that 
Drosha can be regulated by certain transcription factors (such as Smad and p53), 
resulting in the maturation of specific microRNAs due to increased recruitment of the 
corresponding pri-miRNAs to the Drosha complex (Treiber et al., 2012). 
 
The precursor is subsequently transported by exportin-5 (in the presence of Ran-GTP 
cofactor), out of the nucleus and into the cytoplasm (Bohnsack et al., 2004; Yi et al., 
2003). The pre-miRNA is then processed by Dicer (an endonuclease) to create a double 
stranded 20-22 nucleotide long RNA duplex intermediate, which has the same 
overhangs as the pre-miRNA (Zhang et al., 2002). As with Drosha, there are also 
factors which are known to regulate pre-miR processing by Dicer. Lin-28 is one such 
and is involved in the prevention of maturation of a number of let-7 microRNAs within 
embryonic stem cells, resulting in the increase in their target genes’ expression (Treiber 
et al., 2012; Viswanathan et al., 2008). 
 
The two strands of the miRNA-duplex-containing ribonucleoprotein particle (RNP) are 
separated into the guide and passenger strands.  It is the guide strand which is 
incorporated into the RNA-induced silencing complex (RISC) (Gregory et al., 2005; 
Hammond et al., 2000).  The RISC complex is comprised of an Argonaute protein 
(Ago2), Dicer, TRBP [Tar RNA binding protein (a double stranded RNA binding 
protein)], and PACT (protein activator of PKR) (Gregory et al., 2005; Kapinas and 
Delany, 2011). The mature microRNA guides the RISC complex to the complementary 
target site on the mRNA target sequence, resulting in the repression of the 
corresponding gene (Winter et al., 2009). 
 
In plants, the guide strand is usually determined by the relative thermodynamic stability 
of the strands and is the strand with the weakest 5’ base pair ending (Umate and Tuteja, 
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2010). The mature strand may be the 3’ or 5’ strand, and in some cases both may be 
used as the guide strand where necessary (Winter et al., 2009). In humans, in addition to 
the weakest base pairing rule applying to mature microRNA strand selection, where the 
strand with the lowest stable base pairing of the 2
nd
 to  4
th
 nucleotides from the 5’end is 
incorporated into the RISC complex (Schwarz et al., 2003), it is thought that the 5’ 
strand is usually the guide strand due to the synthesis process. The 5’ end of the 5’ arm 
of the hairpin is cleaved by Drosha, whilst the 5’ end of the 3’ arm is cleaved by Dicer. 
Drosha is thought to cleave in a more specific manner and so this may explain why the 
5’ arm of microRNAs is often more highly expressed as it reaches its mature form with 
less errors (Hu et al., 2009).  
 
It was thought that TRBP (a dsRBD protein) was mainly responsible for the inclusion of 
the guide strand into RISC and the stabilisation of Dicer (Gregory et al., 2005; Tomari 
et al., 2004), however more recent data suggests that Dicer may have a more important 
role in selection of the miRNA strand which is incorporated into the RISC complex.  
Dicer is thought to discriminate between strands based upon the 2-4nt 3’ overhangs of 
the two strands of the microRNA duplex.  This mediates the cleavage of the target 
mRNA (Peters and Meister, 2007; Sakurai et al., 2011), at the binding site [usually 
found at the 3’-untranslated region (UTR) of mRNAs] (Duursma et al., 2008).   
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Figure 1.6 MicroRNA synthesis process. The microRNA biosynthesis process, firstly 
the microRNA gene is transcribed to a pri-miRNA by RNA polymerase. This pri-
miRNA is cleaved by Drosha to form a pre-miRNA which is exported out of the 
nucleus and into the cytoplasm where it is further cleaved by Dicer. The subsequent 
microRNA duplex is incorporated into the RISC complex and guides the complex to a 
microRNA binding site in the mRNA resulting in repression of the corresponding gene. 
Diagram adapted from (Howell et al., 2010).  
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Post biogenesis, microRNAs do not remain within cells indefinitely, they are eventually 
broken down and the turnover of microRNAs has been characterised. Some microRNAs 
are known to have long half-lives compared to others with the average being around 5 
days. The panel of microRNAs analysed by Gantier et al showed a range between 4 and 
9 days, but a half-live of up to 12 days for miR-208 has been seen by Van Rooij et al in 
vivo. MicroRNAs in general are also thought to be up to ten times more stable than 
mRNAs (Gantier et al., 2011; Ruegger and Grosshans, 2012; van Rooij et al., 2007; 
Zhang et al., 2012c). In human cultured cells microRNA degradation is controlled by 
ribosomal RNA processing protein 41 (RRP41), polynucleotide phosphorylase 
(PNPase) and XRN1. The first 2 enzymes degrade 3’ to 5’, but the 3rd degrades 5’-3’ 
(Ruegger and Grosshans, 2012). Bail et al have also identified specific sequences found 
in certain microRNAs (specifically miR-382) outside the microRNA’s seed site which 
may be responsible for how long a microRNA’s half-life is, by determining its stability 
(Bail et al., 2010).  
 
It is already known that microRNAs in general are vital for survival with a Dicer knock 
out mouse being embryonic lethal (Bernstein et al., 2003). This also shows that the 
Dicer enzyme itself is vital for microRNA synthesis. The Drosha/DGCR8 complex 
however may be dispensable, with dgcr8 null mouse embryonic stem (ES) cells 
showing a less severe phenotype than dicer null mouse ES cells (Babiarz et al., 2008). 
This could suggest that there is an alternative route for microRNA production pre-Dicer 
cleavage. There has since, however, been subsequent research to suggest that Dicer 
might also be dispensable, but perhaps only with a sub group of microRNAs not vital 
for survival (Cheloufi et al., 2010). 
 
The methods involved with miRNA function are multi-fold, depending on the organism 
in question. There are also some contradicting schools of thought as to which methods 
are generally more predominant.  In plants, it’s thought that microRNAs are able to bind 
directly and subsequently cleave a complementary target site of mRNA through the 
RISC complex, with non-complement matches not tolerated (Tang et al., 2003). Liu et 
al support this by showing that minor mismatches between a target site and microRNA 
seed site result in abrogated repression with most cases in plants. However they also 
discuss a small number of non-complementary target sites which result in less effective 
repression, rather than none, suggesting that these lower levels of repression may have 
been evolutionarily selected (Liu et al., 2014).   
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In mammals, microRNAs are more likely to have less complementarity to their target 
and so inhibit translation of the mRNA rather than cleave it directly, this also results in 
the preservation of the target mRNA structure (Ambros, 2004).   
 
A number of microRNAs are produced in different cell types in different combinations 
and are thought to work co-operatively to regulate cell specific gene pathways. The 
target prediction algorithms currently available in addition to published research, show 
that a single microRNA may have hundreds of individual targets (Brennecke et al., 
2005; Hendrickson et al., 2009), and that genes can be targeted by multiple different 
microRNAs or even have multiple target sites for the same microRNA. It is thought that 
these microRNAs work co-operatively to down-regulate gene expression, and thus can 
result in a stronger suppression (Akbari Moqadam et al., 2013; Hon and Zhang, 2007). 
 
There are thought to be a number of mechanisms by which microRNAs are able to 
suppress gene expression. The first is whereby the microRNA prevents the translation 
initiation complex from forming by binding to its target. Next, the microRNA may bind 
to an area around, for example a stop codon, resulting in an interruption at a late 
initiation step and causing an early termination of translation. A final suggested 
mechanism is the prevention of ribosome assembly by the binding microRNA, resulting 
in translation suppression (Zinovyev et al., 2010). 
 
The machinery involved in repression of target gene expression is also different to the 
RISC complex used in cleavage reactions. To this end complexes involved in repression 
are termed miRNPs (Mourelatos et al., 2002) and the repression complex is also thought 
to include the protein ago1, whereas cleavage complexes contain ago2 (Kapinas and 
Delany, 2011).   
 
MicroRNAs bind to mRNA via specific conserved sites at the 5’ end of the microRNA. 
These are known as seed sites which bind to corresponding complementary ‘target sites’ 
usually found at the 3’ UTR of an mRNA sequence (Fig.1.7) (Akbari Moqadam et al., 
2013). Target sites in the mRNA can also be found within the 5’ UTR as well as coding 
regions of the mRNA (Lee et al., 2009).  However, it is thought that microRNAs which 
bind at 3’UTRs cause a stronger or more efficient suppression of gene expression than 
if they were to bind to the 5’UTR, which could explain why targets in the 3’UTR are 
more prevalent (Moretti et al., 2010), or at least could explain why they are more 
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detectable. One microRNA (miR-605) has been found which targets both the 5’UTR 
and 3’UTR of the same gene, both resulting in down-regulation of the gene’s expression 
(Lee et al., 2009).  
 
In contrast to this, other research suggests that when a microRNA binds to a target site 
within the 5’ UTR of an mRNA it actually results in the activation  of gene expression 
rather than repression (Da Sacco and Masotti, 2012). This activation has been seen with 
miR-122 within the genome of the hepatitis C virus suggesting that perhaps the virus 
has evolved to exploit the microRNA process (Henke et al., 2008; Jangra et al., 2010; 
Jopling et al., 2005). It has also been found that miR-10a can induce the production of 
ribosomal proteins by binding to a site in the 5’UTR of the mRNA (Orom et al., 2008). 
 
As already stated, microRNAs bind to mRNA sequences via specific sites at their 5’ end 
and there are a number of seed sites of different sizes within the sequence of a 
microRNA which are thought to be responsible for binding to an mRNA target, and 
they start at a number of known locations within the microRNA (Fig. 1.7). The first is 
the 6mer, this is a site 6 nucleotides long which starts at the 2
nd
 nucleotide and finishes 
at the 7
th
 (inclusive). The next is the 7merm8. This site is 7 nucleotides long beginning 
at the 2
nd
 nucleotide, and as the name suggests, ends at the 8
th
 nucleotide. There is an 
additional site of the same length entitled 7merA1 however this site begins at the first 
nucleotide, finishing at the 7
th
. The final seed site is the 8mer, this site is 8 nucleotides 
long beginning at the first nucleotide and ending at the 8
th
 (Mitra and Bandyopadhyay, 
2011). 
 
It’s thought that although all 4 of these sites can result in binding sufficient to inhibit 
mRNA expression, the binding of the 8mer site results in a stronger down-regulation of 
the gene (Schnall-Levin et al., 2011). It is also theorised that in addition to the seed sites 
being the main locations of binding, the microRNA sequence can also bind to a mRNA 
sequence with its 3’ end , specifically an area known as the Watson-Crick complement 
(Fig. 1.7) which runs from the 12
th
 to the 17
th
 nucleotide of the microRNA (Mitra and 
Bandyopadhyay, 2011). 
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Figure 1.7 Diagram of microRNA : mRNA interaction patterns. Diagram of all 
known potential binding areas between microRNA sequence and target mRNA. The 
miRNA seed region located at the 5’ end of the microRNA contains the 4 most common 
seed sites: 6mer, 7merm8, 7merA1 and 8mer. Image adapted from Mitraet al (Mitra and 
Bandyopadhyay, 2011). 
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Aside from manual inspection of individual microRNA sequences to compare for target 
mRNA matches, there are a number of algorithms available online which attempt to 
predict the targets of the majority of microRNAs described on miRBase (Griffiths-Jones 
et al., 2006; Griffiths-Jones et al., 2008; Kozomara and Griffiths-Jones, 2011). These 
include TargetScan (Friedman et al., 2009), miRanda (Betel et al., 2008), PITA (Kertesz 
et al., 2007) and PicTar (Krek et al., 2005). However each database uses a different 
algorithm, and if results are compared they often do not overlap as can be seen in 
another online system which combines the results of a number of the databases: The 
microRNA body map (Mestdagh et al., 2011). One of the problems with using these 
online algorithms is that they all show high levels of false positive or false negative 
results (Mitra and Bandyopadhyay, 2011) and all targets must therefore be 
experimentally validated before determining them as definite targets, and microRNA 
target investigation must not solely rely on the current bioinformatics available. 
 
The machinery involved in repression of target gene expression is also different to the 
RISC complex used in cleavage reactions. To this end complexes involved in repression 
are termed miRNPs (Mourelatos et al., 2002) and the repression complex is also thought 
to include the protein ago1, whereas cleavage complexes contain ago2 (Kapinas and 
Delany, 2011).   
 
In addition to their functions, miRNAs can also be characterised into groups based on 
where they are ‘clustered’ in the genome (Houbaviy et al., 2003).  The current theory is 
that these miRNAs may have arisen from the same mRNA molecule, and so 
understandably, miRNAs with similar sequences are found within the same cluster.  In 
fact, not only are they transcribed from the same area, they are also often co-ordinately 
expressed (Cai et al., 2004) and share the same promoter (Treiber et al., 2012).  Clusters 
of microRNAs are termed Intergenic clustered, Intronic clustered or Mirtrons (where the 
microRNA is part of the intron of a gene) (Kapinas and Delany, 2011). However, some 
miRNAs are clustered together with distinctly different sequences; it is thought that 
these particular miRNAs function to target a collection of genes in a coordinative 
manner, rather than being transcribed in a co-coordinative manner (Ambros, 2004). One 
example of this coordinated ‘attack’ on gene expression are the microRNAs let-7 and 
miR-125 in vertebrates.  These two miRNAs are noticeably co-regulated in the 
developmental stage of the fruit fly (Bashirullah et al., 2003).  This suggests that the 
miRNAs can be clustered together depending on their functional targets as well as their 
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sequence. Further data also supports the idea that clustered microRNAs work co-
ordinately to target certain genes, such as the miR-290 cluster targeting Rbl2 (Benetti et 
al., 2008).   
 
An example of genomic clustering within mammals includes the 6 microRNAs; miR-
290, miR-291, miR-292, miR-293, miR-294, and miR-295 found expressed within 
mouse embryonic stem cells (ESC) (Ciaudo et al., 2009; Houbaviy et al., 2003). 
Additional research in humans by Altuvia et al (Altuvia et al., 2005) has discovered that 
37% of the microRNAs studied appeared to cluster in at least groups of two or more and 
Seitz et al has computationally predicted 40 microRNAs clustered with the same 1 Mb 
of the human genome (Seitz et al., 2004).   
  
MicroRNAs are already well-established as effectors of gene regulation in a number of 
diseases such as cancer, where some microRNAs can act as tumour suppressors, whilst 
others stimulate cancer development via their actions upon oncogenes (Raia, 2011).  
MicroRNAs are increasingly being seen as potential biomarkers of diseases and their 
progression, for example miR-155 in breast cancer (Bartels and Tsongalis, 2009). They 
are also involved in many physiological processes, from regulating embryo maturation 
in Arabidopsis thaliana (Willmann et al., 2011) to a possible role in the human 
circadian clock (for example miR-192 and miR-122) (Hansen et al., 2011). 
 
A large number of microRNAs are documented in the Human microRNA Disease 
Database version 2.0 (HMDD v2.0) (Li et al., 2014). This database has recorded 572 
known microRNAs which are known to be involved across 378 human diseases. These 
diseases include AIDS in which miR-198, miR-29a and miR-29b-1 are known to be 
involved, Alzheimer’s disease in which 30 known microRNAs are involved and 
pulmonary disease, where 17 microRNAs are thought to play a role.  
 
Further, microRNAs are no longer considered limited to acting just within cells, but are 
also detected within the blood. It is thought that these circulating microRNAs escape 
degradation by RNAses found within the blood by the presence of Argonaute proteins 
(specifically Argonaute 2) which form a protective complex around the microRNA 
(Arroyo et al., 2011). In addition to their physiological role, these microRNAs are now 
being utilised as biomarkers of various diseases, with over 100 already identified as 
biomarkers (Weiland et al., 2012).  
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1.5 - MicroRNA Involvement Within Osteoarthritis 
MicroRNAs are known to be involved in both chondrogenesis and various arthritic 
diseases including osteoarthritis, and have already been partially documented, but as we 
learn more about these molecules, the true depth of their involvement is only just being 
recognised. 
 
The Dicer knockout mouse, as mentioned earlier, shows the general importance of all 
microRNAs for survival, with the mouse having a lethal phenotype (Bernstein et al., 
2003). A Dicer knockout of zebrafish also shows the importance of Dicer and the 
microRNA population with zebrafish development halting at day 10 (Wienholds et al., 
2003). Further, a conditional knockout of Dicer in early stage limb resulted in a shorter 
limb developing, suggesting that microRNAs also play a vital role in chondrogenesis 
(Harfe et al., 2005). This is supported by Dicer null chondrocytes which showed growth 
defects during chondrogenesis (Kobayashi et al., 2008).  
 
A number of microRNAs are now associated with cartilage and chondrogenesis, 
including miR-199a, miR-124a and miR-96 (Suomi et al., 2008) with the first two 
found to be up-regulated in MSC derived chondrocytes, and miR-96 down-regulated. 
All three were found to target SOX-5 and HIF-1α. The microRNAs miR-145 and miR-
143 were also determined to increase in expression in chondrocytes derived from 
hMSCs (Karlsen et al., 2011; Yan et al., 2011), with miR-145 found to be a key element 
in early chondrogenic differentiation by its targeting of SOX9, resulting in the up-
regulation of markers of hypertrophy (Yang et al., 2011a). 
 
MiR-675 is also well studied, and is known to be influential in chondrogenesis and a 
part of the maintenance of cartilage homeostasis. The microRNA is regulated by SOX9 
during chondrogenesis and indirectly results in an increase in expression of COL2A1. It 
was also found that miR-675 was able to combat type II collagen reduction in SOX9 
inhibited chondrocytes (Dudek et al., 2010). 
 
Expression of the miRNome of chondrocytes undergoing de-differentiation has also 
been investigated. The expression of five microRNAs were found to be higher at early 
chondrocyte passages compared to later stages, these were miR-30d, miR-140-3p, miR-
210, miR-451 and miR-563 (Lin et al., 2011)  suggesting chondrocyte specificity. 
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Comparisons carried out between osteoarthritic and normal cartilage cells have shown 
differential expression of a number of microRNAs. Jones and colleagues (2009) 
discovered 17 out of 157 microRNAs measured to be differentially expressed between 
late stage OA cartilage and normal cartilage, and 30 in OA bone compared to normal.  
These included miR-9 and miR-98 which were found to be upregulated in both OA 
cartilage and bone.  These microRNAs are postulated to be involved in inflammation 
pathways and in particular, miR-9 appears to modulate the expression of MMP13 (Jones 
et al., 2009).  Another paper also suggested a link between MMP13 expression in 
osteoarthritic chondrocytes and microRNAs, showing that miR-27b had a regulatory 
effect upon the expression of the metalloproteinase (Akhtar et al., 2010).  This is 
supported by a further report which found miR-27a and miR-140 to be involved in the 
regulation of MMP13 (Tardif et al., 2009). 
 
Further publications describe the analysis of 723 microRNAs and the discovery of an 
increase in expression of miR-483-5p in OA chondrocytes whilst a further 6 
microRNAs (miR-149-3p, miR-576-5p, miR-582-3p, miR-641, miR-634 and miR-
1227) showed a decrease in expression in OA chondrocytes. These microRNAs are also 
thought to influence the expression of Wnt signalling and TGF-β, suggesting a more in 
depth role in osteoarthritis (Diaz-Prado et al., 2012). 
 
Additional profiling experiments have shown more microRNAs to be both up-regulated 
and down-regulated in diseased cartilage compared to normal. Iliopoulos et al looked at 
the expression of 365 microRNAs in cartilage tissue. They identified 9 to be up-
regulated and 7 to be down-regulated in OA cartilage compared to normal. These 
microRNAs included miR-9, miR-98 and miR-146 which are all known to regulate IL-
1β induced TNF-α, in addition to the targeting of MMP13 by miR-9. This could suggest 
that these microRNAs could be involved in the prevention of OA or in the maintenance 
of healthy cartilage (Iliopoulos et al., 2008). MiR-22 was also examined functionally by 
the same group, and overexpression of the microRNA resulted in an increase in the 
expression of MMP-13 and IL-1β; key factors in OA progression (Iliopoulos et al., 
2008). 
 
Additional research has been carried out upon miR-146a and its role in osteoarthritis, 
finding that it appears to be induced by joint instability in surgically induced OA 
models. This suggests that it could be involved in mechanotransduction of OA (Li et al., 
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2012a) as well as its potential regulation of MMP-13, determined by an inverse pattern 
of expression between MMP-13 and miR-146a (Yamasaki et al., 2009).  
 
The online database HMDD v2.0 shows 8 recorded microRNAs to have published data 
on their influence in osteoarthritis, although this is not an exhaustive list (Table 1.2). 
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MicroRNA Function Reference 
miR-140 Down-regulation of 
ADAMTS-5, and activated 
by Sox9 to target Sp1 
(Miyaki et al., 2009) 
(Araldi and Schipani, 2010) 
(Yang et al., 2011b) 
(Zhang et al., 2012a) 
miR-146a Expressed in low-grade OA 
cartilage, Linked to pain in 
OA and controls knee joint 
homeostasis 
(Yamasaki et al., 2009) 
(Li et al., 2011) 
(Okuhara et al., 2012) 
miR-155 Highly expressed in OA 
cartilage 
(Okuhara et al., 2012) 
miR-181a-1 Highly expressed in OA 
cartilage 
(Okuhara et al., 2012) 
miR-181a-2 Highly expressed in OA 
cartilage 
(Okuhara et al., 2012) 
miR-223 Highly expressed in OA 
cartilage 
(Okuhara et al., 2012) 
miR-27b Regulates MMP13 in OA 
chondrocytes 
(Akhtar et al., 2010) 
miR-675 Down-regulated in OA 
cartilage 
(Steck et al., 2012) 
 
Table 1.2 Known microRNAs associated with osteoarthritis from the HMDD v2.0 
database. Table shows the 8 microRNAs described on the online Human microRNA 
Disease Database v2.0, how each is involved in osteoarthritis and the corresponding 
literature reference. 
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The microRNAs miR-140 and miR-455 have been studied extensively for their role in 
both osteoarthritis and chondrogenesis. MiR-140-3p, miR-140-5p, miR-455-3p and 
miR-455-5p have all been shown to have cartilage selective expression with miR-455-
3p showing expression restricted to the cartilage of developing long bones in the chick 
and mouse (Miyaki et al., 2009; Miyaki et al., 2010; Swingler et al., 2012), and miR-
140 expression specifically located to cartilage in the jaw, head and fins of zebrafish 
(Wienholds et al., 2005) as well as being identified within cartilage tissue of mouse 
embryo limbs at stage E11.5 and within digits of mouse limbs at stage E14.5 
(Tuddenham et al., 2006). MiR-140 is also SOX-9 inducible; a factor heavily involved 
in chondrocyte development (Yang et al., 2011b).  
 
A miR-140 null mouse developed by two separate research groups showed mild 
dwarfism with possible inhibition of chondrocyte differentiation. In addition, knockout 
mice showed a higher OA score compared to wild type controls and OA scores were 
significantly increased in knockout mice compared to wild type in a surgical OA 
susceptibility model (involving the resection of the medial meniscotibial ligament to 
induce joint instability). Further to this ADAMTS-5 and Dnpep (Aspartyl 
Aminopeptidase) were found to be direct targets of miR-140 (Miyaki et al., 2010; 
Nakamura et al., 2011) with MMP-13 expression also thought to be mediated by the 
microRNA (Liang et al., 2012). In addition, an antigen-induced arthritis model with an 
overexpression of miR-140 in chondrocytes showed an apparent decrease in OA score 
suggesting that miR-140 could have a protective role (Miyaki et al., 2010). Further data 
shows miR-140 to be decreased in expression in both OA cartilage (Miyaki et al., 2009) 
and OA chondrocytes (Tardif et al., 2009) compared to normal tissue and cells. In 
contrast however, another study found miR-140 to increase in expression when 
measured in end stage hip OA cartilage tissue, corresponding with a decrease in 
ADAMTS-5 (a known target of miR-140) (Swingler et al., 2012) suggesting that the 
expression profile of miR-140 changes as the disease progresses, shifting away from the 
original protective role. 
 
Further targets of miR-140 have subsequently been identified. IGFBP-5 (Insulin-like 
growth factor binding protein 5) is one such direct target and has been found to have an 
increased expression in osteoarthritic cartilage (Tardif et al., 2009). 
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Functional studies have been carried out on a range of microRNAs in association with 
cartilage, one study from 2010, showed miR-34a to be involved in chondrocyte 
apoptosis.  Silencing of the microRNA resulted in reduced apoptosis of chondrocytes in 
a rat OA model, it was also shown to reduce interleukin-1 mediated down-regulation of 
type II collagen (Abouheif et al., 2010) suggesting a potential role for this microRNA in 
OA prevention. 
 
In addition to microRNA profiling array studies, there have also been forays into the 
cartilage and osteoarthritic miRNome using next generation sequencing. One such study 
in rat cartilage using the Solexa platform identified 246 previously identified and 86 
novel microRNAs (Sun et al., 2011b). These types of studies have also been used to 
investigate the miRNome of other tissues and diseases. For example, Wu et al identified 
546 precursor microRNAs in breast cancer tissue using SOLiD sequencing in an 
investigation to identify potential cancer biomarkers (Wu et al., 2011). An additional 
study used next generation sequencing to identify 146 known microRNAs within tissue 
of the rat heart left ventricle as well as 68 novel microRNAs, which provides a further 
insight into cardiovascular diseases (Collins et al., 2013). On a more specific cell based 
level, Fehniger et al used a next generation sequencing project to identify the miRNome 
of natural killer cells. They identified 302 known microRNAs and 21 novel microRNAs 
within these cells, providing additional information to elucidate the function of 
microRNAs in natural killer cells and therefore their implicated roles within the 
immune system (Fehniger et al., 2010). 
 
There are over 2500 mature human microRNAs described on miRBase (Griffiths-Jones 
et al., 2006; Griffiths-Jones et al., 2008; Kozomara and Griffiths-Jones, 2011) however 
only a fraction of them have been functionally analysed. An increasing number are 
becoming associated with cartilage and osteoarthritis, and it is likely, that as detection 
and identification technologies improve, soon there will be a comprehensive miRNome 
of osteoarthritis available. This will aid progression in both the diagnosis and hopefully 
prevention of osteoarthritis.  
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1.6 – Aims And Objectives 
The hypothesis of this project was that cartilage contains as yet unidentified 
microRNAs which may contribute to skeletal development or osteoarthritis. We aimed 
to address this hypothesis by the purification of small RNAs from primary 
chondrocytes, followed by the creation of a small RNA sequencing library for next 
generation llumina sequencing to profile the miRNome of osteoarthritic cartilage. Novel 
microRNA candidates would undergo computational and experimental validation, and 
potential targets of a number of microRNAs would be uncovered through the use of a 
whole genome array combined with a computational study, and subsequently validated 
by sub-cloning and luciferase assays. 
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Chapter 2 – Materials and Methods 
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2.1 Cell Lines 
2.1.1 SW1353 
SW1353 cells were obtained from the American Type Culture Collection [ATCC 
(Manassas, VA, USA)] (no. HTB-94). The line originates from a primary grade II 
chondrosarcoma and is a useful model for chondrocyte culture as there are some 
similarities in morphology and behaviour, although the phenotype is not completely 
comparable to primary chondrocytes (Gebauer et al., 2005). Cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) + GlutaMAXTM [Life Technologies 
(Glasgow)] [+10% (v/v) heat inactivated Foetal calf serum (FCS) [PAA Laboratories 
(Somerset)] 100U/ml penicillin, 100µg/ml streptomycin [Gibco (Glasgow)].  
 
2.1.2 DLD-1 
DLD-1 Parental and DLD-1 Dicer null cell lines (kind gifts from Prof. Tamas Dalmay, 
University of East Anglia, Norwich Research Park, Norwich, UK) were developed at 
Horizon Discovery (Cambridge, UK) and originated from a colorectal adenocarcinoma. 
DLD-1 Dicer null is a homozygous knock out of Dicer and is assumed to be 
tumorigenic, produced through the homozygous disruption of the helicase domain in 
exon 5 of Dicer 1 (Cummins et al., 2006). The cell lines are isogenic apart from the 
Dicer expression. Cells were maintained in DMEM F12 + GlutaMAX
TM
 (Life 
Technologies) [+10% inactivated FCS (PAA Laboratories), 40U/ml penicillin, 40μg/ml 
streptomycin (Gibco)].  
 
2.1.3 DF1 
The DF1 cell line (a kind gift from Prof. Andrea Munsterberg, University of East 
Anglia, Norwich Research Park, Norwich, UK). The cell line originated from chicken 
embryo and is a spontaneously transformed fibroblast cell type (Foster and Foster, 
1997). Cells were maintained in DMEM + GlutaMAX
TM
 (Life Technologies) [+10% 
(v/v) heat inactivated FCS (PAA Laboratories) 100U/ml penicillin, 100µg/ml 
streptomycin (Gibco)].  
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2.2 Human Tissue Panel RNA 
RNA for 20 different human tissues (10µg RNA per tissue from a pool of 3 patients) 
was obtained from FirstChoice
®
 Human Total RNA Survey Panel [Applied Biosystems 
(Glasgow)]. 
 
2.3 Tissue Samples 
Femoral head and knee cartilage were obtained from clinically diagnosed end stage 
osteoarthritic [HOA (Hip OA), KOA (Knee OA)] and trauma [NOF (Neck of femur)] 
patients undergoing total joint replacement surgery at the Norfolk and Norwich 
University Hospital in collaboration with Prof. Simon Donell (Consultant Orthopaedic 
Surgeon and Honorary Professor, University of East Anglia, UK). OA was diagnosed 
using clinical history and examination in addition to X-ray analysis.  Fracture patients 
had no known history of joint disease and their cartilage was free of lesions at the time 
of removal. All subjects gave informed consent, and the study was performed with 
ethical approval. Tissue obtained for use in next generation sequencing included one 
female and two males of an age range of 56 – 71 years. Tissue obtained for use in the 
whole genome microarray included two females and one male of an age range of 61 – 
81 years. 
 
2.4 Human Cartilage Dissection 
Cartilage from KOA showing degeneration was removed from the entire surface of both 
tibial plateaus and femoral condyles including medial and lateral compartments. In the 
case of hip tissue, cartilage from HOA showing degeneration was removed from the 
entire surface of the femoral head of the hip and all tissue was removed from the 
femoral head of NOF. However any areas containing lesions observed on tissue 
designated NOF were not used. 
 
Cartilage samples were removed from the joint using a sterile scalpel and washed in 
sterile phosphate buffered saline (PBS) solution (Life Technologies) containing 
100U/ml penicillin, 100µg/ml streptomycin (Gibco) and cut into 2-5mm pieces. These 
sections were either snap frozen in liquid nitrogen-cooled n-hexane [Sigma-Aldrich 
(Dorset)] or processed to isolate primary chondrocytes (see section 2.5). 
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2.5 Primary Chondrocyte Isolation 
Dissected cartilage sections were incubated at 37°C shaken at 180rpm ~18 hours in 
filter sterilised digestion media: [0.1% (w/v) collagenase type 1A (Sigma-Aldrich) and 
0.4% (w/v) Hepes (Sigma-Aldrich) in DMEM + GlutaMAX
TM
 (Life Technologies) 
containing 100U/ml penicillin, 100µg/ml streptomycin (Gibco) and 2.5µg/ml Fungizone 
(amphotericin B, Gibco) at 5ml/g of cartilage. The digestion mixture was filtered 
through 70μm nylon cell strainers (BD Falcon) and centrifuged at 180g for 5 minutes 
and the supernatant discarded.  The cell pellet was washed in 5ml DMEM + 
GlutaMAX
TM
 (Life Technologies) containing 100U/ml penicillin, 100µg/ml 
streptomycin (Gibco) and 2.5µg/ml Fungizone (amphotericin B, Gibco) and centrifuged 
at 180g for 5 minutes. The cell pellet was re-suspended in DMEM + GlutaMAX
TM
 (Life 
Technologies) [+10% (v/v) heat inactivated FCS (PAA Laboratories) 100U/ml 
penicillin, 100µg/ml streptomycin (Gibco)]. Cells were seeded at 4x10
4 
cells/cm
2
 and 
incubated at 37°C, 5% CO2 and allowed to adhere for ~8 days. The media was changed 
following adherence, and at 80-90% confluency, cells were either frozen and stored in 
liquid nitrogen, or utilised in in vitro assays up to passage 1. Images of isolated and 
cultured primary chondrocytes for 6 days post digestion are shown in figure 2.1. 
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Figure 2.1 Images of primary chondrocyte isolation. Cells obtained from digestion of 
osteoarthritic knee cartilage, and cultured in monolayer. Images show cell adherence, 
and growth from day 1 to 6 post digest. At confluency seen at day 6 (>80%) cells are 
frozen and stored in liquid nitrogen. 
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2.6 Cell Culture 
Primary human chondrocytes, SW1353 and DF1 cells were cultured in DMEM + 
GlutaMAX
TM
 (Life Technologies) [+10% (v/v) heat inactivated FCS (PAA 
Laboratories) 100U/ml penicillin, 100µg/ml streptomycin (Gibco)]. DLD-1 parental and 
Dicer null lines were cultured in DMEM F12 + GlutaMAX
TM
 (Life Technologies) 
[+10% inactivated FCS (FCS) (PAA Laboratories), 40U/ml penicillin, 40μg/ml 
streptomycin (Gibco)]. Culturing conditions consisted of 37°C in 5% (v/v) CO2. Cells 
were passaged using 0.25% (w/v) trypsin-1mM EDTA (Life Technologies). Cells were 
frozen for storage by the following: trypsinisation, centrifugation at 180g for 5 minutes, 
resuspension in 90% (v/v) FCS, 10% (v/v) DMSO) and incubation in a cell freezing 
chamber (VWR) at -80°C overnight. Cells were stored long term in a liquid nitrogen dry 
store. 
 
2.7 RNA Extraction 
2.7.1 RNA Extraction From Frozen Cartilage – Using mirVanaTM miRNA 
Isolation Kit [Ambion (Glasgow)] 
All materials were RNase free. Snap frozen cartilage was crushed under liquid nitrogen 
into powder using a BioPulverizer (Biospec).  1.25ml Trizol (Life Technologies) was 
added to 50mg ground cartilage and vortexed for 30 seconds 4°C.  1/5 volume Trizol 
(Life Technologies) of chloroform (Fisher Scientific) was added, vortexed for 15 
seconds and centrifuged at full speed for 10 minutes at 4°C.  The aqueous phase was 
recovered and 1.25 x the aqueous volume of 100% (v/v) ethanol (Sigma-Aldrich) was 
added.  The MirVana
TM
 method continued from this point as per manufacturer’s 
instructions with the following exceptions: at the elution stage, 50µl elution solution 
was put through the column twice. RNA was quantified using Nanodrop 2000 [Thermo 
Scientific (Loughborough)] and stored at -80°C. 
 
2.7.2 RNA Extraction From Monolayer Cells – Using mirVanaTM miRNA Isolation 
Kit (Ambion) 
The protocol was carried out according to manufacturer’s instructions with the 
following exceptions: at the elution stage, 50µl elution solution was run through the 
column twice. RNA was quantified using Nanodrop 2000 (Thermo Scientific) and 
stored at -80°C. 
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2.7.3 RNA Extraction From Post Digest Phase Of Primary Cell Isolation – Using 
mirVana
TM
 miRNA Isolation Kit (Ambion) 
A minimum of 3x10
6 
cells were obtained from digestion media during primary 
chondrocyte isolation (see section 2.5). Cells were centrifuged at 180g for 5 minutes 
RT, and washed with Hank’s balanced salt solution (HBSS) (Life Technologies) before 
continuation of the mirVana
TM
 isolation method as per manufacturer’s instructions with 
the following exceptions: at the elution stage, 50µl elution solution was run through the 
column twice. RNA was quantified using Nanodrop 2000 (Thermo Scientific) and 
stored at -80°C. 
 
2.7.4 RNA Enrichment For Small RNAs From Total RNA– Using mirVanaTM 
miRNA Isolation Kit (Ambion) 
The protocol to enrich for small RNAs from total RNA sample was carried out 
according to manufacturer’s instructions with the following exceptions: at the elution 
stage, 50µl elution solution was run through the column twice. RNA was quantified 
using Nanodrop 2000 (Thermo Scientific) and stored at -80°C. 
 
2.8 Ethanol RNA Precipitation 
To improve RNA quality, to each RNA sample, 1/10 volume 3M sodium acetate pH4.5 
(Fisher Scientific) and 2.5x volume 100% (v/v) ethanol (Sigma-Aldrich) was added. 
Sample was then incubated at -80°C overnight before being centrifuged at 4°C for 15 
minutes at full speed to recover the RNA. Supernatant was discarded and 500μl ice cold 
75% ethanol (v/v) (Sigma-Aldrich) added, the sample was centrifuged again at 4°C for 
15 minutes at full speed. The supernatant was discarded and the pellet air dried and re-
suspended in a smaller volume of sterile water than the original sample. 
 
2.9 cDNA Synthesis 
2.9.1 cDNA Synthesis – Cells-to-cDNA II With MMLV 
Cells in a 96 well plate [Fisher Scientific (Loughborough)] format were washed twice 
using room temperature PBS, and 30µl ‘Cells-to-cDNA’ Lysis buffer (Ambion) was 
added.  The lysate was transferred to a 96-well PCR plate (Applied Biosystems) and 
incubated at 75°C for 15 minutes.  2U DNase I (Ambion) and 10x DNase I buffer 
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(Ambion) were added to each well and incubated at 37°C for 15 minutes followed by 
75°C for 5 minutes.  8µl from each well were transferred to a new PCR plate where 
2.5mM dNTPs [Bioline (London)] and 200ng random hexamers [Invitrogen (Glasgow)] 
were added to each well and incubated at 70°C for 5 minutes.  The samples were chilled 
on ice before 4μl 5x RT buffer (Invitrogen), 2µl DTT (0.1M) (Invitrogen), 100U 
MMLV reverse transcriptase (Invitrogen), and 20U RNasin ribonuclease inhibitor 
(Promega) were added to each well up to a total volume of 20μl in analytical grade H2O 
(Sigma-Aldrich). Samples incubated at 37°C for 50 minutes then 75°C for 15 minutes.  
To each well, 30µl analytical grade H20 (Sigma-Aldrich) was added and cDNA stored 
at -20°C. 
 
2.9.2 cDNA Synthesis - Reverse Transcription 
400ng of random hexamers (Invitrogen), or specific microRNA RT primers [ABI 
(Glasgow)], were added to up to 1μg RNA (see sections 2.7) and incubated at 70°C for 
10 minutes in a 11μl reaction.  4µl 5x RT buffer (Invitrogen), 2µl DTT (0.1M) 
(Invitrogen), 2.5mM dNTPs (Bioline), 200U Superscript (Invitrogen) and 40U RNase 
inhibitor [Promega (Southampton)] were added per reaction to a total of 20μl and 
incubated at 42°C for 1 hour, then at 70°C for 10 minutes.  The cDNA was stored at -
20°C. 
 
2.9.3 cDNA Synthesis - miRCURY LNA
TM
 Universal RT MicroRNA PCR 
Universal cDNA Synthesis Kit [Exiqon (Copenhagen)] 
The protocol followed the manufacturer’s instructions with the following exceptions: 
half volumes of all reagents were used with the same concentration of total RNA 
extracted using mirVana
TM
 miRNA Isolation Kit (Ambion) (see section 2.7). 
 
2.10 Quantitative Real Time PCR (qRT-PCR) 
2.10.1 qRT-PCR With Primers And Probes 
Primers and probes for MMP1 and MMP13 were designed as described in (Nuttall et al., 
2003). Primer and probe sets for microRNA-140, microRNA-455, 18S and ACAN were 
designed by ABI. SNORA36A primers were designed by Exiqon. All other primers 
were designed using the Universal Probe Library Assay Design Center by Roche 
Applied Science and used with probes from the Universal Probe Library [Roche 
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Applied Science (West Sussex)]. Primer and probe sequences are documented in 
Appendix 1. 
 
All genes were normalised to the 18S RNA housekeeping gene to ensure there were no 
differences in mRNA concentration between samples. Any samples with 18S RNA Ct 
levels over 1.5 Ct from the median were excluded from subsequent analysis. Ct is the 
threshold cycle during a PCR run where the signal is statistically significantly above 
baseline and therefore detectable. 18S has previously been established in our lab as the 
optimal housekeeping gene (out of a number of potential normalising genes tested) 
when using cartilage samples and chondrocyte cell lines. 
 
Standard curves were prepared for each gene and microRNA to account for 
primer/probe set efficiency. 18S RNA cDNA standards were diluted: 4, 2, 1, 0.5, 0.25, 
0.125ng/10μl. The remaining genes’ standards were diluted: 20, 10, 5, 2.5, 1.25, 
0.625ng/10μl. 
 
PCR was carried out using the Applied Biosystems 7500 Taqman system in MicroAmp 
optical 96-well plates (Applied Biosystems). 18S RNA assays required 1ng cDNA and 
all other genes required 5ng cDNA per reaction. Per reaction, 2x Taqman Universal 
PCR Master Mix (Applied Biosystems), 100nM forward and reverse primers (Sigma-
Aldrich) and 200nM universal probe (Roche) or specific probe (Sigma-Aldrich) were 
added and made up to a total reaction volume of 25µl with analytical grade H2O 
(Sigma-Aldrich). Optical adhesive covers (Applied Biosystems) were used to seal the 
plates.  PCR cycling conditions were; 50°C for 2 minutes, 95°C for 10 minutes and 40 
cycles of [95°C for 15 seconds followed by 60°C for 1 minute] Ramp- rate 1.6°C/s. 
Microsoft Excel was used to analyse the data. 
 
2.10.2 qRT-PCR Using miRCURY LNA
TM
 Universal RT MicroRNA PCR SYBR 
Green Master Mix Universal RT (Exiqon) 
Locked Nucleic Acid (LNA) primers for novel microRNAs were designed using the 
Exiqon web based assay tool (primer sequences not known). LNA primers for miR-140-
3p, miR-140-5p, miR-455-3p, miR-455-5p, and U6 RNA were designed by Exiqon 
(primer sequences not known). All genes were normalised to the U6 RNA housekeeping 
gene to ensure there were no differences in miRNA concentration between samples. 
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Any samples with U6 Ct levels over 1.5 Ct from the median were excluded from 
subsequent analysis. Ct is the threshold cycle during an RT-PCR run where the signal is 
above baseline and therefore detectable. 
 
PCR was carried out as per manufacturer’s instructions using the Applied Biosystems 
7500 Taqman system with MicroAmp optical 96-well plates (Applied Biosystems). 
Optical adhesive covers (Applied Biosystems) were used to seal the plates.  PCR 
cycling conditions were; 50°C for 2 minutes, 95°C for 10 minutes and 40 cycles of 
[95°C for 10 seconds followed by 60°C for 1 minute]. Ramp-rate was 1.6°C/s, followed 
by a melt curve analysis. The cycling conditions for the melt curve analysis were: 95°C 
for 15 seconds, 60°C for 1 minute, 95°C for 30 seconds and finally 60°C for 15 
seconds. Ramp rate was 1.6°C/s. Melt curves ensure specificity of primers is known 
when using SYBR green. Microsoft Excel was used to analyse the data. 
 
2.11 DNA Polyacrylamide Gel Electrophoresis 
qRT-PCR products from miRCURY LNA
TM
 Universal RT microRNA PCR (Exiqon) 
(see section 2.10.2) on RNA isolated from NOF and KOA cartilage, were run on 15% 
(w/v) polyacrylamide gels in 0.5xTBE buffer to resolve small fragments (~21bp).  The 
gel was stained with ethidium bromide (Sigma-Aldrich) and imaged under UV light. 
10bp ladder (Invitrogen) run alongside and microRNA-140-3p was used as a size 
control. 
 
2.12 Northern Blot 
12% (w/v) Polyacrylamide gels were prepared, for one gel: 3.15g urea (Sigma-Aldrich) 
heated with 1.5ml sterile water (Sigma-Aldrich).  2.8125ml (40%) (w/v) acrylamide 
[BIO-RAD (Hertfordshire)] was added followed by 0.75ml 5X TBE and mixed. 75µl 
10% (w/v) ammonium persulfate (Sigma-Aldrich) and 3.75µl TEMED (BIO-RAD) 
were added and the gel poured rapidly and left to set for 30 minutes.  
 
Total RNA extracted using mirVana
TM
 miRNA Isolation Kit (Ambion) (see section 
2.7.2) and RNA enriched for small RNAs (see section 2.7.4) were added to the same 
volume of sample buffer and heated at 70°C for 3 minutes. The wells were syringed and 
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the gel pre-run at 80V for 20 minutes.  The wells were syringed a second time before 
the samples were added and the gel run at 100V for 2 hours. 
The RNA was transferred from the gel to a Hybond-NX membrane [Amersham 
Biosciences (Buckinghamshire)] using a semi-dry transfer apparatus, run at 175V for 35 
minutes. Whatmann filter paper was soaked in cross-linking solution [10ml sterile water 
(Fisher Scientific), 122.5µl 12.5M 1-methylimidazole (Sigma-Aldrich) and 20µl conc. 
hydrochloric acid to pH8, this was combined with 3.73g EDC (1-ethyl-3-
dimethylaminopropyl carbodiimide) (Sigma-Aldrich) and made up to 12ml with sterile 
water]. The Hybond-NX membrane was placed on top of the soaked filter paper. This 
was wrapped in Saran wrap and baked at 60°C for 1-2 hours.  The Hybond-NX 
membrane (Amersham Biosciences) was pre-hybridised for 1-2 hours at 37°C with 
10ml ULTRAhyb-oligo buffer (Life Technologies).  Simultaneously, the probe solution 
[1µl 10µM oligonucleotide (Sigma-Aldrich) without 5’ phosphate, 4µl 5x forward 
buffer (Invitrogen), 12µl sterile water (Fisher Scientific), 2µl ATP [γ-32P] 
(3000Ci/mmol) [Perkin Elmer (Cambridgeshire)], 10U T4 polynucleotide kinase 
(Invitrogen] for hybridisation was incubated at 37°C for 1 hour.  The probe solution was 
added to the Hybond-NX membrane (Amersham Biosciences) and the membrane was 
incubated in a hybridisation oven at 37°C for ~16 hours. The membrane was washed for 
3x 20 minutes at 37°C using wash buffer (0.2x SSC; 0.1% (w/v) SDS). The final wash 
was poured away and the membrane wrapped in Saran wrap and placed in a cassette 
RNA side up with Fujifilm plate on top at 4°C to develop for 5 days. 
 
The film was imaged on a Molecular Imager (BIO-RAD) using imaging software 
Quantity One. Membranes were stripped with boiling SSC (0.1% (w/v) SDS/5mM 
EDTA) and stored at -20°C. Oligonucleotide sequences are documented in Appendix 2. 
 
2.13 LDH Cytotoxicity Assay (Promega) 
This assay was carried out as per manufacturer’s instructions for ‘CytoTox96 Non-
Radioactive Cytotoxicity assay’ (Promega). 
2.14 Deep Sequencing Of MicroRNAs 
Total RNA was extracted from primary chondrocyte cells taken immediately after 
digestion from osteoarthritic human knee cartilage from three patients using mirVana
TM
 
miRNA Isolation Kit (Ambion) (see section 2.7.3). Small RNAs were enriched from 
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10µg total RNA using mirVana
TM
 miRNA Isolation Kit (Ambion) (see section 2.7.4). 
The small RNA library was prepared using Illumina Small RNA V1.5 Sample 
Preparation Guide, however the sRNA adaptors were substituted with High Definition 
(HD) adapters (Sorefan et al., 2012). 
 
200ng RNA enriched for small RNA was ligated to adenylated 3’ HD adapter with 
truncated T4 RNA ligase 2 [New England Biolabs (Hertfordshire)]. The ligated 
fragment was then ligated to 5’ HD adapter using T4 RNA ligase 1 (New England 
Biolabs). The ligated fragment was reverse transcribed as per protocol and size 
fractionated on an 8% (w/v) PAGE gel. A band corresponding to 100bp was gel purified 
and analysed on an Illumina Genome Analyzer IIX with 50nt read length [Baseclear 
(Netherlands)].   
 
2.15 MicroRNA siRNA Transfection 
Primary osteoarthritic cells isolated from KOA cartilage tissue (see section 2.5) were 
plated at 2.5x10
5
 per well of a 6 well tissue culture plate (Fisher Scientific) and 
incubated overnight at 37°C 5% (v/v) CO2
 
in DMEM + GlutaMAX
TM
 (Life 
Technologies) [+10% (v/v) heat inactivated FCS (PAA Laboratories),  100U/ml 
penicillin, 100µg/ml streptomycin (Gibco)]. Two hours before treatment, the media was 
replaced with DMEM + GlutaMAX
TM
 (Life Technologies) [+10% (v/v) heat inactivated 
FCS (PAA Laboratories)]. 
 
Cells were transfected in serum-free and antibiotic-free DMEM + GlutaMAX
TM
 (Life 
Technologies) [using Lipofectamine 2000 (Invitrogen)] with novel microRNA mimics 
at 30nM (Qiagen), novel microRNA inhibitors at 50nM (Qiagen), or non-targeting 
controls [All Stars negative control at 30nM (Qiagen), miScript Inhibitor negative 
control at 50nM (Qiagen)]. Non-targeting siRNAs and mock transfections were used as 
further controls. 
   
Cells were incubated for 6 hours at 37°C 5% (v/v) CO2 in serum-free and antibiotic-free 
DMEM + GlutaMAX
TM
 media (Life Technologies). The media was then replaced with 
DMEM + GlutaMAX
TM
 (Life Technologies) [+10% (v/v) heat inactivated FCS (PAA 
Laboratories) 100U/ml penicillin, 100µg/ml streptomycin (Gibco)] and transfected cells 
were incubated for 48 hours at 37°C 5% (v/v) CO2. 
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RNA was extracted using the mirVana
TM
 miRNA Isolation Kit (Ambion) (see section 
2.7.2). Gene and microRNA expression analysis was carried out using quantitative real 
time PCR (see sections 2.10.1 and 2.10.2). 
 
2.16 Functional Analysis of Novels 2, 7 and 11 – Whole-Genome 
Expression Using Bead Arrays Microarray (Source Bioscience) 
Primary chondrocyte cells isolated from KOA patients (see section 2.5) were seeded at 
passage 1 at 2.5x10
5
 per well of a 6 well tissue culture plate (Fisher Scientific) and 
incubated overnight at 37°C 5% (v/v) CO2
 
in DMEM + GlutaMAX
TM
 (Life 
Technologies) [+10% (v/v) heat inactivated FCS (PAA Laboratories), 100U/ml 
penicillin, 100µg/ml streptomycin (Gibco)]. Cells were transfected with siRNA mimics 
and inhibitors for novel microRNAs 2, 7 and 11 (see section 2.15). 
 
RNA was extracted using the mirVana
TM
 miRNA Isolation Kit (see section 2.7.2) and 
quantified with Nanodrop 2000 (Thermo Scientific). RNA samples were subsequently 
cleaned using an ethanol precipitation (see section 2.8), and analysed on the Experion
TM
 
system (BIO-RAD) with Experion RNA StdSens Analysis Kit (BIO-RAD) for RNA 
quality. 1μg of each transfected RNA sample with an RQI of over 7 were sent to Source 
Bioscience (Nottingham) for an Illumina Human HT12v4 whole genome microarray. 
 
2.17 De-differentiation Assay of Human Articular Osteoarthritic Knee 
Primary Chondrocytes 
For this assay, RNA was extracted from 6 stages of primary chondrocytes from the 
same patient (see section 2.7). RNA was firstly extracted from KOA Cartilage, and 
KOA post digest cells. Cells digested from cartilage were then seeded at 4x10
4 
cells/cm
2
 
into 2x 25cm
2
 tissue culture flasks (Fisher Scientific) in DMEM + GlutaMAX
TM
 (Life 
Technologies) [+10% (v/v) heat inactivated FCS (PAA Laboratories)  100U/ml 
penicillin, 100µg/ml streptomycin (Gibco)], incubated at 37°C, 5% (v/v) CO2 and 
allowed to adhere for ~8 days. This stage was labelled as passage 0 (P0). At ~80-90% 
confluency the cells from one flask were lysed and underwent RNA extraction (see 
section 2.7.2). The cells within the second flask were washed in HBSS (Life 
Technologies) and passaged with 0.25% (w/v) trypsin-1mM EDTA (Life 
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Technologies). Trypsinised cells were seeded at a 1/5 concentration into 2x 25cm
2
 
tissue culture flasks (Fisher Scientific) and labelled passage 1 (P1). This RNA 
extraction and passage stage was repeated until RNA from each stage P0 to P3 was 
obtained. RNA from each stage underwent reverse transcription (see sections 2.9.2 and 
2.9.3) and qRT-PCR analysis (see sections 2.10.1 and 2.10.2). 
 
2.18 In situ Hybridisation 
2.18.1 Mouse Tissue In Situ Hybridisation Preparation 
Strain C57BL/6 mouse embryos were obtained at stages E11.5, limbs at stage E14.5. 
Tissue was fixed with 4% (v/v) Paraformaldehyde (PFA) (Sigma-Aldrich) in PBS and 
dehydrated with increasing MeOH (Fisher Scientific) concentration washes from 25% 
to 100% made up in PBST [PBS with 0.1% (v/v) Tween 20 (Sigma-Aldrich)]. Samples 
were stored at -20°C. 
 
2.18.2 In Situ Hybridisation Of Novel MicroRNA In Mouse Embryo 
Tissue was rehydrated with decreasing MeOH (Fisher Scientific) concentration washes 
from 100% (v/v) to 25% (v/v) made up in PBST. Proteinase K (Sigma-Aldrich) at 
10μg/ml was used to digest the tissue for 30 mins followed by 2 PBST washes. Tissue 
was fixed in 4% (v/v) PFA (Sigma-Aldrich) for 20 minutes and a needle was used to 
prick the necks of whole embryos.  
 
A pre-hybridisation stage was carried out at 57°C for 2.5 hours in hybridisation buffer 
consisting of 50% (v/v) formamide (Sigma-Aldrich), 5xSSC, 0.1% (v/v) Tween 20 
(Sigma-Aldrich), 10mM citric acid pH6 (Sigma-Aldrich), 50μg/ml heparin (Sigma-
Aldrich) and 100μg/ml tRNA (Sigma-Aldrich) made up in PBS. The prehybridisation 
buffer was replaced with fresh buffer and 20pmol Novel 11 LNA insitu hybridisation 
probe (Exiqon) and the tissue was incubated overnight at 57°C.  
 
The hybridisation buffer was removed and the tissue washed at 57°C with a second 
hybridisation buffer containing 50% (v/v) formamide (Sigma-Aldrich), 5xSSC, 0.1% 
(v/v) Tween 20 (Sigma-Aldrich) and 10mM citric acid pH6 (Sigma-Aldrich). This was 
followed by washes in decreasing concentrations (75% - 25%) of hybridisation buffer in 
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2xSSC at 57°C, and then decreasing concentrations (75% - 25%) of 0.2xSSC in PBST 
at room temperature. 
 
The tissue was washed in blocking solution [2% (v/v) Normal goat serum (Sigma-
Aldrich), 2mg/ml BSA (Sigma-Aldrich), 0.1% (v/v) Triton X-100 (Sigma-Aldrich) and 
0.05% (v/v) Tween 20 (Sigma-Aldrich) made up in PBS] for a minimum of 2.5 hours at 
room temperature. The tissue was subsequently incubated overnight at 4°C with Anti-
Digoxigenin-AP Fab fragments antibody [Roche (West Sussex)] at a final dilution of 
1:5000 in fresh blocking solution. 
 
Over the next 2-3 days, multiple 2 hour washes in room temperature PBST were carried 
out to remove excess antibody. This was followed by 3-4 days of colour development: 
25-50μl BCIP/NBT liquid substrate system (Sigma-Aldrich) in 3.5ml developing 
solution (100mM Tris-HCl pH9.5, 50mM MgCl2, 100mM NaCl, 0.1% (v/v) Tween 20, 
2mM Levamisole). 
 
To halt the colour reaction, the tissue was washed with 1mM EDTA (Life 
Technologies) pH8 in PBS for 15 minutes at room temperature followed by 3x washes 
with PBST. In order to post-fix the tissue, the samples were incubated in 4% (v/v) PFA 
(Sigma-Aldrich) for 30 mins, washes with PBST to remove the PFA, and then stored at 
4°C in PBST. 
 
2.19 Mouse Hip Avulsion Cartilage Wounding Assay 
Mouse femoral heads were dissected out of 3-5 week old C57BL/6 strain mice (beyond 
5 weeks, the secondary centre of ossification in the hip epiphysis will have completely 
mineralised, and cartilage is unobtainable). The hip joint was disarticulated to expose 
the femoral head and the cartilage surface was twisted off using forceps (Stanton et al., 
2011). The cartilage was washed in sterile PBS (Life Technologies) with 100U/ml 
penicillin, 100µg/ml streptomycin (Gibco). Cartilage samples were incubated in 250μl 
DMEM (Life Technologies) with 100U/ml penicillin, 100µg/ml streptomycin (Gibco)] 
at 37°C 5% (v/v) CO2 in wells of a 96 well tissue culture plate (Fisher Scientific). 
Tissue was harvested into 500μl Trizol (Life Technologies) at the time points: 1, 3, 6, 
12, 24 and 48 hours and stored at -80°C. The 0 hour time-point was collected 
immediately upon removal of cartilage from the mouse and stored in trizol (Life 
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Technologies) at -80°C. RNA was extracted (see section 2.7.1) and gene and microRNA 
expression analysed with qRT-PCR (see sections 2.10.1 and 2.10.2). 
2.20 Sub-Cloning  
2.20.1 Plasmids and gDNA 
PmirGLO Dual-luciferase miRNA Target Expression Vector was purchased from 
Promega. Genomic DNA was used as a template for PCR amplification. The genomic 
DNA was extracted from SW1353 cells. SW1353 cells were harvested in 0.25% (w/v) 
trypsin-1mM EDTA (Life Technologies) and centrifuged at 180g for 5 minutes at room 
temperature. The cell pellet was washed in 200μl PBS (Life Technologies) and re-
suspended in 150μl. 400μl of Lysis buffer [0.1M Tris-HCL (Sigma-Aldrich) pH 7.5, 1% 
(w/v) SDS], was added followed by 10μl proteinase K (20mg/ml) (Sigma-Aldrich) and 
the sample was incubated at 50°C for 2 hours. An volume equal to the sample total of 
phenol: chloroform: isoamyl alcohol (25:24:1) saturated with 10mM Tris, pH8.0, 1mM 
EDTA (Sigma-Aldrich) was added, this was followed by centrifugation at full speed for 
10 minutes. The upper phase was transferred to a fresh centrifugation tube and an equal 
volume of chloroform (Fisher Scientific) was added, this was mixed by vortex and 
centrifuged at full speed for 10 minutes. The upper phase was removed and 2x volume 
of 100% ethanol (v/v) (Sigma-Aldrich) was added, this was centrifuged at full speed for 
10 minutes. The resulting DNA pellet was washed with 2ml 70% ethanol (v/v) (Sigma-
Aldrich) and centrifuged at full speed for 5 minutes. The pellet was dried at room 
temperature for 5 minutes and dissolved in 100μl nuclease free water (Sigma-Aldrich). 
2.20.2 CaCl2 Competent DH5α Cell Preparation 
DH5α bacterial colonies were grown from glycerol stock on LB/AGAR plate. One 
colony was inoculated into 5ml LB broth [1% (w/v) Tryptone (Fisher Scientific), 2% 
(w/v) Yeast Extract (Fisher Scientific) and 0.5% (w/v) Sodium Chloride (Fisher)] and 
incubated overnight at 37°C, 180rpm. 2x1ml of DH5α culture transferred to 2x 1l flasks 
and incubated at 37°C, 180rpm for 2.5 hours until the OD of the culture is between 0.4 
and 0.6 OD600. 
 
The culture was split into 50ml ice cold Falcon tubes (Fisher Scientific) and incubated 
on ice for 20 minutes. This was followed by centrifuging the cultures for 10 minutes at 
1500g, 4°C. The pellet was gently re-suspended in 5ml 0.1M CaCl2 (Fisher Scientific) 
and incubated on ice for 10 minutes before being centrifuged at 1500g, 4°C for 10 
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minutes. The pellet was re-suspended gently in 1ml ice cold 0.1M CaCl2 (Fisher 
Scientific) and incubated on ice for 1 hour. 400μl glycerol (Fisher Scientific) was added 
to 1ml DH5α and snap frozen in liquid nitrogen and stored at -80°C. 
2.20.3 Polymerase Chain Reaction 
AccuTaq LA 10x Buffer (Sigma-Aldrich), 5mM dNTPs (Bioline), 400pmol forward 
and reverse primers (Sigma-Aldrich), 100ng gDNA, 1μl DMSO (Sigma-Aldrich), 37µl 
sterile water (Fisher Scientific) and 5U AccuTaq
TM
 LA DNA Polymerase (Sigma-
Aldrich) were mixed on ice and cycled through the following cycling conditions: 1) 
95°C: 2mins, 2) 95°C: 1min, 3) 50-60°C: 50sec, 4) 68°C: Extension time, 5) 68°C 
10mins, 6) 4°C: ∞. Primer sequences are documented in Appendix 3. 
 
2.20.4 Mini-Prep – QIAprep Spin Miniprep Kit [Qiagen (Manchester)] 
The protocol was followed as per manufacturer’s instructions. 
 
2.20.5 Mini-Prep – QIAprep Spin Miniprep Kit (Without Filters) (Qiagen) 
1.5ml of bacterial culture was pelleted at full speed in a centrifuge for 1 minute. The 
bacterial pellet was re-suspended in 100μl mini-prep buffer P1 (Qiagen), to this 200μl 
mini-prep buffer P2 (Qiagen) was added and mixed by inversion. This was followed by 
the addition of 150μl mini-prep buffer N3 (Qiagen) and mixed by inversion. The prep 
was centrifuged at full speed in a centrifuge at room temperature for 3 minutes and the 
supernatant was removed to a new tube and 1ml of 100% ethanol (Sigma-Aldrich) was 
added. This was vortexed and centrifuged at full speed for 10 minutes. The supernatant 
was removed and the pellet washed with 70% (v/v) ethanol (Sigma-Aldrich). The pellet 
was allowed to air dry and then re-suspended in 40μl sterile water.  
2.20.6 Gel Purification [Zymoclean (Cambridge)] 
Gel purification of plasmids and cDNA was carried out as per manufacturer’s 
instructions with the following exceptions; a third wash step was added (200μl DNA 
wash buffer), and the sample in the filter was centrifuged for 10 minutes. This was 
followed by a room temperature incubation for 15 minutes and elution with 12μl elution 
buffer. 
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2.20.7 Phenol: Chloroform Purification 
The DNA volume was made up to 200µl with sterile water. 200μl phenol: chloroform: 
isoamyl alcohol (25:24:1) saturated with 10mM Tris, pH8.0, 1mM EDTA  (Sigma-
Aldrich) was added and the sample was vortexed and centrifuged for 10mins at full 
speed at room temperature. The aqueous layer was removed to a fresh 1.5ml 
microcentrifuge tubes, 2.5x aqueous volume of 100% (v/v) ethanol (Sigma-Aldrich) and 
0.1x aqueous volume 3M sodium acetate (pH5.2) were added. The tube was inverted to 
mix and centrifuged for 10mins at full speed. The supernatant was removed and the 
pellet washed with 70% (v/v) ethanol (Sigma-Aldrich) and centrifuged for 1min at full 
speed. The pellet was air dried and re-suspended in 20µl sterile water. 
 
2.20.8 Restriction Digests 
2.20.8.1 Sal1 Digestion Of Plasmid And Inserts 
Plasmids and subcloned cDNA were digested prior to ligation. 5µg plasmid DNA or 
1µg subcloned DNA were mixed with 10x buffer D (Promega), and 20U Sal1 restriction 
enzyme (New England Biolabs) in a total 50µl reaction at 37°C for 1 hour. 
2.20.8.2 Directional Digest 
In order to ensure correct direction of insert in pmirGLO vector, site specific digestions 
were carried out. The reaction consisted of 10U restriction enzyme, 10x restriction 
buffer, 1μg/μl BSA (Promega), and 100ng construct made up to 10μl with sterile water. 
This was incubated at 37°C for 1 hour and then separated on a 1% (w/v) agarose gel to 
assess band size. 
 
2.20.9 Vector De-Phosphorylation 
0.1x volume of 10x Antarctic Phosphatase reaction buffer (Biolabs) and 5U Antarctic 
Phosphatase (Biolabs) were added to Sal1HF (high fidelity) (Biolabs) digested vector 
and incubated for 15 mins at 37°C. 
 
2.20.10 GoTaq (Promega) dATP Extension Of Products 
After the PCR with Accutaq (Sigma-Aldrich), an A-tail extension was carried out upon 
the dsDNA. The reaction mix consisted of 5x clear GoTaq buffer, 1.25U GoTaq DNA 
Polymerase, 2mM dATP and DNA template (see section 2.20.6), made up to 50μl with 
sterile water. This was incubated at 72°C for 15 minutes. 
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2.20.11 Ligation Using pGEM-T Easy Vector System (Promega)  
The protocol was followed as per manufacturer’s instructions. 
 
2.20.12 Transformation of dsDNA in pGEM-T Easy Vector System (Promega)  
2μl ligation reaction (see section 2.20.11) was added to 80μl DH5α competent E.coli 
cells and incubated on ice for 20 minutes before being incubated for 30 seconds at 
42°C. 950μl LB was added and incubated for 2 minutes on ice, followed by a 90 min 
incubation at 37°C in a shaking incubator. 100μl of the transformation was plated onto 
LB agar plates with 100μg/μl AMP, 0.003% (v/v) X-GAL, 0.1mM (v/v) IPTG and 
incubated at 37°C overnight. 
 
2.20.13 Ligation and Transformation Of Inserts With pmirGLO Vector 
Ligations of 3:1 ratio of DNA to plasmid were used. The ligation reaction consisted of 
5x ligase buffer (Invitrogen), 1mmol ATP (Sigma-Aldrich), 2U T4 DNA ligase 
(Invitrogen) were mixed on ice in a 20µl reaction with 100ng digested vector and 
between 25-50ng insert. The ligations were incubated overnight at 14°C. 
  
Half the ligation reaction was added to 50μl DH5α competent E.coli cells and incubated 
on ice for 20 minutes before being incubated for 30 seconds at 42°C. 300μl of LB was 
added and incubated for 2 minutes on ice, followed by a 90 min incubation at 37°C in a 
shaking incubator. Transfections were plated onto LB agar plates with 100μg/μl AMP 
and incubated at 37°C overnight. 
 
2.20.14 Source Bioscience Sequencing 
1μg of each plasmid was sent to Source Bioscience for sequencing using Source 
Bioscience stock primers T7 Reverse. 
 
2.20.15 Transformation of Constructs And Glycerol Stock Production 
100ng pmirGLO plasmid was added to 50μl DH5α competent E.coli cells and incubated 
on ice for 20 minutes before being heat shocked for 30 seconds at 42°C and finally 
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incubated on ice for 2 minutes. The transformation was plated onto LB agar plates with 
100μg/μl AMP and incubated at 37°C overnight.  
 
One colony was grown overnight in 5ml LB media with 100μg/μl AMP at 37°C, 
180rpm. 500μl of culture was mixed with 500μl sterile glycerol (Fisher Scientific) and 
stored at -80°C. 
2.21 Transfection Of Cloned Constructs Into DF1 Cells 
DF1 cells were plated onto a 96 well plate (Fisher Scientific) at a density of 
3.75x10
4
/cm
2 
in DMEM + GlutaMAX
TM
 (Life Technologies) [+10% (v/v) heat 
inactivated FCS (PAA Laboratories)] and incubated overnight at 37°C, 5% (v/v) CO2. 
The first transfection treatments were prepared, treatment one: containing (per well) 
100ng of cloned DNA construct (in pmir-GLO) with 50nM of either microRNA mimic 
(Qiagen), inhibitor (Qiagen), non-targeting control [All Stars negative control (Qiagen), 
miScript Inhibitor negative control (Qiagen)] or a mock treatment and made up to 25μl 
with DMEM + GlutaMAX
TM 
(Life technologies). Non-targeting siRNAs and mock 
treatments were used as negative controls. This treatment was incubated at room 
temperature for 5 mins. 
 
The second transfection preparation; Lipofectamine 2000 (Invitrogen) made up to 25μl 
with DMEM + GlutaMAX
TM 
(Life Technologies) was incubated at room temperature 
for 5 mins (per well). 
 
25μl of the Lipofectamine 2000 preparation was added to each siRNA and mock 
preparation (per well) and incubated at room temperature for 20 minutes. The final 
treatment was added to the cells in a final volume of 100μl per well and incubated for 
24 hours at 37°C, 5% (v/v) CO2. 6 hours after transfection, culture media was replaced 
with DMEM + GlutaMAX
TM
 (Life Technologies) [+10% (v/v) heat inactivated FCS 
(PAA Laboratories)]. 
 
2.22 Luciferase Assay – Dual Luciferase Reporter Assay System 
(Promega) 
DF1 cells transfected with pmirGLO constructs (see section 2.21) were harvested as 
follows. Media was removed from wells of 96 well tissue culture plate (Fisher 
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Scientific), and cells washed with cold sterile PBS solution (Life Technologies). All 
liquid was subsequently removed before 70μl 1x cell lysis buffer (Promega) was added 
per well and left to gently shake for 30 minutes at room temperature. 10μl from each 
well was transferred to an opaque white 96 well plate, 50μl of re-suspended Luciferase 
Assay Substrate (Promega) was added per well and firefly luciferase activity measured 
on a spectrophotometer [EnVision 2103 Multilabel plate reader (Perkin Elmer)] 
(Luminescence 700 setting, 560nm) using Wallac EnVision Manager software. An 
additional 50μl Stop and Glow solution with 2% (v/v) substrate (Promega) was added 
per well and Renilla activity measured. Firefly luciferase relative light units were 
normalised to Renilla relative light units to account for the transfection efficiency. 
 
2.23 Data Analysis, Statistics And Bioinformatics 
2.23.1 Data Analysis Of qRT-PCR – Comparative Ct Method 
In order to compare across all genes and microRNAs profiled with qRT-PCR (see 
section 2.10.1 and 2.10.2), the efficiency of primers and probes were assumed to be 
equal and the data was transformed by log102
-ΔCt
, where:  
ΔCt = target gene Ct – housekeeping gene Ct  
(NB. 18S RNA for mRNA or U6 RNA for microRNA). Primer efficiency was checked 
with standard curve analysis prior to analysis using the comparative Ct method. 
 
2.23.2 Data Analysis Of qRT-PCR – Standard Curve Method 
Relative gene expression was determined with standard curves generated from a 
positive control, to allow for efficiency of the primers and reaction. All genes measured 
were then normalised to 18S RNA Cts for mRNA or U6 RNA Cts for microRNAs. 
Relative quantification (RQ) of expression levels were determined by the following 
steps carried out for each gene and 18S RNA. 
1) RQ=(Ct-slope)/intercept 
2) Transforming to the inverse log10 
3) Normalising of the gene (step 2) to (step 2) for 18S RNA 
 
2.23.3 Statistical Analysis Of qRT-PCR Data 
The statistical methods used in the analysis of data included one-way ANOVA with a 
post hoc Tukey test to compare between more than two samples, using the statistical 
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software package ‘PASW Statistics 18’ (formerly SPSS) and Prism v.5, and the Student 
t-test which compares between two samples, using Prism v.5. 
 
2.23.4 NGS Deep Sequencing Bioinformatics  
The dataset obtained from NGS sequencing (see section 2.14) was initially analysed 
with miRCat online software [microRNA Categoriser - The UEA sRNA toolkit: animal 
version (Moxon et al., 2008)] by biomathematician Dr Helio Pais (School of 
Computing, UEA). 
 
The MiRCat software maps the sequences obtained from the sequencing project to the 
genome of interest (in this case human). It then identifies regions with sRNAs 
containing at least 5 reads. Other criteria taken into account by miRCat are: the 
identified loci must not have more than four non-overlapping sRNAs, each sRNA must 
be 200nt or less away from another sRNA, and at least 90% of the identified sRNAs in 
the locus must have the same orientation. 
 
The second stage carried out by miRCat analysis includes choosing the most abundant 
sRNA read at any locus as the most likely microRNA. It then obtains the sequences 
surrounding the sRNA to analyse with RNAfold to determine the sRNA secondary 
structure (of which the usual microRNA structure is a stable, partially double stranded 
stem-loop, often called a hairpin). 
 
The secondary structure is subsequently trimmed and analysed to determine 1) the 
number of sequential mismatches between the microRNA complementary strands 
(miRNA and miRNA*) of which there must be fewer than 3. 2) The number of paired 
nucleotides between the microRNA complementary strands of which there must be at 
least 17 around the ~25nt of the mature sequences. 3) The length of the hairpin structure 
must be at least 50nt. And 4) At least 50% of the bases within the hairpin structure must 
be paired.  
 
Finally, the hairpin structure with the lowest adjusted minimum free energy is chosen to 
be the most likely precursor miRNA for the aforementioned miRNA candidate. 
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After the initial miRCat analysis of the sequencing dataset, which generated a large 
number of candidate microRNAs, further analysis was carried out to triage the dataset 
down to a manageable number to validate. Potential novel microRNA candidates were 
filtered based on their read number, presence in a DLD-1 cell line NGS dataset and 
fold-change in comparison to NGS dataset for Dicer knock out cell line (both datasets 
obtained by Professor T. Dalmay, UEA Norwich).  In addition, the presence of an exact 
(or near exact) complementary miRNA strand in datasets obtained from miRCat 
(Moxon et al., 2008) were also used as criteria. In addition to triaging for novel 
microRNAs, the entire dataset were periodically run through the online microRNA 
database ‘miRBase’ (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008; Kozomara 
and Griffiths-Jones, 2011) to check for any known microRNAs which may be present. 
 
2.23.5 MicroRNA Target Search Using RStudios 
The computer language R was utilised with open source RStudios (R Core Team, 2013) 
software and the open source package Biostrings_2.28.0.tar.gz (Pages et al.).  
To search for novel microRNA targets in 3’UTRs of the human genome as downloaded 
from Ensembl Biomart.  
 
The R code used for this analysis is as follows:- 
1) Utr3<-readDNAStringSet(“Doc.”) 
2) a<-vcountPattern(“seq”,Utr3) 
3) k<-strsplit(names(utr3),”\\ “) 
4) m=c() 
for(i in k){ 
m=rbind(m,i[1])} 
5) Targets<-cbind(a,m) 
 
Genes determined to have novel microRNA target sites within their 3’UTR were ranked 
based on number and size of target match. 
 
2.23.6 Candidate novel microRNA species conservation analysis 
The candidate sequences novel 2, novel 7 and novel 11 were analysed for their presence 
in the genome of all species characterised using Ensembl (Flicek et al., 2014). Exact 
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sequence matches were labelled in green with all other matches being partial or in 
different genomic locations to the equivalent sequence in humans.  
 
The estimated time of divergence between all species investigated was determined using 
the online software ‘Time Tree: The Timescale of Life’ (Hedges et al., 2006; Kumar 
and Hedges, 2011).  
 
These data were combined into an evolutionary tree of all species containing an exact or 
partial match to the candidate novel microRNAs using Microsoft office PowerPoint. 
 
2.23.7 Bioinformatics For Genome Array 
The dataset received from Source Bioscience for the whole genome microarray (see 
section 2.16) was normalised using RStudios with the Lumi package (R Core Team, 
2013) by Miss Linh Le (School of Biological sciences, UEA). First quality assessment 
was carried out to identify any poor quality arrays by looking for unusual signal 
distributions. This was followed by background correction and normalisation by a 
between-array quantile method. 
Normalised data was analysed to find fold change expression between each microRNA 
siRNA and the corresponding scrambled control. This was combined with the novel 
microRNA computational target search (see section 2.23.5). Potential gene targets were 
ranked based on their fold change expression (potential target expression increased with 
inhibitor and decreased with mimic) and number and size of novel microRNA target 
sites. 
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Chapter 3 – MicroRNA Profiling of Osteoarthritic 
Cartilage 
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3.1 Introduction 
Chapter 1 described the importance of microRNAs in osteoarthritis and cartilage 
development in addition to their vital role in many other pathologies and developmental 
processes. 
Online databases such as miRBase (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 
2008; Kozomara and Griffiths-Jones, 2011) describe the thousands of microRNAs 
which have already been discovered in humans as well as across many other species. 
However, the total population of microRNAs within humans and in any specific tissue 
is still largely unknown. MicroRNA expression and populations have been characterised 
in a number of tissues such as the thymus, testes and placenta (Barad et al., 2004), and 
microRNA arrays have mapped microRNA expression in others such as bone marrow, 
skeletal muscle, brain, breast, lung, spleen, heart, kidneys, liver, ovary and prostate, as 
well as a number of foetal tissues (Liu et al., 2004). The drawback with these studies 
however, is that a limited number of around 300 microRNAs are chosen for the custom 
microarrays. This is only 9.5% of the total number of human microRNAs registered on 
miRBase (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008; Kozomara and 
Griffiths-Jones, 2011) and thus not a thorough analysis of what could potentially be 
present in these tissues. 
To this end, in order to establish the entire microRNA population and relative 
expression of microRNAs within articular cartilage, a deep sequencing project was 
carried out. This does however bring its own problems in that the technology behind 
sequencing is in itself not perfect. Significant bias towards specific nucleotide 
sequences can be seen across existing platforms as described in a paper from Sorefan et 
al. (Sorefan et al., 2012). This is supported by further literature investigating bias 
detection in existing platforms (Hafner et al., 2008; Jayaprakash et al., 2011; Sun et al., 
2011a). 
The apparent strong bias results in a potentially large number of microRNAs being 
overlooked, as the system will detect only certain sequences. This is due to a preference 
of the RNA ligases used in small RNA cloning and library preparation, for certain 
secondary structures. The efficiency of RNA ligases has been shown to be dependent 
upon the secondary structure at the site of ligation (Nandakumar and Shuman, 2004; 
Yin et al., 2003). To support this, Sorefan et al. compared the minimum free energy of 
secondary structures of test small RNA libraries with detection rates from the 
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sequencing results and discovered the sequences with the most stable structures were 
those most commonly detected (Sorefan et al., 2012). 
To measure bias, Sorefan et al. used a synthesised small RNA library composed of 
randomised oligonucleotide substrates where all sequences were of the same known 
concentration and therefore should all be detected at the same rate by the platform. 
When processed through an existing Illumina platform, only 42% of the presumed 
sequences were detected, this suggests that previous microRNA sequencing projects 
may have missed out on a large subset of the population. In addition Sorefan et al. 
discovered that the existing microRNAs reported in miRBase appear to be of a structure 
preferred by the ‘biased’ adapters. 
To address this bias, Sorefan et al. developed modified, ‘High Definition’ (HD), 
degenerate adapters for use in the small RNA library preparation. These consisted of 
four random nucleotides added to the 5’ end and 3’ end of the existing 3’ and 5’ 
adapters respectively. When run through the same platform, they detected 81% of the 
sequences assumed to be present in the synthesised library. This is a substantial 
increase, and whilst there is obviously still some bias in sequence detection it is not as 
extreme as before. It appears that although the bias seen from the RNA ligases towards 
specific small RNA structures may have been resolved, there is still an issue 
surrounding the bias of detection which needs to be studied. Additional research from 
other labs has also investigated the issue of sequence bias in next generation sequencing 
and have proposed similar solutions to increase the detection rate of microRNAs 
(Jayaprakash et al., 2011; Sun et al., 2011a). 
The new HD adapters developed by Sorefan et al. were utilised within the small RNA 
sequencing experiment on the Illumina platform for this project in an attempt to detect 
as many known and potentially novel microRNAs as possible within the still existing 
limitations of the method. The aim was to identify (as far as possible) the microRNA 
population of osteoarthritic cartilage with an aim of furthering the understanding of 
which microRNAs may be involved in the disease pathogenesis and progression, as well 
as chondrogenesis. 
Small RNA was extracted from primary chondrocytes isolated from osteoarthritic knee 
cartilage obtained from total knee replacement surgery, in addition to extraction from 
cartilage tissue and primary chondrocytes grown in monolayer. A small RNA library 
from chondrocytes immediately after digestion from cartilage was created using the 
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Illumina method along with the aforementioned HD adapters. This was subjected to 
deep sequencing and the data were analysed using miRCat software (Moxon et al., 
2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
3.2 Results 
3.2.1 Expression of key microRNAs in primary chondrocytes  
In order to examine the expression of known key microRNAs in cartilage and isolated 
or cultured chondrocytes, both strands of the microRNAs miR-140 and miR-455 were 
measured using qRT-PCR from RNA purified from snap frozen cartilage tissue, 
chondrocytes isolated directly from the digestion media [termed Post Digest (PD)], 
passage 0 chondrocytes (P0) cultured in monolayer and allowed to reach confluency, 
and passage 1, 2 and 3 primary chondrocytes allowed to reach confluency.  This de-
differentiation assay showed a decreasing trend in expression from cartilage tissue to 
passage 3 for miR-140-3p (A), miR-455-3p (C) and miR-455-5p (D). For miR-140-5p 
expression in both cartilage and post digest chondrocytes was statistically significant 
from all other stages with p ≤0.001 (Fig. 3.1). 
 
MiR-455-3p (C) expression in cartilage was significantly different from all other stages 
of chondrocytes apart from Post Digest, with p ≤0.001 between cartilage and cells at 
passage 0, 2 and 3, and a p ≤0.01 between cartilage and cells at passage 1. Chondrocytes 
from Post Digest showed expression significantly different from all subsequent 
passages with p ≤0.001 between PD and passage 3, p ≤0.01 between PD and passage 2 
and p ≤0.05 between PD and passages 0 and 1 (Fig. 3.1). 
 
MiR-455-5p (D) expression in cartilage showed a significant difference between all 
other stages of chondrocytes with p ≤0.01 between cartilage and Post Digest and p 
≤0.001 between cartilage and all subsequent monolayer chondrocyte stages. Expression 
at the Post Digest level showed significance between passages with p ≤0.01 between PD 
and passage 0 and p ≤0.001 between PD and subsequent passages (Fig. 3.1). 
 
In contrast to miR-140-3p, miR-455-3p and miR-455-5p which all showed a decreasing 
trend in expression from cartilage to passage 3, miR-140-5p (B) increases in expression 
from cartilage to the post digest stage before falling again through subsequent passages 
to passage 3 (p<0.001). Expression between PD and all other samples for miR-140-5p 
was significantly different with p ≤0.001. The expression of miR-140-5p in cartilage 
also showed statistical significance compared to monolayer cells with p values of ≤0.01 
between passages 1, 2 and 3 (Fig. 3.1). 
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The expression of seven human collagen genes was also measured across the de-
differentiation assay (Fig. 3.2). COL1A1 (A) showed a statistically significant increase 
in expression from cartilage tissue to passage 3. A significant difference was seen 
between cartilage and passage 3 with p ≤0.01. There was a significant difference of p 
≤0.05 between PD and passage 2, and p ≤0.001 between PD and passage 3. A 
significant value of p ≤0.05 was also seen between passage 0 and passage 3.  
 
The embryonic version of COL2A1 (VA) (B) did not show a specific trend in 
expression with a higher expression level seen at the cartilage as well as the passage 2 
stage compared to all other chondrocyte passages, however none of these changes were 
significantly different. In comparison the adult version of collagen 2A1 (VB) (C) 
showed a strong decrease in expression from cartilage across all the passages. A 
significant difference was seen between cartilage tissue and all passaged chondrocyte 
stages with p ≤0.001 between cartilage and passages 0, p ≤0.001 between cartilage and 
passage 2 and p ≤0.001 between cartilage and passage 3. In addition, a significant 
difference of p ≤0.01 was seen between cartilage and passage 1.  
 
Expression of COL3A1 (D) did not show a trend across de-differentiation with none of 
the changes showing statistical significance.  
 
COL9A1 (E) showed a statistically significant decreasing pattern of expression through 
chondrocyte de-differentiation with p ≤0.001 between cartilage and all cultured 
chondrocytes. Similarly, COL10A1 (F) also had a pattern of decreasing expression from 
cartilage to passage 3, however none of the changes in expression were significantly 
different.  
 
COL11A1 (G), showed a similar expression pattern to COL1A1 with expression 
increasing from cartilage to isolated and cultured chondrocytes up to passage 3. 
Statistics showed a significance between cartilage and passage 3 (p ≤0.05) and the Post 
Digest stage and passage 3 (p ≤0.01).  
 
Finally COL27A1 (H) expression generally decreased through de-differentiation with 
the highest expression level seen in cartilage tissue. None of the changes in expression 
were statistically significantly different. 
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Figure 3.3 shows the expression of MMP1 (A), MMP13 (B) and aggrecan (C) in the de-
differentiation assay. MMP1 showed low expression in cartilage tissue which then 
increased significantly at the post digest stage (p ≤0.01). Expression then steadily 
decreased across the subsequent passages. Significance is seen between cartilage tissue 
and passage 0 (p ≤0.05), post digest with passage 1 (p ≤0.05), between PD and passage 
2 (p ≤0.01), and between PD and passage 3 (p ≤0.001). 
MMP13 (B) shows a similar pattern to MMP1, with expression initially low in cartilage 
tissue and isolated cells before increasing at passage 0 and then decreasing through 
passage 1 to 3. There is a statistically significant difference seen between cartilage and 
passage 0 (p ≤0.001), post digest and passage 0 (p ≤0.05), and finally passage 0 with 
passage 2 (p ≤0.001) and 3 (p ≤0.001). 
Aggrecan (C) expression decreased slightly from cartilage to passage 0 before 
increasing again to passage 3; however there was no statistical significance.  
Morphology changes in the de-differentiation assay were shown in the images from 
(Fig. 3.4). Chondrocytes become more fibroblastic and elongated in shape from passage 
0 to passage 3. 
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Figure 3.1 MicroRNA expression in articular chondrocyte isolation and expansion. 
Expression levels of (A) miR-140-3p, (B) miR-140-5p, (C) miR-455-3p, (D) miR-455-
5p were measured by qRT-PCR from RNA isolated from: osteoarthritic knee cartilage 
tissue, isolated chondrocytes (post digest) and subsequent P0, P1, P2, and P3 passaged 
chondrocytes from monolayer culture. Data were normalised to U6 RNA expression. (* 
= p ≤0.05, ** = p ≤0.01, *** = p ≤0.001. RNA was obtained from 8 patients for 
chondrocytes and 4 patients for tissue. A one way Anova analysis with a post hoc 
Tukey test was used to test for significance). 
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Figure 3.2 Collagen gene expression in articular chondrocyte isolation and 
expansion. Expression levels of (A) COL1A1, (B) COL2A1 VA, (C) COL2A1 VB, (D) 
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COL3A1, (E) COL9A1, (F) COL10A1, (G) COL11A1 and (H) COL27A1 were 
measured by qRT-PCR from RNA isolated from: osteoarthritic knee cartilage tissue, 
isolated chondrocytes (post digest) and subsequent P0, P1, P2, and P3 passaged 
chondrocytes. Data were normalised to 18S RNA expression. (* = p ≤0.05, ** = p 
≤0.01, *** = p ≤0.001. RNA was from 8 patients for chondrocytes and 4 patients for 
tissue. A one way Anova analysis with a post hoc Tukey test was used to test for 
significance). 
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Figure 3.3 Gene expression in articular chondrocyte isolation and expansion. 
Expression levels of (A) MMP1, (B) MMP13, (C) ACAN were measured by qRT-PCR 
from RNA isolated from: osteoarthritic knee cartilage tissue, isolated chondrocytes 
(post digest) and subsequent P0, P1, P2, and P3 passaged chondrocytes. Data were 
normalised to 18S RNA expression. (* = p ≤0.05, ** = p ≤0.01, *** = p ≤0.001. RNA 
was from 8 patients for chondrocytes and 4 patients for tissue. A one way Anova 
analysis with a post hoc Tukey test was used to test for significance). 
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Figure 3.4 Images of primary chondrocytes. Obtained from primary chondrocytes 
isolated from osteoarthritic knee cartilage tissue. Each image represents passages 0, 1, 2, 
and 3 in sequence and shows elongation of chondrocytes at passages 2 and 3 as well as 
slower growth. 
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3.2.2 Profile of existing microRNAs in osteoarthritic primary chondrocytes 
Due to the high level of miR-140-5p (a microRNA heavily implicated in osteoarthritis) 
(Araldi and Schipani, 2010; Swingler et al., 2012; Tardif et al., 2009) expression seen at 
the post digest stage in previous experiments compared to cartilage tissue and cultured 
chondrocytes, and the difficulty with obtaining high enough quality RNA directly from 
cartilage; RNA was extracted from chondrocytes isolated immediately after digestion to 
use with deep sequencing on the Illumina system with the addition of newly developed 
HD adapters (Sorefan et al., 2012). This was carried out with the aim to identify novel 
microRNAs with a potential role in osteoarthritis, in addition to establishing the entirety 
of the human osteoarthritic miRNome. A small RNA library was created following 
‘Illumina Small RNA V1.5 Sample Preparation’ guidelines using RNA from the knee 
cartilage of 3 osteoarthritic individuals. HD adapters (Sorefan et al., 2012) were utilised 
in order to reduce sequence bias and the samples were run on an Illumina Genome 
Analyzer IIX. 
The initial dataset obtained from deep sequencing was analysed using miRCat software 
(Moxon et al., 2008) by bioinformatician Dr H. Pais (School of Computing, UEA). The 
miRCat algorithm maps the sequences obtained from the sequencing project to the 
human genome. It identifies potential microRNAs using a number of criteria. These 
include: the number of reads of the sRNA sequence in a given area, the orientation of 
the sequences, and the nucleotide distance between individual sRNAs. Additional 
identification stages involve choosing the most abundant sRNAs at any one genetic 
locus as candidates as well as calculating the predicted secondary structure to compare 
with typical structures of validated microRNAs. Finally the length of sequence and 
number of mismatches between the complementary strands of the candidate 
microRNAs were taken into account. This resulted in a preliminary list of candidate 
microRNAs which fulfilled the conditions of the miRCat algorithm. 
Known microRNAs within this initial candidate list were confirmed using the online 
database miRBase which lists all published microRNA sequences (Griffiths-Jones, 
2004; Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008; Kozomara and Griffiths-
Jones, 2011). 990 individual known microRNAs were noted in the dataset of which 630 
were present in all three patients, 151 in two patients and 209 in one patient. The most 
highly expressed 100 known microRNAs present in all three patients in terms of read 
number per 10
7 
reads are shown in figure 3.5 (Read counts from each patient per 
microRNA with the top 100 are shown in Appendix 5). The most highly expressed ten 
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known microRNAs by read number are shown in figure 3.6. Ranked from highest read 
count to lowest are miR-140-3p, miR-10b, miR-101, miR-140-5p, miR-26a, let-7b, 
miR-320a, miR-23b, let-7a and miR-23a. The average read count of miR-140-3p 
showed a statistically significant difference from all other microRNAs detected with p ≤ 
0.001.  
The total sequencing space of the sequencing performed was 20 million reads per 
sample. Figure 3.6 shows miR-140-3p (the most highly expressed microRNA in the 
dataset) accounted for 40% of that space with an average total read number of 
8,031,127. In comparison, its complementary strand miR-140-5p, comprised only 2% of 
the total sequencing space (438,388 total reads), and hence in ranking, miR-140-5p was 
4
th
 overall in terms of read number. Figure 3.7 shows the expression (measured by qRT-
PCR) of both strands of microRNA-140 in post digest stage chondrocytes (A) and in 
SW1353 cells in culture (B). There is a statistically significant increase of miR-140-3p 
expression of 5 fold and 2 fold seen in both models respectively (p ≤0.001 and p ≤0.01) 
compared to miR-140-5p. 
Expression of miR-140-3p and miR-140-5p was also measured by northern blot analysis 
in SW1353 RNA and quantified with standard curves (Fig. 3.8). Approximately 2.5 
fmoles of miR-140-3p and less than 1 fmole of miR-140-5p were found in 10μg 
SW1353 RNA. 
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Figure 3.5 Known microRNAs detected from deep sequencing. Average read 
number of most highly expressed 100 known microRNAs shown in read number per 10
7
 
reads were obtained by deep sequencing (analysed with miRCat and miRBase software) 
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of cDNA transcribed from RNA obtained from chondrocytes of 3 patients isolated 
immediately after digestion. 
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Figure 3.6 Ten most highly expressed known microRNAs from deep sequencing. 
Average read number of most highly expressed 10 known microRNAs shown in read 
number per 10
7
 reads were measured by deep sequencing of cDNA transcribed from 
RNA obtained from chondrocytes of 3 patients isolated immediately after digestion. 
(*** = p ≤ 0.001 analyzed by one way Anova with post hoc Tukey test). 
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Figure 3.7 MicroRNA-140 expression in chondrocytes. (A) Expression of both 
strands of miR-140 were measured by qRT-PCR from RNA of chondrocytes isolated 
directly after digestion of cartilage tissue. RNA was obtained from the same samples of 
3 patients used for deep sequencing (B) Expression of both strands of miR-140 were 
obtained by qRT-PCR from RNA isolated from the SW1353 cell line.  Data were 
normalised to U6 RNA expression. (n=3, ** = p ≤0.01, *** = p ≤0.001 analyzed by a 
Student T-test). 
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Figure 3.8 Expression of microRNA-140 on northern blots. Expression of (A) 
miR140-3p and (B) miR140-5p measured by northern blot using 10µg SW1353 total 
RNA. Standard curves were created using DNA oligonucleotide positive controls at 
concentrations of 10 fmole to 1 fmole to quantify the level of microRNA expression 
present in 10µg SW1353 RNA. 
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3.2.3 Candidate novel microRNA discovery in primary osteoarthritic chondrocytes 
The dataset produced from the deep sequencing was analysed by Dr Helio Pais (School 
of Computing, UEA) utilising the MiRCat algorithm to identify candidate microRNA 
sequences, and miRBase V.17 (released in April 2011) database to determine how many 
were already published online on the database. 1621 candidate microRNAs were 
determined to be completely novel by this process. Out of the 1621 sequences, 61 were 
found across all three species (shown in figure 3.9). Average read counts per 10 million 
reads ranged from 328.91 to 0.49. Exact sequences and read counts of the 61 are shown 
in Appendix 4. 
16 candidate microRNAs were chosen to study further. These are shown in table 3.1. 
The novels are labelled 1 to 16 and range in read count from 328.91 to 0.49. Sequence 
length ranges from 18 to 24 nucleotides.  
Triaging from the initial pool of 1621 candidate novel microRNAs to 16 was based on, 
first of all, whether they were present in all three patients, as presence in more than one 
patient increases the chance that the candidate is real. Secondly, the presence of the 
complementary strand of the candidate microRNA within the expression profile was 
also used as a positive selection. Both strands of a microRNA are more commonly 
being found to be expressed and functional as opposed to having just one dominant 
strand. 
Finally, the candidates were cross-referenced with other sequencing projects obtained 
by Professor Tamas Dalmay’s lab (School of Biological Sciences, UEA) to see if they 
appeared in other tissues or cell lines, this would provide support to their microRNA 
status if they were detected elsewhere, and suggest that they were not just artefacts of a 
specific experiment. The two cell lines compared were DLD-1 wild type and DLD-1 
dicer knockdown. In addition to just comparing presence of the sequences between the 
projects, Dicer is an enzyme known to be vital to microRNA synthesis. If the 
candidate’s expression was down-regulated in the Dicer knock down cell line compared 
to the wild type, then this added credibility to the candidacy, suggesting that the 
sequence was processed by the Dicer enzyme. However, this factor was only included 
in combination with the previously mentioned criteria, and a candidate was not 
discarded if it fulfilled the others but did not appear to be Dicer dependent. 
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At the time of writing miRBase has been updated a further 3 times since the initial 
sequencing analysis to V.20, and a number of microRNAs originally considered novel 
have now been described. Within the chosen top 16, 6 can now be found on miRBase. 
Candidate novel 2 is described as hsa-miR-6509-5p (Joyce et al., 2011), candidate novel 
7 is known as hsa-miR-664b-3p (Friedlander et al., 2012), candidate novel 8 is a 
truncated form of hsa-miR-1277-5p (Morin et al., 2008). Candidate novel 10 is 
described as hsa-miR-487a-5p in humans (Fu et al., 2005) and a similar sequence can be 
found as oar-miR-487a-5p in sheep (Caiment et al., 2010). Candidate novel 11, 
although still not annotated in humans can be found in mouse and rat as mmu-miR-
3085-3p and rno-miR-3085 respectively (Chiang et al., 2010; Linsen et al., 2010). 
Finally candidate novel 12 can be found in humans as hsa-miR-539-3p (Sewer et al., 
2005), with marginally altered sequences found in mouse, rat and sheep as mmu-miR-
539-3p, rno-miR-539-3p and oar-miR-539-3p respectively (Caiment et al., 2010; 
Landgraf et al., 2007; Sewer et al., 2005). Additionally, candidate novel 15 was present 
in miRBase V.19 but has since been removed and annotated as a fragment of tRNA. 
Although these microRNAs have now been described on miRBase, none have been 
experimentally validated, with identification coming only from sequencing data or 
bioinformatics analysis. 
The literature identifying candidate novels 8, 10 and 12 as microRNAs were published 
before the version of miRBase used during the initial data analysis; however those 
microRNAs were not identified in the analysis carried out for this project. This could be 
due to an error within the data analysis, or potentially the data from the literature 
referenced was not added to the miRBase database until after V.17 and hence not 
available for inclusion in the initial results. 
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Figure 3.9 Read numbers of candidate novel microRNAs from deep sequencing. 
Average read number of the 61 candidate microRNA sequences (found in all three 
104 
 
patients) shown in read number per 10
7
 reads were measured by deep sequencing 
(analysed with miRCat and miRBase software) of cDNA transcribed from RNA 
obtained from chondrocytes of 3 patients isolated immediately after digestion. 
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Table 3.1 Candiate microRNAs summary. DNA sequences, nucleotide length, patient 
read numbers and average read numbers of the 16 triaged candidate microRNAs taken 
from sequencing data, read number per 10
7 
reads. 
 
 
 
 
 
 
 
 
 
 
 
Novel ID Sequence (5 ’- 3’) No. bases 
Read number per 10,000,000 
KOA15/11 KOA16/11 KOA17/11 Average 
Novel 1 AAGTTTCTCTGAACGTGTAGAGC 23 39.44366915 54.17209332 51.62952183 48.41509476 
Novel 2 ATTAGGTAGTGGCAGTGGAAC 21 0.433446914 0.492473576 0.537807519 0.487909336 
Novel 3 CTGAAGATCTAAAGGTCCCTGGT 23 356.72681 418.1100657 211.8961625 328.9110127 
Novel 4 GGGGGTGTAGCTCAGTGG 18 133.9350964 191.0797473 215.1230076 180.0459504 
Novel 5 TGAATCCAGCGATCCGAGT 19 66.31737781 126.5657089 57.54540453 83.47616376 
Novel 6 TCGAACTTGACTATCTAGAGGA 22 6.93515062 7.387103634 157.0397956 57.12068327 
Novel 7 TTCATTTGCCTCCCAGCCTACA 22 14.30374815 15.75915442 13.44518798 14.50269685 
Novel 8 TATATATATATATGTACGTAT 21 30.34128396 56.63446119 46.25144664 44.40906393 
Novel 9 GATGCCTGGGAGTTGCGATCTG 22 14.73719507 19.20646945 21.51230076 18.48532176 
Novel 10 GTGGTTATCCCTGCTGTGTTCG 22 8.668938275 35.45809744 10.75615038 18.29439537 
Novel 11 TCTGGCTGCTATGGCCCCCTC 21 3.034128396 14.28173369 18.28545565 11.86710591 
Novel 12 ATCATACAAGGACAATTTCTTT 22 2.600681483 14.77420727 1.613422557 6.329437102 
Novel 13 AGCTGGACTGAAGACTATCTGGC 23 1.300340741 3.447315029 2.151230076 2.299628615 
Novel 14 CGCCTGCCCTCTCGGTGTCGGA 22 0.433446914 0.492473576 0.537807519 0.487909336 
Novel 15 GGAGATCCTGGGTTCGAATCCC 22 16.03753581 15.75915442 18.82326317 16.8733178 
Novel 16 GACCCCAGAAAAGGTGTTGGTTGA 24 8.668938275 2.954841454 2.151230076 4.591669935 
106 
 
3.3 Discussion 
Published profiles of microRNA expression have used a variety of tissue sources or 
methods of culturing chondrocytes. These include varying passage numbers, with little 
information on the comparison between microRNAs taken directly from osteoarthritic 
cartilage and isolated chondrocytes grown in culture.  In order to establish the best 
source of RNA for the sequencing experiment and to enable the optimum discovery of 
new microRNAs, we compared the expression of two specific known microRNAs 
(miR-140 and miR-455) in RNA extracted directly from cartilage with that from 
isolated chondrocytes (post digest) and those cultured in monolayer and allowed to 
grow to confluency. We also investigated their expression at three subsequent passages.  
 
The de-differentiation assay (Fig. 3.1) showed significant expression of all four 
microRNAs measured in cartilage and at initial isolation (PD) of primary chondrocytes. 
Interestingly miR-140-5p showed an increase in expression after initial cell extraction 
compared to expression within cartilage tissue, whereas 140-3p, 455-3p and 455-5p 
showed a decreasing trend from cartilage to passage 3. This cartilage specificity is 
supported in the literature (Miyaki et al., 2009; Miyaki et al., 2010; Swingler et al., 
2012). In addition, Hong et al have also shown the activity of a number of microRNAs 
in a de-differentiating chondrocyte assay, and found miR-140 to dramatically decrease 
through chondrocyte passage (Hong and Reddi, 2013). The expression pattern shown by 
miR-140-5p could suggest a potential stress or wounding response of miR-140-5p to the 
digestion conditions which cells undergo to enable isolation from tissue. It has 
previously been shown that some microRNAs can respond to stressful conditions in 
plants such as drought, low temperatures and high salinity (Liu et al., 2008). The same 
group have also discovered stress-related elements in the promoter regions of the 
microRNAs which appeared to respond to stress. Leung et al discuss how microRNAs 
may play a larger role than once thought in a cell’s response to stress, with microRNAs 
thought to be involved in the restoration of cell homeostasis post stress (Leung and 
Sharp, 2010).  
 
Although there is little existing information regarding potential responses of 
microRNAs to wounding conditions in cartilage, there have been investigations into the 
microRNA response to mechanical loading. It has been shown that in tendon fibroblasts 
in adult rats, the expression of a number of microRNAs were shown to significantly 
alter in response to mechanical loading. These included miR-100, miR-378, miR-1, 
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miR-133a, miR-133a*, miR-133b, miR-206, miR-140-5p, let-7a, let-7e, miR-338, 
miR381, and miR743a  (Mendias et al., 2012). Interestingly, although the group 
examined the expression levels of both miR-140-5p and miR-140-3p, only miR-140-5p 
showed a significant decrease in expression when under loading conditions compared to 
sedentary. In contrast, miR-140-3p showed no statistically significant difference 
between the two conditions. This is similar to the results seen in figure 3.1, suggesting 
that miR-140-5p is more responsive to certain stress conditions than its complementary 
strand miR-140-3p. 
 
A number of matrix genes as well as the collagenases MMP1 and MMP13 were 
measured through the stages of the de-differentiation assay. As chondrocytes undergo 
de-differentiation, they change both in morphology and  gene expression pattern as they 
become more fibroblastic over time. (Stokes et al., 2001). Figure 3.4 shows the 
morphological changes of primary chondrocytes during de-differentiation from passage 
0 to 3 in monolayer culture. Over time in monolayer culture, the chondrocytes become 
more elongated and similar in morphology to fibroblasts.  
 
Figure 3.2 shows the expression of several collagen genes during de-differentiation. 
Several collagen genes known to be cartilage specific show an expected decrease in 
expression from cartilage tissue to passage 3. These are COL2A1, COL9A1 and 
COL27A1, this is supported by literature investigating collagen expression in de-
differentiation and re-differentiation (Stokes et al., 2001). These collagens are known to 
be cartilage specific, and so expression decreases as chondrocytes lose their phenotype 
(Boot-Handford et al., 2003; Stokes et al., 2002; Stokes et al., 2001). COL11A1 is also 
thought to be cartilage specific, however Figure 3.2 shows an increasing trend in 
expression for COL11A1 through the assay as chondrocytes begin to lose their 
phenotype. This data contradicts research by Stokes et al who found a decrease in 
COL11A1 through subsequent passages in de-differentiating monolayer chondrocytes 
(Stokes et al., 2001). 
 
Aggrecan, another ECM component, has been shown previously to decrease during de-
differentiation (Stokes et al., 2001), as well as degrading in osteoarthritis (Lark et al., 
1997). But in the current study, aggrecan expression shows no obvious trend. 
Expression decreases slightly from cartilage tissue to passage 0, before increasing up to 
passage 3. However these changes do not show statistical significance. 
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Other collagens known to be expressed by fibroblasts include collagens type I and III 
(Stokes et al., 2001), and these show an increasing expression trend from cartilage to 
passage 3 (Fig. 3.2) as the chondrocytes lose their phenotype and become more 
fibroblastic. This is pattern of expression is supported by the literature (Stokes et al., 
2001). 
 
The expression of collagenases MMP1 and MMP13 are known to be up regulated in 
osteoarthritis (Bluteau et al., 2001). In this study, looking at de-differentiation (Fig. 3.3) 
they appear to have the highest expression at the post digest stage for MMP1 and the 
passage 0 stage for MMP13 before gradually decreasing down the remaining passage 
stages. Expression in RNA extracted directly from cartilage tissue is significantly lower 
for both MMPs compared to isolated and cultured chondrocytes, however only MMP1 
shows a statistical significance between cartilage tissue and isolated (PD) chondrocytes 
(p ≤ 0.01). This is supported by existing literature which also showed that expression of 
both MMPs was up-regulated in vitro compared with in vivo osteoarthritic and normal 
tissue (Bau et al., 2002). 
 
Several attempts were made to get high amounts of good quality RNA from cartilage 
tissue, but this proved difficult (data not shown). The relatively high expression of 
selected known microRNAs seen at the post digest stage combined with the high quality 
of RNA needed for deep sequencing meant that RNA isolated from post digest 
chondrocytes were used for the miRNome profiling. The post digest stage was chosen 
as it was thought that a stage which showed a high level of expression of chondrocyte 
specific microRNAs would be the ideal stage to search for the entire miRNome of the 
tissue, and miR-140-5p is the best characterised microRNA implicated in osteoarthritis 
to date (Miyaki et al., 2009; Miyaki et al., 2010; Swingler et al., 2012). 
 
To identify the miRNome, an Illumina next generation sequencing platform was utilised 
due to the design of the bias-reducing HD adapters for this specific platform (Sorefan et 
al., 2012). The adapters were intended to reduce the RNA ligase bias seen in previous 
editions of the platform.  
We were able to identify a list of 1621 candidate novel microRNA sequences (61 found 
in all three patients) in addition to 990 previously described microRNAs (630 found in 
all three patients). This total number is much larger than any previous study, for 
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example, one deep sequencing study in rat cartilage using the Solexa platform identified 
246 previously identified and 86 novel microRNAs (Sun et al., 2011b). 
The difference in microRNA detection between the three patients suggests a potential 
detection bias still present within the system, or potentially a true detection rate, with 
the differences seen actually due to different osteoarthritic mechanisms between the 
three patients resulting in slightly different miRNome profiles. The idea that 
osteoarthritis can be separated into disease subtypes is gaining more evidence and might 
explain the differential microRNA expression patterns seen between different patients. 
(Davis, 1988; Driban et al., 2010). This has also been explored in terms of mRNA 
profiling of OA disease subtypes, showing for example that primary OA (thought to be 
previously defined as the development of the disease without an obvious mechanistic 
cause) can actually be divided into subsets based on genetic and hormone expression, as 
well as age related factors (Herrero-Beaumont et al., 2009). 
MiRCat software (Moxon et al., 2008) was used to analyse the sequences of small 
RNAs obtained from the deep sequencing to determine whether they fulfilled the 
criteria for microRNAs or not. Factors considered by the algorithm when designating 
microRNA status to a sequence included; location, abundance, secondary structure, the 
number of mismatches between the microRNA and its complementary strand, and 
hairpin length. These sequences were then run through miRBase (Griffiths-Jones et al., 
2006; Griffiths-Jones et al., 2008; Kozomara and Griffiths-Jones, 2011) to check for 
previously discovered microRNAs, and the remaining novel microRNA candidates 
were triaged to a reasonable number for experimental validation. The initial pool of 
1621 novel microRNAs was reduced to 16 based on, first of all, whether they were 
present in all three patients, as presence in more than one patient increases the chance 
that the candidate is real. Secondly, the presence of the complementary strand of the 
candidate microRNA within the expression profile was also used as a positive selection. 
Both strands of microRNAs are more commonly being found to be expressed and 
functional as opposed to having only one dominant strand, although often one strand is 
usually found to be expressed more highly in specific conditions or tissues. 
Finally, the candidates were cross-referenced with other sequencing projects obtained 
by Professor Tamas Dalmay’s lab (School of Biological Sciences, UEA) to see if they 
appeared in other tissues or cell lines, which would provide support to their microRNA 
status if they were detected elsewhere, and suggest that they were not just artefacts of a 
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specific experiment. The two cell lines compared were DLD-1 wild type and DLD-1 
dicer knockdown. In addition to just comparing presence of the sequences between the 
projects, Dicer is an enzyme known to be vital to microRNA synthesis. If the 
candidate’s expression was down-regulated in the Dicer knock down cell line compared 
to the wild type, then this added credibility to the candidacy, suggesting that the 
sequence (like existing validated microRNAs) was processed by the Dicer enzyme. 
However, this factor was only included in combination with the previously mentioned 
criteria, and a candidate was not discarded if it fulfilled the others but did not appear to 
be Dicer dependent. This is due to recent literature showing that not all validated 
microRNAs are Dicer dependent, and that some (for example miR-451) are still 
synthesised without the presence of the enzyme, utilising a redundancy system of Ago 
proteins (Betancur and Tomari, 2012; Cheloufi et al., 2010). 
In addition the three novel candidates with the highest read number across all three 
patients were included (candidate microRNAs 3, 4 and 5), as expression is an important 
factor when considering downstream validation techniques (Appendix 4 shows the 
criteria fulfilled by each of the 61 novel microRNAs to be found across all three 
patients). 
In addition to the large number of microRNAs (both known and potentially novel) 
detected in the osteoarthritic chondrocyte RNA, we also found that the most highly 
expressed microRNA was miR140-3p. Previous literature has always speculated 
miR140-5p to be the mature strand which is most used as the guide strand in cartilage, 
with the miR-140-3p strand as the passenger strand (McAlinden et al., 2013; Shin, 
2008; Swingler et al., 2012). However, other data from rat cartilage (Sun et al., 2011b), 
as well as our own from sequencing in chondrocytes and subsequent validation 
experiments has shown this not to be the case and that in fact miR-140-3p is the 
dominant microRNA guide strand expressed in chondrocytes and osteoarthritis. It is 
also now shown in miRBase (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008; 
Kozomara and Griffiths-Jones, 2011) that miR-140-3p appears to have more reads than 
miR-140-5p across the deep sequencing projects submitted, suggesting it is more often 
the guide strand than miR-140-5p. There is also literature to support the higher 
expression of miR-140-3p over miR-140-5p in cartilage tissue (Kobayashi et al., 2008; 
Pando et al., 2012). 
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This function of miR-140-3p as the dominant strand is also supported by the theory that 
the guide strand of miRNA duplexes usually has the most thermodynamically unstable 
5’ end (Manavella et al., 2012) combined with a stable seed-site duplex (Hibio et al., 
2012) and often begins with a uridine base as it appears to be the base usually (although 
not always) preferred by the RISC complex (Kawamata et al., 2011). MiR-140-3p 
begins with a uridine base whereas miR-140-5p begins with a cytosine at the 5’ end.  
The sequencing experiment showed a 20-fold difference in detection between the two 
miR-140 strands, with miR-140-3p taking up 40% of the total sequencing space 
available compared to the 2% of miR-140-5p. 
qRT-PCR analysis supports the findings of the deep sequencing on miR-140, and shows 
a much higher expression of miR-140-3p than miR-140-5p in primary osteoarthritic 
chondrocytes taken from the post digest phase as well as in cells of the chondrosarcoma 
cell line SW1353  (Fig. 3.7) (showing 4 and 2 fold up-regulations respectively).  
SW1353 cells are a useful model for chondrocyte culture as there are some similarities 
in morphology and behaviour, although the phenotype is not completely comparable to 
primary chondrocytes (Gebauer et al., 2005).  
Northern blots also support this, showing 2.5 fold higher expression of miR-140-3p than 
miR-140-5p (Fig. 3.8). However the difference in expression was not as extreme in 
these methods as in the sequencing. The experimental techniques of northern blotting 
and quantitative RT-PCR used are known to be more reliable quantitatively than deep 
sequencing which is more useful for profiling the many different microRNAs and their 
isoforms rather than determining exact expression values (Baker, 2010). This is shown 
further by an extensive study carried out by Git et al., where a comparison of microarray 
profiling, real-time PCR, and deep sequencing on microRNA detection was carried out 
and found there was a low overlap in microRNA detection between the different 
techniques (Git et al., 2010). This all suggests that there is still some bias within each 
system towards possibly specific structures or sequences of which miR-140-3p may fit 
the profile, supporting the fact that any deep sequencing project must be supported with 
follow up experimental evidence.  
However, this study has shown a large number of microRNAs (both known and 
potentially novel) to form the miRNome of osteoarthritic chondrocytes. This is a 
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substantial increase on previous published works, and the next step is to confirm that 
these candidate novel sequences are true microRNAs. 
Validation is the focus of chapter 4, which will present a combination of experimental 
validation techniques used to validate the candidate novel microRNAs and ascertain if 
they are true microRNAs or if the sequences prove to be either false positives or an 
alternate sRNA molecule. 
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Chapter 4 – Experimental Validation of Novel 
MicroRNAs 
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4.1 Introduction 
Chapter 3 described the experimental methodology employed to profile the miRNome 
of osteoarthritic primary chondrocytes obtained from human articular cartilage and the 
results of a deep sequencing experiment. Aside from the 990 known microRNAs, 1621 
previously undescribed microRNAs were discovered, termed candidate novel 
microRNAs. The next step post-discovery was validation to ensure that the sequences 
determined to be microRNAs by the MiRCat software (Moxon et al., 2008) were true 
microRNAs and not other small RNAs, anomalies or products of degradation which 
happened to fulfil the identification criteria by chance.  
As discussed previously, deep sequencing technology is not infallible, as seen in the 
strong bias observed in existing platforms (Sorefan et al., 2012) and the fact that there 
are substantial differences seen in detection between various platforms and technologies 
(Git et al., 2010). Although part of this bias (associated with RNA ligases) was negated 
with the use of HD adapters for this project, there is still some bias remaining, as shown 
by Sorefan et al (Sorefan et al., 2012) where the number of different sequences detected 
within a known pool was increased from 42 to 81%. Although this is an impressive 
increase, there still appears to be 19% of sequences completely undetected.  
The fact that there is bias remaining is also shown in the results of Chapter 3 by the 
unusually high miR-140-3p read counts (Fig. 3.6) which do not correspond 
quantitatively to experimental validation using northern blots and qRT-PCR (Fig. 3.7 
and 3.8). In addition to bias towards specific structures, false positives are also a 
possibility with some sequences designated as microRNAs by miRCat potentially being 
simply products of degradation which happen to fulfil the criteria imposed by the 
miRCat (Moxon et al., 2008) algorithm. 
Due to the problem of false positives, an important aspect of miRNome profiling is 
experimental validation of these sequences. Experimental validation involves firstly, 
size validation using northern blots to determine the expected microRNA size of ~22nt 
sequence. This is also combined with a functional validation, investigating the candidate 
microRNA’s response to the presence and absence of Dicer (an enzyme vital to 
microRNA synthesis). Finally, expression of the sequences was measured across a 
number of models, including chondrogenesis assays using both human mesenchymal 
stem cells and mouse ATDC5 cells. Expression of the chosen candidates was also 
examined in a de-differentiation assay where primary chondrocyte cells were isolated 
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from human articular cartilage and cultured to passage 3 in monolayer, losing 
chondrocyte phenotype and becoming more fibroblastic.  
In order to establish tissue specificity of the candidates, expression was also measured 
by qRT-PCR across a human tissue panel consisting of over 20 different human tissue 
types including articular cartilage. Expression was measured between osteoarthritic and 
non-diseased cartilage tissue to determine if the novel microRNAs changed in 
expression during disease. In addition to measuring the candidate microRNA expression 
in osteoarthritic tissue, expression changes were also measured in a controlled cartilage 
explant injury model to discover if expression of the microRNAs responded to 
wounding. 
All 16 of the candidate novel microRNAs documented in Chapter 3 (Table 3.1) 
underwent experimental validation, however only three (candidate novel microRNAs 2, 
7 and 11) will be discussed in detail here. The detailed results from the remainder will 
be documented in Appendices 6, 7, 8 and 9. 
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4.2 Results 
4.2.1 Candidate novel microRNA size and function validation  
In order to validate the candidate novel microRNAs, a number of techniques were used. 
Northern blotting is considered to be the gold standard for sizing microRNAs, and the 
northern blots of candidate microRNAs (A) novel 2, (B) novel 7 and (C) novel 11 are 
shown in figure 4.1. Total RNA was obtained from SW1353 cells using the miRVana 
microRNA isolation method. MiR-140-3p and U6 were used as size and loading 
controls respectively (Fig. 3.8 A) and northern blots of the remaining 13 candidates are 
shown in the Appendix 6. 
A band of the correct size (~21bp) is seen for candidate microRNA novel 7 suggesting 
that this candidate is indeed a true microRNA as it fulfils the size requirements.  
No signal was seen for either candidate novel microRNAs 2 and 11. This indicates that 
expression levels may be too low to be detected by this method but they may still 
however be microRNAs. Expression of the candidates was quantified with standard 
curves using DNA oligonucleotides of the complementary sequences; approximately 1 
fmole of novel 7 was seen in 10μg SW1353 total RNA.  
The Dicer enzyme is a vital part of the microRNA synthesis process and is involved in 
the production of the mature microRNA. If Dicer is not present, then the mature 
microRNA does not form. Expression of the candidate microRNAs was measured by 
qRT-PCR in RNA isolated from the wild type DLD-1 cell line in addition to the 
isogenic homozygous knock out of Dicer DLD-1 cell line, immature microRNAs are 
known to accumulate in the Dicer null cells with a reduction of mature microRNAs 
present (Cummins et al., 2006). 
Figure 4.2 shows the expression of candidate microRNAs (A) novel 2, (B) novel 7, and 
(C) novel 11 in each cell line (the expression of the remaining candidates is shown in 
Appendix 7). All three candidate novel microRNAs showed a decrease in expression in 
the Dicer knockout cell line compared to the wild type. The down-regulation was 
statistically significant for both novel 7 and novel 11 with p ≤0.05. The down-regulation 
of novel 2 approaches significance with p = 0.06. 
In order to ensure the phenotype was maintained during the experiment, expression of 
Dicer RNA was also measured in both cell lines (Fig. 4.3 A). Expression decreased 
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significantly with p ≤0.001 in the Dicer knock out line compared to the wild type by 
approximately 2-fold. As a further control, the expression of four known microRNAs 
was also measured in both cell lines to compare their expression pattern with that of the 
candidate novel microRNAs. Four microRNAs significantly decreased in expression in 
Dicer -/- cells compared with wild type, (B) miR-140-3p, (C) miR-140-5p, (D) miR-
455-3p and (E) miR-455-5p. These changes were significantly different for miR-140-3p 
(p ≤0.01), miR-140-5p (p ≤0.001) and miR-455-5p (p ≤0.05) when analysed with a 
Student t-test. 
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Figure 4.1 Assessment of candidate novel microRNA using northern blots. 
Expression of candidate microRNA (A) novel 2, (B) novel 7 and (C) novel 11 was 
measured by northern blot using 10µg SW1353 total RNA. Standard curves were 
created using DNA oligonucleotide positive controls at concentrations of 10 fmole to 1 
fmole to quantify the level of microRNA expression present in 10µg SW1353 total 
RNA. The small RNA U6 was used as a standard reference for the northern blot. 
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Figure 4.2 Candidate novel microRNA expression in DLD-1 parental and DLD-1 
Dicer null cell lines. Expression of candidate microRNA (A) novel 2, (B) novel 7 and 
(C) novel 11 were obtained by qRT-PCR from RNA purified from DLD-1 wild type 
(parental) and DLD-1 Dicer null cell lines. Data were normalised to U6 RNA 
expression. Data shows mean +/- SEM, n = 12. (*, p ≤0.05 analyzed by a Student T 
test). 
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Figure 4.3 Gene and microRNA expression in DLD-1 parental and DLD-1 Dicer 
null cell lines. Expression of (A) Dicer 1, (B) miR-140-3p, (C) miR-140-5p, (D) miR-
455-3p, and (E) miR-455-5p were obtained by qRT-PCR from RNA of DLD-1 wild 
type (parental) and DLD-1 Dicer null cell lines. Data were normalised to U6 RNA 
expression for microRNAs and 18S RNA expression for Dicer 1. Data shows mean +/- 
SEM, n = 12 (*, p ≤0.05, **, p ≤0.01, ***, p ≤0.001 analyzed by a Student t-test). 
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4.2.2 Candidate novel microRNA expression in human tissues 
The deep sequencing project established that the microRNA candidates were detected in 
osteoarthritic knee cartilage. The next step was to validate this using qRT-PCR. In order 
to ensure specific detection, locked-nucleic acid primers (Exiqon) were used. The 
products obtained from qRT-PCR were run on polyacrylamide gels to ensure specificity 
of the LNA primers (data not shown). The product from miR-140-3p was used as a size 
control. Additional minor products were shown in addition to the expected product for 
the primer sets of six of the sixteen candidate microRNAs. Candidate microRNAs novel 
2, novel 7 and novel 11 all showed specific detection with only one product present. 
Expression of the candidate microRNA sequences novel 2, novel 7 and novel 11 were 
measured in cartilage obtained from neck of femur (NOF) fractures, and osteoarthritic 
hip and knee total joint replacements (all remaining candidate microRNAs were 
measured and data are shown in Appendix 8). Known microRNAs miR-140-3p, 140-5p, 
455-3p and 455-5p were also measured to explore the pattern of expression in these 
samples of microRNAs already known to be involved in osteoarthritis (Miyaki et al., 
2009; Swingler et al., 2012). 
Both candidate microRNA novels 2 and 11 [Figure 4.4 (A) and (C)] show a trend of 
increased expression in hip osteoarthritis compared to NOF; however these do not reach 
statistical significance when tested with a student t-test. Candidate microRNA novel 7 
(B) appears to be expressed at equivalent levels between NOF and osteoarthritic hip 
cartilage suggesting it is not regulated in late stage disease.  
Expression of miR-140-3p shows no apparent change between diseased and normal 
tissue [Fig. 4.5 (A)], however (B) miR-140-5p, (C) miR-455-3p and (D) miR-455-5p all 
show an increase in expression in osteoarthritic cartilage. Both strands of miR-455 show 
a statistically significant difference between the two conditions with p ≤0.01. MiR-140-
5p approaches significance with p = 0.0587. 
Figure 4.6 shows expression of a number of marker genes in HOA cartilage and 
cartilage obtained from NOF. A disintegrin and metalloproteinase domain with 
thrombospondin motif 5 (ADMTS5) (A), matrix metalloproteinase 3 (MMP3) (B) and 
aggrecan (ACAN) (D) are increased in NOF cartilage compared with osteoarthritic hip 
cartilage (p ≤0.05, p ≤0.05 and p ≤0.001 respectively). 
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Matrix metalloproteinase 13 (MMP13) (C) shows a trend of increased expression in OA 
compared to NOF but this doesn’t reach significance because of wide inter-patient 
variation. Type II collagen (COL2A1) (E) has an increased expression in osteoarthritic 
cartilage tissue compared to NOF (p ≤0.001).  
Figure 4.7 shows the expression of candidate microRNAs (A) novel 2, (B) novel 7 and 
(C) novel 11 in osteoarthritic cartilage obtained from total knee joint replacement 
(KOA) compared to neck of femur fracture cartilage (NOF). All three showed decreased 
expression in KOA cartilage, with candidate microRNA novel 2 showing a statistically 
significant down-regulation (p ≤0.01).  
The expression of 4 known microRNAs were also measured in KOA and NOF tissue 
(Fig. 4.8) and all showed a decreased expression in KOA cartilage compared to NOF. 
However, only (A) miR-140-3p showed a statistically significant difference (p ≤0.05).  
To assess whether the expression of these candidate novel microRNAs was cartilage 
specific or selective, their expression was measured using qRT-PCR across 23 different 
human tissue types (Fig. 4.9). These were adipose, bladder, brain, cervix, colon, 
oesophagus, heart, kidney, liver, lung, ovary, placenta, prostate, small intestine, skeletal 
muscle, spleen, testes, thymus, thyroid, trachea, osteoarthritic knee cartilage tissue 
(KOA), osteoarthritic hip cartilage (HOA) and neck of femur fracture cartilage (NOF). 
The cartilage tissue was obtained from the Norfolk and Norwich University Hospital 
from 9 patients (3 HOA, 3 NOF and 3 KOA). RNA from all remaining tissues was from 
a pool of 3 patients obtained from Applied Biosystems, the data for expression in all 
tissues other than cartilage shows n= 3 technical replicates. Candidate microRNA novel 
2 (A) showed highest expression values in RNA from cervix and skeletal muscle tissue. 
Candidate microRNA novel 7 (B) appeared to be most highly expressed in cervix and 
skeletal RNA, with expression in cartilage tissue relatively high as well. In contrast, 
Candidate microRNA novel 11 (C) showed the highest expression in cartilage RNA 
compared to all other tissues tested. The expression of the remaining candidate 
microRNAs is shown in Appendix 9. 
Figure 4.10 shows the expression of miR-140-3p (A), miR-140-5p (B), miR-455-3p (C) 
and miR-455-5p (D) across the same 23 human tissues. Both miR-140-3p and miR-140-
5p show highest expression in all the cartilage tissues, supporting the fact that miR-140 
is a cartilage selective microRNA. MiR-455-3p appears to be most highly expressed in 
cervix tissue, with the expression in cartilage being comparable to the remaining tissues. 
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MiR-455-5p on the other hand shows the expression of the microRNA in osteoarthritic 
cartilage tissue (KOA and HOA) to be similar to cervix tissue, with expression in NOF 
and other tissues much lower. 
 
In addition to analyzing the expression of candidate microRNAs in a number of tissues 
to assess their tissue and disease specificity, a cartilage injury assay was carried out 
using mouse hip avulsion (Chong et al., 2013; Stanton et al., 2011). (Fig. 11). The 
cartilage was removed from the hip joints of 3 week old mice and cultured over a period 
of 48 hours. Expression of the three candidate microRNAs; (A) novel 7 and (B) novel 
11 was measured over set time points during the 48 hour period. Candidate microRNA 
novel 2 was not measured as it is not found within the mouse genome. Candidate 
microRNA novel 7 increased in expression from hour 0 to 48. A statistically significant 
difference was seen between 48 hours and all other time points of 0, 1, 3, 6, 12 and 24 
hours (p ≤0.001, p ≤0.001, p ≤0.001, p ≤0.05, p ≤0.001, and p ≤0.05 respectively). 
Candidate microRNA novel 11 appears to show a cyclic expression pattern with peaks 
in expression seen at 3 and 48 hours, however none of these changes reach statistical 
significance. 
 
Figure 4.12 shows the expression of (A) miR-140-3p, (B) miR-140-5p and (C) miR-
455-5p in the hip avulsion assay (the miR-455-3p sequence is not conserved between 
mouse and human and therefore not measured). All three microRNAs showed an 
increase in expression through the time points, peaking at 48 hours, with miR-140-3p 
and miR-140-5p reaching statistical significance.  
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Figure 4.4 Candidate novel microRNA expression in HOA and NOF cartilage 
tissue. Expression levels of candidate microRNAs (A) novel 2, (B) novel 7 and (C) 
novel 11 were obtained by qRT-PCR from RNA isolated from: osteoarthritic hip 
cartilage tissue (HOA) and neck of femur fracture cartilage (NOF). Data were 
normalised to U6 RNA expression. Data shows mean +/- SEM, n = 6 (analyzed by a 
Students T test, no significance was seen).  
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Figure 4.5 MicroRNA expression in HOA and NOF cartilage tissue. Expression 
levels of (A) miR-140-3p, (B) miR-140-5p, (C) miR-455-3p and (D) miR-455-5p were 
obtained by qRT-PCR from RNA isolated from: osteoarthritic hip cartilage tissue 
(HOA) and neck of femur fracture cartilage (NOF). Data were normalised to U6 RNA 
expression. Data shows mean +/- SEM, n = 6 (**, p ≤0.01 analyzed by Student t-test). 
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Figure 4.6 Gene expression in HOA and NOF cartilage tissue. Expression levels of 
(A) ADAMTS5, (B) MMP3, (C) MMP13, (D) ACAN, (E) COL2A1 were obtained by 
qRT-PCR from RNA isolated from: osteoarthritic hip cartilage tissue (HOA) and neck 
of femur fracture cartilage (NOF). Data normalised to 18S RNA expression. Data shows 
mean +/- SEM, n = 6. (*, p ≤0.05, **, p ≤0.01, ***, p ≤0.001 analyzed by Student t-
test). 
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Figure 4.7 Candidate novel microRNA expression in KOA and NOF cartilage 
tissue. Expression levels of candidate microRNAs (A) novel 2, (B) novel 7 and (C) 
novel 11 were obtained by qRT-PCR from RNA isolated from: osteoarthritic knee 
cartilage tissue (KOA) and neck of femur fracture cartilage (NOF). Data were 
normalised to U6 RNA expression. Data shows mean +/- SEM, n = 6. (**, p ≤0.01 
analyzed by Student t-test). 
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Figure 4.8 MicroRNA expression in KOA and NOF cartilage tissue. Expression 
levels of (A) miR-140-3p, (B) miR-140-5p, (C) miR-455-3p and (D) miR-455-5p were 
obtained by qRT-PCR from RNA isolated from: osteoarthritic knee cartilage tissue 
(KOA) and neck of femur fracture cartilage (NOF). Data were normalised to U6 RNA 
expression. Data shows mean +/- SEM, n = 6 (*, p ≤0.05 analyzed by Student t-test). 
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Figure 4.9 Candidate novel microRNA expression across a human tissue panel. 
Expression levels of candidate microRNAs (A) novel 2, (B) novel 7 and (C) novel 11 
were obtained by qRT-PCR from RNA isolated from 23 human tissues including 
adipose, bladder, brain, cervix, colon, oesophagus, heart, kidney, liver, lung, ovary, 
placenta, prostate, small intestine, skeletal muscle, spleen, testes, thymus, thyroid, 
trachea, osteoarthritic knee cartilage tissue (KOA), osteoarthritic hip cartilage (HOA) 
and neck of femur fracture cartilage (NOF). Data were normalised to U6 RNA 
expression. RNA of all cartilage samples was from 3 patients. RNA from all remaining 
tissues was from a pool of 3 patients with n= 3 technical replicates. 
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Figure 4.10 MicroRNA expression across a human tissue panel. Expression levels of 
(A) miR-140-3p, (B) miR-140-5p, (C) miR-455-3p and (D) miR-455-5p were obtained 
by qRT-PCR from RNA isolated from 23 human tissues including adipose, bladder, 
brain, cervix, colon, oesophagus, heart, kidney, liver, lung, ovary, placenta, prostate, 
small intestine, skeletal muscle, spleen, testes, thymus, thyroid, trachea, osteoarthritic 
knee cartilage tissue (KOA), osteoarthritic hip cartilage (HOA) and neck of femur 
fracture cartilage (NOF). Data were normalised to U6 RNA expression. RNA of all 
cartilage samples was from 3 patients. RNA from all remaining tissues was from a pool 
of 3 patients with n= 3 technical replicates. 
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Figure 4.11 Candidate novel microRNA expression in a cartilage injury model. 
Expression levels of candidate (A) novel 7 and (B) novel 11 were obtained by qRT-
PCR from RNA isolated from hip cartilage removed from 3-5 week old mice and 
incubated in culture medium for 48 hours. RNA was isolated at the time points; 0, 1, 3, 
6, 12, 24 and 48 hours. Data shows mean +/- SEM, n = 8. Data were normalised to U6 
RNA expression (*, p ≤0.05, ***, p ≤0.001 analyzed by a one way ANOVA with a post 
hoc Tukey test). 
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Figure 4.12 MicroRNA expression in a cartilage injury model. Expression levels of 
(A) miR-140-3p, (B) miR-140-5p and (C) miR-455-5p were obtained by qRT-PCR 
from RNA isolated from hip cartilage removed from 3 week old mice and incubated in 
culture medium for 48 hours. RNA was isolated at the time points; 0, 1, 3, 6, 12, 24 and 
48 hours. Data shows mean +/- SEM, n = 8. Data were normalised to U6 RNA 
expression (*, p ≤0.05, **, ≤0.01, ***, p ≤0.001 analyzed by a one way ANOVA with a 
post hoc Tukey test). 
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4.2.3 Candidate novel microRNA expression during chondrocyte 
differentiation and de-differentiation 
Further to exploring the expression of candidate microRNAs in a variety of human 
tissues, the expression of candidate microRNAs novel 2, novel 7 and novel 11 were 
measured in a number of differentiation and de-differentiation of chondrocyte assays. 
Figure 4.13 shows a mesenchymal stem cell (MSC) chondrogenesis assay, where MSC 
cells are induced through chondrogenesis with TGFβ3, ITS+L (Insulin-Transferrin-
Selenium + L-ascorbic acid), ascorbic acid and dexamethasone to form chondrocytes, 
resulting in the formation of a cartilage disc at day 14. This assay was conducted by Dr 
M. Barter (Newcastle University, UK). RNA was isolated from the assay at set time 
points, and qRT-PCR was used to measure microRNA expression. Figure 4.13 shows 
candidate microRNA (A) novel 2, (B) novel 7 and (C) novel 11 expression at time 
points 0, 3, 7 and 14 days. Candidate microRNA novel 2 showed an increase in 
expression up to day 7 before decreasing again at day 14.  A statistically significant 
difference was seen between day 0 and day 7 (p ≤0.05) and between day 7 and day 14 
(p ≤0.05). Candidate microRNA novel 7 showed an increase in expression through all 
time points, peaking at day 14, becoming statistically significant, even by day 3 (p 
≤0.05). Finally, candidate microRNA novel 11 expression was at its highest at day 0, 
and subsequently decreased at each time point to day 14, however none of these 
changes were statistically significant. 
The expression of a number of known microRNAs was also measured by Dr M. Barter 
by microarray (data not shown).The data showed that miR-140-3p, miR-140-5p, miR-
455-3p and miR-455-5p increased during chondrogenesis, with the highest expression 
of each seen in the cartilage disc at day 14.  
Figure 4.14 shows the expression of candidate microRNA (A) novel 7 and (B) novel 11 
in an ATDC5 (mouse embryonic carcinoma cell) chondrogenesis assay, where ATDC5 
cells are induced through chondrogenesis by stimulation with insulin, resulting in the 
development of chondrocytes. This assay was conducted by Dr T. Swingler (UEA). 
RNA was isolated from this assay at set time points, and qRT-PCR was used to measure 
microRNA expression. Figure 4.14 shows candidate microRNA (A) novel 7 and (B) 
novel 11 expression at time points 1, 21, and 42 days in both induced and control cells. 
Novel 2 was not measured as the sequence is not present in the mouse genome. The 
expression of candidate microRNA novel 7 increased through time in both control and 
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induced cells, peaking at day 42. Candidate microRNA Novel 11 expression decreased 
over time in both induced and control cells, apart from day 42 where there was a 
considerable decrease in expression in induced cells compared to control. However 
none of these changes were statistically significant. 
The known microRNAs miR-140-3p and miR-140-5p were also measured in the 
ATDC5 assay in figure 4.15 (A) and (B) respectively. The expression of both 
microRNAs is relatively low at all 3 time points in both induced and control cells except 
for induced cells at day 42. At this point there is a significant increase in expression 
with p ≤ 0.001 between induced cells at day 42 and every other time point.  
As well as determining the expression of candidate novel microRNAs during 
chondrogenesis, expression was also measured during a chondrocyte de-differentiation 
model (figure 4.16), where expression is measured in RNA obtained from osteoarthritic 
cartilage, cells directly isolated from this cartilage, and primary chondrocytes passaged 
in monolayer culture. 
Candidate microRNA novel 2 showed a decrease in expression from cartilage to 
passage 3; however this decrease was not statistically significant. Candidate microRNA 
novel 7 showed the highest expression in cartilage tissue, but this decreased 
significantly in cells isolated immediately after digestion (PD) (p ≤0.001) and 
expression decreased through all subsequent passaged cells. Candidate microRNA 
novel 11 showed a decreasing expression from cartilage to monolayer chondrocytes, 
and then a continued low expression across passage (p ≤0.001 between cartilage and 
post digest and p ≤0.001 between post digest and passage 0). 
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Figure 4.13 Candidate novel microRNA expression in a mesenchymal stem cell 
chondrogenesis assay. Expression levels of candidate microRNA (A) novel 2, (B) 
novel 7 and (C) novel 11 were measured by qRT-PCR from RNA obtained from 
mesenchymal stem cells induced through chondrogenesis to form cartilage discs. RNA 
samples were taken at time points during the assay: day 0, 3, 7, 14. Data shows mean 
+/- SEM, n = 3, data were normalised to U6 RNA expression (*, p ≤0.05, and ***, p 
≤0.001 analyzed by a one way ANOVA with a post hoc Tukey test). 
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Figure 4.14 Candidate novel microRNA expression in an ATDC5 chondrogenesis 
assay. Expression levels of candidate microRNA (A) novel 7 and (B) novel 11 were 
measured by qRT-PCR from RNA obtained from ATDC5 mouse carcinoma cells 
induced through chondrogenesis. Control samples were not induced through 
chondrogenesis. RNA samples were taken at time points during the assay: day 1, 21, 42. 
Data shows mean +/- SEM, n = 3, data were normalised to U6 RNA expression (from 
one experiment).  
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Figure 4.15 MicroRNA expression in an ATDC5 chondrogenesis assay. Expression 
levels of (A) miR-140-3p and (B) miR-140-5p were measured by qRT-PCR from RNA 
obtained from ATDC5 mouse carcinoma cells induced through chondrogenesis. Control 
samples were not induced through chondrogenesis. RNA samples were taken at time 
points during the assay: day 1, 21, 42. Data shows mean +/- SEM, n = 3, data were 
normalised to U6 RNA expression (***, p ≤ 0.001, analyzed by a one way ANOVA 
with a post hoc Tukey test). 
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Figure 4.16 MicroRNA expression in articular chondrocyte isolation and 
expansion. Expression levels of candidate microRNA (A) novel 2, (B) novel 7 and (C) 
novel 11 were measured by qRT-PCR from RNA isolated from: osteoarthritic knee 
cartilage tissue, isolated chondrocytes (post digest) and subsequent P0, P1, P2, and P3 
chondrocytes passaged through monolayer culture. Data were normalised to U6 RNA 
expression. (*, p ≤0.05, and ***, p ≤0.001. RNA was obtained from 8 patients for 
chondrocytes and 4 patients for tissue, data shows mean +/- SEM, a one way ANOVA 
analysis with a post hoc Tukey test was used to test for significance). 
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4.2.4 Candidate novel microRNA expression in vivo 
Expression of the candidate novel microRNAs was measured in a number of in vitro 
assays as described previously in this chapter. In order to complement that data, the 
expression of one of the candidates, novel 11, was also measured in vivo using in situ 
hybridisation.  
Figure 4.17 shows the localisation of candidate microRNA novel 11 in the whole mouse 
embryo at stage E11 and limb at stage E14. Whilst no localised staining is noticeable in 
the limb (C), there appears to be some localisation along the spine (A) seen in the dorsal 
view of the whole E11 embryo. This expression cannot be seen in the lateral view of the 
whole embryo (B) and doesn’t appear to be present between the spinal segments. 
MiR-449 (a brain specific microRNA) was used as a control (Fig. 4.18) and expression 
was measured in vivo in whole E11 embryos and whole E14 limbs. No noticeable 
expression was seen in any area of the (A) dorsal or (B) lateral view of the whole 
embryo or the (C) whole limb. 
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Figure 4.17 Expression of candidate microRNA novel 11 during mouse 
development. In situ hybridization was carried out upon whole-mount mouse embryos 
(A, B) and dissected limbs (C). Expression of candidate novel 11 was not detected in 
limbs at E14 (C). Very faint staining was seen in the spinal cord of E11 embryo (A) but 
not between the vertebrae or in the E11 lateral view (B). Background staining on all 
tissue was relatively high. 
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Figure 4.18 Expression of control microRNA miR-449 during mouse development. 
In situ hybridization was carried out upon whole-mount mouse embryos (A, B) and 
dissected limbs (C). Expression of miR-449 was not detected in E11 whole embryos (A, 
B) or limbs at E14 (C). 
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4.2.5 Genetic location and evolution of candidate novel 
microRNAs 
Experimental validation is an important aspect of microRNA discovery. However a 
bioinformatics assessment is also useful. Figures 4.19, 4.20, 4.21 describe the location 
of the 3 candidate microRNAs investigated within their host genes. 
Novel 2 is located within WD Repeat Domain 91 (WDR91) (Fig. 4.19). It is found 
within the 4
th
 intron of each transcript of WDR91 except ENST00000485942, where it 
is found within the 1
st
 intron. 
Novel 7 is located within small nucleolar RNA, H/ACA box 36A (SNORA36A) (Fig. 
4.20). Unlike novel 2 it is not an intronic microRNA, being located in the only exon of 
SNORA36A. 
Novel 11 is located within cartilage acidic protein 1 (CRTAC1) (Fig. 4.21). It is found 
within the last intron of each transcript (the 11
th
, 14
th
 and 13
th
 respectively of 
ENST00000413387, ENST00000370597 and ENST00000298819). However the 2
nd
 
transcript is known to undergo splicing during transcription which would result in the 
removal of the microRNA sequence. 
In order to predict the presence of the candidate microRNAs within multiple species 
aside from humans, an analysis was carried out using Ensembl (www.ensemble.org) to 
search for each sequence within the species’ genomes available . Figures 4.22, 4.23 and 
4.24 show all species where the sequence was present (in either partial or complete 
form), and presents this in as an evolutionary tree, with species linked by time of 
divergence. The presence of an exact copy of the candidates is denoted by a green box. 
The candidate microRNA novel 2 (Fig. 4.22) sequence is found in partial form in a 
number of species, but the exact sequence is found within Homo sapiens, Pan 
troglodytes, Pongo abelii, and Callithrix jacchus.  
The candidate microRNA novel 7 (Fig. 4.23) sequence is found in partial form in a 
number of species, but the exact sequence is found within Homo sapiens, Pan 
troglodytes, Gorilla gorilla, Pongo abelii, Nomascus leucogenys, Macaca mulatta and 
Callithrix jacchus.  
The candidate microRNA novel 11 (Fig. 4.24) sequence is found in partial form in a 
number of species, but the exact sequence is found within Homo sapiens, Pan 
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troglodytes, Gorilla gorilla, Pongo abelii, Nomascus leucogenys, Macaca mulatta, 
Callithrix jacchus, Microcebus murinus, Mustela pustorius furu, Ailuropoda 
melanoleuca, Canis familiaris, Felis catus, Erinaceus europaeus, Vicugna pacos, Equus 
caballus, Myotis lucifugis, Pteropus vampyras, Rattus norvegicus, Mus musculus, 
Loxodonta Africana, Procavia capensis, Ictidomys tridecemlineatus, Dipodomys ordii 
and Tupaia belangeri. 
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Figure 4.19 Candidate microRNA novel 2 genetic location within its host gene. The 
diagram shows the intron location of the candidate microRNA novel 2 within the 
multiple transcripts of its host gene, WD Repeat Domain 91. The boxes represent exons 
and the dashes represent introns. 
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Figure 4.20 Candidate microRNA novel 7 genetic location within its host gene. The 
diagram shows the intron location of the candidate microRNA novel 7 within the 
transcript of its host gene, small nucleolar RNA, H/ACA box 36A. The box represents 
the exon and the dashes represent introns. 
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Figure 4.21 Candidate microRNA novel 11 genetic location within its host gene. 
The diagram shows the intron location of the candidate microRNA novel 11 within the 
transcript of its host gene, cartilage acidic protein 1. The boxes represent exons and the 
dashes represent introns. 
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Figure 4.22 Candidate microRNA novel 2 species evolutionary tree. The diagram 
shows each species that the sequence is present in and the time of divergence between 
each. Green species indicates the presence of an exact sequence match. All other species 
contain a partial match. Time of divergence is measured in number of millions of years 
ago. 
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Figure 4.23 Candidate microRNA novel 7 species evolutionary tree. The diagram 
shows each species that the sequence is present in and the time of divergence between 
each. Green species indicates the presence of an exact sequence match. All other species 
contain a partial match. Time of divergence is measured in number of millions of years 
ago. 
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Figure 4.24 Candidate microRNA novel 11 species evolutionary tree. The diagram 
shows each species that the sequence is present in and the time of divergence between 
each. Green species indicates the presence of an exact sequence match. All other species 
contain a partial match. Time of divergence is measured in number of millions of years 
ago. 
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4.3 Discussion 
The study of microRNAs is still a newly developing field, and as the technology 
progresses ever further, so too are more new sequences being discovered. This is shown 
by the large number of both new and known microRNAs found in cartilage during this 
project (shown in chapter 3).  
However, in order to properly describe the miRNome of osteoarthritic cartilage, the 
microRNAs discovered must be proven to be true microRNAs by subsequent 
experimental validation, this is due to the problems of false positives in the detection 
process. False positives occur when the identification software falsely allocates a 
sequence to microRNA status. This could be due to degradation products fulfilling the 
identification criteria by chance, or perhaps a genuine small RNA sequence, however 
not a microRNA as they are currently described. 
The first step was to identify the size of each candidate sequence using northern 
blotting. This is useful to identify if the sequence is the correct and expected size of a 
microRNA (~21bp). If the sequence is shown to be of a larger size by northern blot, 
then this suggests that the sequence discovered during the deep sequencing was indeed a 
product of degradation, and that the northern blot is detecting the original, entire 
sequence. Figure 4.1 shows the northern blots for 3 of the candidate microRNAs 
(northern blots were carried out for all 16 candidates and the remainder can be seen in 
Appendix 6). Candidate novel 7 (Fig. 4.1 B) showed a band of the usual microRNA size 
when compared to the size of miR-140-3p on northern blot. On the other hand, both 
candidate microRNAs 2 and 11 (Fig. 4.1 A and C) showed no detection by northern 
blot. Positive controls using synthesised DNA oligonucleotides of the complement 
sequences to the candidates worked well (as shown by the standard curves for each 
candidate) suggesting that the experiment itself and the primers used were working. The 
lack of detection could be explained by a very low expression value and so a band is not 
visible. In addition, RNA obtained from SW1353 cells was used for northern blotting 
due to the large amount of RNA needed, this is in contrast to the RNA obtained from 
primary chondrocytes used with the deep sequencing project, and could give another 
reason as to the lower expression of all known and candidate microRNAs detected with 
northern blot.  
This low expression is supported by the pattern of expression seen from the deep 
sequencing project although this data came from primary chondrocytes rather than 
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SW1353 cells. Read numbers for all the potential candidates was relatively low 
compared to known described microRNAs. MiR-140-3p had an average read number of 
8,031,127 in primary chondrocytes. Expression level of the same microRNA in 10μg of 
SW1353 chondrocyte cells was 2.5 fmoles when measured by northern blot. In 
comparison, miR-140-5p was barely detected by northern blot, yet had an average read 
number of 438,388 although this is high compared to other known microRNAs detected 
through deep sequencing (miR-140-5p was the 4
th
 most highly detected microRNA). 
This suggests that, although northern blotting is the gold standard for sizing 
microRNAs, it could be less sensitive compared to other detection methods. This theory 
is supported in the literature by Fehr et al who showed higher sensitivity of detection 
with qRT-PCR than northern blot when measuring expression of MMP3 mRNA (Fehr 
et al., 2000). 
This apparent difference in detection efficiency between deep sequencing and northern 
blotting could explain why novel 2 and novel 11 remain undetected by northern blot 
(their respective average read numbers from sequencing were 0.488 and 11.867), but are 
likely to still be expressed at some level within chondrocytes and could still be classed 
as microRNAs. The remaining 14 candidate microRNAs were also investigated using 
northern blotting. 12 of the 14 were detectable by northern blot, with 1 being of correct 
size and 11 appearing to have products too large to be classified as microRNAs. Three 
of those showed multiple bands, all of which were too big for microRNAs. Since 
completing the deep sequencing project and validation process, a number of the 
candidates of interest were subsequently identified and recorded on miRBase (Griffiths-
Jones et al., 2006; Griffiths-Jones et al., 2008; Kozomara and Griffiths-Jones, 2011). 
Candidate novel 8 has been identified as hsa-miR-1277-5p (Morin et al., 2008) although 
it has not been experimentally validated. The microRNA has also been implicated in 
laryngeal cancer (Xu et al., 2013). Candidate novel 10 is recorded as hsa-miR-487a-5p, 
whilst the -5p strand has only been identified via sequencing, the complementary -3p 
strand of miR-487a has been experimentally validated with northern blot (Fu et al., 
2005). This contrasts with data from this project which observed multiple bands, all 
larger than a microRNA, for miR-487a-5p on a northern blot in RNA obtained from 
chondrocytes. The difference seen could be due to the cell type utilised, as Fu et al 
examined expression in human fetal liver RNA. MiR-487a has also been identified as a 
down-regulated microRNA in laryngeal carcinoma (Wang et al., 2010) and is thought to 
play a role in combatting the drug resistance of certain breast cancers (Ma et al., 2013). 
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There is also an entry of the same microRNA found in sheep (Caiment et al., 2010) 
however this sequence has a substituted base in its seed site. This could theoretically 
mean that the two versions of this microRNA may repress different targets, as they will 
be targeting slightly different mRNA sites. Candidate novel 12 has been described but 
not experimentally validated  in both human and sheep as hsa-miR-539-3p (Landgraf et 
al., 2007) and oar-miR-539-3p (Caiment et al., 2010) respectively, although oar-miR-
539-3p possesses an additional adenine base at its 5’ end which would alter its seed site, 
resulting in a different set of gene targets to the human form. MiRBase also describes 
miR-539-3p in both rat and mouse; however, the sequences of these are slightly 
different to both the human and sheep forms at their 5’ end and result in widely 
different seed sites. 
Aside from using size as a validation attribute of microRNAs. There is also functional 
validation to investigate. The synthesis process of microRNAs has been described in 
detail (Bohnsack et al., 2004; Borchert et al., 2006; Gregory et al., 2005; Gregory et al., 
2004; Lee et al., 2003) including a number of aspects of the process known to be vital in 
the production of mature microRNA sequences. One of these enzymes is Dicer, which 
is involved in cleaving the hairpin loop from the pre-microRNA structure, resulting in 
the formation of the mature miRNA duplex which subsequently splits into the guide and 
passenger strand (Gregory et al., 2005). If Dicer is missing from this process then 
mature microRNAs cannot be detected. 
In order to investigate the response of the candidate microRNAs to the absence and 
presence of Dicer, firstly the enzyme was knocked down in SW1353 cells using a Dicer 
specific siRNA (data not shown). Expression of a number of known microRNAs as well 
as the Dicer RNA was measured by qRT-PCR at a number of time points including 48 
hours, 72 hours and 1 week (data not shown). Although the expression of Dicer was 
seen to decrease in cells treated with the inhibitor compared to a control, no noticeable 
difference was seen in microRNA expression. Some microRNAs are known to have 
long half-lives with the average being around 5 days. The panel of microRNAs analysed 
by Gantier et al showed a range between 4 and 9 days, but a half-live of up to 12 days 
for miR-208 has been seen by Van Rooij et al in vivo (Gantier et al., 2011; van Rooij et 
al., 2007). 
MicroRNAs in general are thought to be up to ten times more stable than mRNA 
(Gantier et al., 2011; Ruegger and Grosshans, 2012; Zhang et al., 2012c). This could 
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explain the lack of altered expression seen in the experiment, as although no new 
mature sequences were being produced, the existing mature microRNAs were still 
present within the system and had yet to degrade during the experimental timeframe. 
To this end, the timeframe of the experiment was extended to over 1 week; however, 
Dicer knock down over this period was toxic to the cells.   This suggests that although a 
longer time period was needed in order to see a measurable effect on microRNA 
expression, this was having a detrimental effect upon the health of the cells which was 
itself skewing the qRT-PCR results. This cell survival issue is supported by existing 
literature which looked at Dicer knock out mouse models (Bernstein et al., 2003), and 
shows that the knockout mouse is embryonic lethal. 
A solution to this Dicer knock down problem was to utilise an existing Dicer null cell 
line, DLD-1. This is a commercially produced tumorigenic cell line which is able to 
survive and grow despite having Dicer knocked out. The expression of candidate 
microRNAs in addition to known microRNAs and Dicer RNA were measured by qRT-
PCR and expression compared with that from the isogenic wild type DLD-1 line. 
Figure 4.2 shows that each of the 3 candidate microRNAs (novel 2, novel 7 and novel 
11) have a decreased expression in Dicer knockout cells compared to control  
suggesting that they are all dependent upon Dicer, indicating in turn that they are indeed 
microRNAs. 
As a control, the expression of Dicer 1 and a number of known microRNAs were also 
measured by qRT-PCR (figure 4.3). Dicer 1 was found to have a significantly lower 
level of expression in the Dicer knock down cell-line compared to wild type, although 
there does appear to be some minimal expression which could explain the detection of 
mature microRNAs (albeit at lower levels than in wild type cells). The expression of 
miR-140-3p, miR-140-5p and miR-455-5p showed a statistically significant down-
regulation in Dicer deficient cells. Although the expression of miR-455-3p also 
decreased in the Dicer knocked down cells, this was only a 1.5-fold difference 
compared to the 5-fold down regulation of miR-455-5p. These data show that these 
microRNAs are regulated by the Dicer enzyme; however different microRNAs appear 
to be affected at different rates, suggesting that perhaps there is an alternative 
microRNA synthesis pathway, or a form of redundancy within the system, allowing 
microRNAs to continue to be processed even without Dicer. This theory is supported in 
the literature, suggesting that not all microRNAs are Dicer dependent and that Ago 
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proteins may substitute to play a role in the manufacturing method. One of these 
microRNAs is miR-451, which although is processed by Drosha, appears to reach 
maturation without the activity of Dicer (Betancur and Tomari, 2012; Cheloufi et al., 
2010). This then begs the question of classification: are these molecules still 
microRNAs but which can be synthesised through a different pathway, or are they a 
new subset of small RNAs with similar functions to microRNAs? 
Kobayashi et al carried out a conditional knock out of Dicer in mouse cartilage and 
subsequently analysed, by microarray, the expression of a number of microRNAs in the 
RNA compared to a control. They discovered a reduction of 60-70% in expression of 
microRNAs from neonatal Dicer null growth plates in addition to decreased 
chondrocyte proliferation, accelerated chondrocyte hypertrophy, and a fold change 
decrease of 4.76 in MMP13 expression. They postulate that the continued presence of 
these microRNAs (albeit at lower levels) is due to the inherent stability of microRNAs, 
and could therefore be a carryover of pre-existing miRNAs (Kobayashi et al., 2008). 
However, if Dicer was absent from birth, that suggests there were never any 
microRNAs to be ‘carried over’ in the first place, reinforcing the theory that there is at 
least a second microRNA maturation pathway in effect, although possibly not 
functioning with the same efficiency as Dicer (Cheloufi et al., 2010). Another 
possibility is the relatively recent discovery of circulating microRNAs in human plasma 
protected by AGO2 complexes (Arroyo et al., 2011). These could potentially be the 
source of the detected microRNAs in the Dicer null chondrocytes; however cartilage is 
a predominantly avascular tissue, rendering that theory less likely unless there was 
contamination from cells other than chondrocytes during the RNA extraction.  
In addition to the initial validation methods, expression of the candidates was measured 
using qRT-PCR in a range of tissues.  In order to determine if the candidates were 
altered in OA, expression was measured in both osteoarthritic hip cartilage and non-
diseased neck of femur (NOF) fracture cartilage. NOF cartilage is used as a control for 
osteoarthritic cartilage. It is unfortunately not a perfect control as the cartilage is 
obtained from trauma patients, usually the elderly, and often the fractures result from 
other diseases such as osteoporosis. However, there may not be a perfect control tissue 
for cartilage (since even post-mortem cartilage is unloaded), but it is well validated in 
the literature (Kevorkian et al., 2004; Price et al., 2002). 
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Figure 4.4 showed that both candidate microRNA novel 2 and novel 11 show a trend to 
increase in OA, however the increased expression was not statistically significant 
compared to NOF cartilage. Candidate novel 7 showed a similar expression in OA 
compared to normal cartilage suggesting that expression of that candidate is not affected 
by the disease.   
Expression was also measured in osteoarthritic knee cartilage to compare with 
expression in normal cartilage tissue from the hip (Fig. 4.7). In contrast to figure 4.4, 
expression of all 3 candidate microRNAs was highest in normal hip cartilage compared 
to osteoarthritic knee cartilage with candidate microRNA novel 2 showing a statistically 
significant increase of p ≤0.01. This suggests that the baseline level of expression is 
actually higher to begin with in hip cartilage tissue than knee cartilage, and that a 
comparison using the same tissue type is more pertinent to detect differences in 
osteoarthritis. When comparing Ct values obtained from qRT-PCR analysis of the 
candidate microRNAs between hip and knee tissue, there are distinct differences. For 
each microRNA measured, Ct values were higher by one Ct or more for each candidate 
in knee tissue compared to both osteoarthritic and normal hip (the lower the Ct number, 
the higher the expression level). 
In addition to assessing candidate microRNA expression in OA, the expression of a 
number of known microRNAs and mRNAs were measured. Figure 4.5 and 4.8 shows 
the expression of miR-140-3p, miR-140-5p, miR-455-3p and miR-455-5p in 
osteoarthritic hip (HOA) versus normal hip (NOF) cartilage and osteoarthritic knee 
(KOA) versus normal hip (NOF) cartilage respectively. When comparing expression 
within the same tissue type (Fig. 4.5) (cartilage from hip) expression of all 4 
microRNAs is increased in osteoarthritic tissue with a statistical significance of p ≤0.01 
for miR-455-3p and miR-455-5p, and a statistical value approaching significance of p 
=0.0587 for miR-140-5p. This supports the fact that these microRNAs are known to 
have altered in expression in OA with the expression of miR-140-5p and miR-455-3p 
often seen to increase in OA cartilage (Miyaki et al., 2009; Swingler et al., 2012). 
However, there is also literature observing a decreased expression of miR-140 in 
osteoarthritic chondrocytes (Miyaki et al., 2009; Tardif et al., 2009). This differing 
expression could be due to different stages of OA cartilage being analysed. 
However, in figure 4.8, expression of all 4 microRNAs is higher in normal hip cartilage 
tissue than osteoarthritic knee cartilage with p ≤0.05 for miR-140-3p. This suggests that, 
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as with the candidate microRNAs, the baseline expression of a number of microRNAs 
is overall higher in hip cartilage than knee cartilage. This means it is always more 
accurate to compare between 2 tissue types of the same origin. 
The gene expression examined in HOA versus NOF cartilage tissue (Fig. 4.6) included 
ADAMTS5, MMP3, MMP13, ACAN and COL2A1. MMP3 showed significantly higher 
expression level in NOF cartilage (p ≤0.001) and MMP13 appeared to increase in HOA 
tissue however it wasn’t statistically significant. The expression seen from both of these 
MMPs is supported by TILDA data which saw the same expression pattern (Swingler et 
al., 2009). This is also reinforced by additional literature using qRT-PCR to quantify the 
expression of the MMPs in osteoarthritic cartilage compared with NOF (Kevorkian et 
al., 2004). 
ADAMTS5 showed a decreased expression in osteoarthritic cartilage (p ≤0.05), this does 
contradict some existing theories that ADAMTS5 is one of the major aggrecanases 
involved in osteoarthritis (Stanton et al., 2005), although most of these studies have 
focussed on in vivo mouse experiments. Other research utilising RNA obtained from 
human cartilage of the hip (HOA and NOF) however agree with the data of this project 
in that ADAMTS5 expression is significantly lower in OA cartilage (Kevorkian et al., 
2004). This suggests that the expression of ADAMTS5 could differ depending upon the 
stage of osteoarthritis at which it is measured. The data obtained by Kevorkian et al as 
well as from this project was obtained from end-stage OA patients.  
ACAN expression is higher when measured in NOF cartilage compared to HOA (p 
≤0.05), this makes sense as it has been shown that in late stage OA cartilage, ACAN 
production by chondrocytes is reduced (Goldring, 2000) in addition to increased 
degradation of the proteoglycan (Sandell and Aigner, 2001). This is supported by 
additional research by Brew et al who found a 4-fold decrease in ACAN expression in 
osteoarthritic cartilage compared to normal controls, measured by qRT-PCR (Brew et 
al., 2010). 
Finally COL2A1 expression was measured in osteoarthritic and normal hip cartilage, 
and showed a significant increase in OA tissue (p ≤0.001). Although matrix proteins are 
generally degraded during osteoarthritis, it is thought that some (like type II collagen) 
show high expression rates in late stage OA as a repair response, with a higher matrix 
remodelling rate (Aigner et al., 2001) this could explain the high levels of COL2A1 seen 
during this project in osteoarthritic cartilage compared to NOF. It is also thought that 
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proteoglycans also increase their production  rate during OA as part of a potential repair 
response, however, this production cannot compensate for the continued destruction 
(Aigner et al., 1997). 
In addition to being detected within cartilage tissue by qRT-PCR, a human tissue panel 
(Fig. 4.9) was utilised to determine if each candidate microRNA was selectively 
expressed in cartilage or if it was present within a number of tissues at similar levels. 
Candidate microRNA novel 11 does appear to indeed be cartilage selective, with 
expression much higher in all articular cartilage samples than for any other tissue type. 
Candidate microRNA novel 2 on the other hand showed highest expression in RNA 
from the cervix and skeletal muscle tissue. Candidate microRNA novel 7 also showed 
high expression in cervix and skeletal muscle RNA, however, expression in cartilage 
tissue was also relatively high. 
Figure 4.10 shows the expression of miR-140-3p, miR-140-5p, miR-455-3p and miR-
455-5p across the same 23 human tissues. Both miR-140-3p and miR-140-5p showed 
highest expression in all the cartilage tissues, supporting the fact that miR-140 is a 
cartilage selective microRNA (Miyaki et al., 2009; Miyaki et al., 2010; Swingler et al., 
2012). MiR-455-3p appears to be most highly expressed in RNA from cervix tissue, 
with the expression in cartilage being comparable to the rest of the panel. MiR-455-5p 
on the other hand shows the expression of the microRNA in osteoarthritic cartilage 
tissue (KOA and HOA) to be similar to cervix tissue, with expression in NOF much 
lower. Again, miR-455 is known to be an important microRNA in cartilage and 
osteoarthritis (Swingler et al., 2012; Zhang et al., 2012b). 
A cartilage injury model in the form of a hip avulsion assay (Fig. 4.11) was carried out 
to investigate if the candidate microRNAs would respond to that type of stress as an 
alternative experiment to simply measuring expression between osteoarthritic and 
control cartilage.  
This mouse hip avulsion model was developed by Dr. T. Vincent at the Kennedy 
Institute of Rheumatology. The femoral caps of dislocated hip joints of ~5 week old 
mice are removed and cultured in situ. RNA is subsequently extracted from the cartilage 
and gene expression analyzed by qRT-PCR. Vincent et al discovered an activation of 
the MAP kinase pathways in addition to the NF-κB pathway post injury. Furthermore, it 
was discovered that a number of the genes regulated by the surgical joint destabilization 
mouse model were also regulated by the mouse hip injury model, showing a link 
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between the pathways activated in both injury and surgically induced OA (Chong et al., 
2013). 
For this project the cartilage layer of a 3-5 week old C57BL/6 mouse femoral head was 
removed intact and incubated in cell culture medium for 2 days (Chong et al., 2013; 
Stanton et al., 2011). RNA was extracted directly from the cartilage at set time points 
(0, 1, 3, 6, 12, 24 and 48 hours) and analyzed by qRT-PCR. 
Candidate microRNA novel 7 showed an increase in expression at each time point, 
peaking at 48 hours with statistical significance. This suggests that the candidate is 
responsive to injury even though there was no differential expression between 
osteoarthritic and normal cartilage tissue. This indicates that the injury model may 
activate different pathways to end stage osteoarthritis, or that the model could be more 
similar to early osteoarthritis and that novel 7 plays a more significant role in early OA 
rather than during the latter stages. 
Candidate novel 11 showed a slight cyclical expression pattern unlike novel 7, with 
expression peaking at 3 and 48 hours (however without statistical significance). This 
again contrasts the differential expression seen between osteoarthritic and non-
osteoarthritic tissue. 
Three known microRNAs were also measured in the injury model (Fig. 4.12); miR-140-
3p, miR-140-5p and miR-455-5p (miR-455-3p is not conserved between mouse and 
human and therefore was not measured). All three showed an increase in expression 
over time during the model, with the highest expression seen at 48 hours. This response 
to injury supports the earlier data described in chapter 3 (Fig. 3.1) showing miR-140-5p 
increasing in expression from cartilage to the post digest stage before decreasing again 
through passaged chondrocytes. This suggests that the earlier response was indeed due 
to injury rather than just the conditions of digestion. However, the other microRNAs 
measured also increased in expression across the injury model, yet did not increase at 
the post digest stage of isolated chondrocytes. This could suggest that although miR-
140-5p responds to both injury and stress, the remaining microRNAs respond most 
strongly to injury, with stressed conditions having a lesser effect. Although this model is 
used as an injury response model, the effects seen in microRNA expression could also 
be due in part to unloading of the joint in combination with inflammation.  
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Measuring expression of microRNAs during chondrogenesis assays is another means to 
establish if these microRNAs are likely functional in chondrocytes. Figure 4.13 
describes the data obtained from a mesenchymal stem cell chondrogenesis assay. 
This assay was carried out by Dr M. Barter (Newcastle University, UK), who assessed 
the expression of a number of known microRNAs across the assay by microarray (data 
not shown).  The data showed that miR-140-3p, miR-140-5p, miR-455-3p and miR-
455-5p increased during chondrogenesis, with the highest expression of each seen in the 
cartilage disc at day 14.  This supports previous research which show these microRNAs 
to be involved in chondrocyte development (Barter, 2012; Swingler et al., 2012). 
During the MSC assay candidate microRNA novel 2 showed a stable expression 
throughout the assay except at day 7 where there was a spike in expression, suggesting 
that novel 2 is not regulated in this model. Candidate microRNA novel 7 shows an 
increase from day 0 through day 3 and 7, with expression at day 14 subsequently 
remaining constant. This suggests that candidate microRNA novel 7 is involved in 
chondrogenesis.  Candidate microRNA novel 11 shows increased expression at day 0 of 
the assay, but this drops at day 3 and remains low for the remainder of the assay. This 
suggests that candidate microRNA novel 11 may not be involved in chondrogenesis 
although this contrasts with the expression of the candidate measured in the human 
tissue panel which suggested that novel 11 was cartilage selective. Interestingly, 
expression of novel 11 increases in SOX9 treated cells (data not shown), which is a 
marker of chondrogenesis (Ikeda et al., 2004). 
An additional chondrogenesis assay was examined by qRT-PCR using cells obtained 
from a mouse cell line: ATDC5 [original assay carried out by Dr. T. Swingler (UEA)]. 
This is shown in figure 4.14 with candidate microRNA novel 7 showing an increase 
across time in both cells induced to undergo chondrogenesis and those acting as a 
control. Candidate microRNA novel 11 showed a comparable decrease in expression in 
both induced and control cells however at day 42, induced cells appear to decrease 
significantly (although not statistically) compared to control cells suggesting that any 
role novel 11 plays in chondrogenesis is minor. These data supports that seen within the 
MSC chondrogenesis assay suggesting novel 7 is implicated in chondrogenesis. 
However none of the changes seen here were statistically significant. In addition to 
measuring expression of candidate microRNAs, miR-140-3p and miR-140-5p were also 
measured by qRT-PCR (Fig. 4.15) and both microRNAs showed a significant increase 
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in expression in treated cells at day 42 compared to the previous time points (with p 
≤0.001 between day 42 and all other time points) and compared to control this 
expression pattern is supported by the published report on this assay (Swingler et al., 
2012). 
To compare with and support the data from the chondrogenesis assays, candidate 
microRNA expression was also measured in an assay of human articular chondrocyte 
de-differentiation (Fig. 4.16). Many versions of this assay have been investigated with 
some extending past passage 3, and others only examining chondrocytes in culture. 
Hong et al observed miR-140 decreasing in expression during de-differentiating 
chondrocytes, but subsequently increase again during chondrocyte redifferentiation 
(Hong and Reddi, 2013). Lin et al on the other hand only examined chondrocytes after 
isolation from cartilage, however, their assay continued onto passage 5. Lin et al 
observed 13 microRNAs to be up-regulated across dedifferentiation and 12 down-
regulated by microarray analysis. They also found miR-140-3p and miR-140-5p to be 
down-regulated in dedifferentiated chondrocytes compared to differentiated 
chondrocytes which supports the results seen across this project (Lin et al., 2011). A 
paper from Martinez-Sanchez et al also focusses on a model of chondrocyte 
dedifferentiation, looking specifically at miR-145 and how it regulates SOX9 (a key 
transcription factor in the synthesis of cartilage matrix) in dedifferentiated chondrocytes 
(Martinez-Sanchez et al., 2012). The same lab have also published data showing how 
SOX9 regulates another chondrocyte specific microRNA miR-675 by analysing 
expression across both dedifferentiation and redifferentiation (Dudek et al., 2010). 
Although candidate microRNA novel 2 appeared to have similar expression at each 
stage from cartilage to passage 3, both novel 7 and novel 11 showed a decrease in 
expression from cartilage to isolated and expanded chondrocytes. Expression of 
candidate microRNA novel 7 decreased significantly from cartilage to PD but then 
remained stable, whereas novel 11 showed a decrease in expression at each subsequent 
stage between. As the chondrocytes progress through the assay they begin to lose their 
phenotype, becoming more fibroblastic. This suggests that both novel 7 and 11 are 
selectively expressed in chondrocytes due to their expression levels decreasing through 
the assay. 
As candidate microRNA novel 11 has already been shown to be cartilage selective (Fig. 
4.9 C) in the human tissue panel, and chondrocyte selective in the de-differentiation 
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model (Fig. 4.16 C); expression was measured in the development of mouse embryos 
using whole-mount in situ hybridisation (Fig. 4.17). Whole embryos of stage E11 and 
limbs from stage E14 were analysed [a developmental stage where a known cartilage 
selective microRNA is readily detected (Tuddenham et al., 2006)] . In whole mouse 
embryos, staining appears along the spine (A), suggesting it may be present within the 
cartilage of the spine. However unlike miR-455 which is a known cartilage expressed 
microRNA (Swingler et al., 2012), candidate microRNA novel 11 was not detected 
along inter digital regions of the E11 embryo (B) or E14 limb (C). A control (Fig. 4.18) 
was carried out with miR-449 [a known developmental brain specific microRNA 
(Saugstad, 2010)] and no specific staining was noted in any section of the embryo.  
However, it should be noted that this experiment was not an exhaustive assay across 
embryonic stages, and this would be informative since e.g. miR-140-5p is only 
expressed after E11.5 in mouse embryo limbs (Tuddenham et al., 2006).  
In addition to functional validation, a bioinformatics assessment was also carried out 
upon the 3 candidate microRNAs novel 2, novel 7 and novel 11. Ensembl 
(www.ensemble.org)   (Flicek et al., 2014) and BLAST were utilised to identify the host 
gene of each candidate. Candidate microRNA novel 2 (Fig. 4.19) is found within an 
intron of WD Repeat Domain 91 (WDR91) (on chromosome 7) which is, as yet, an 
unvalidated protein encoding gene. We found WDR91 to have a similar expression 
pattern in HOA cartilage compared to NOF (data not shown), differing from the 
expression of candidate novel 2 which is increased in HOA cartilage, suggesting that in 
NOF cartilage, candidate novel 2 is not transcribed from its host gene at the same rate as 
in osteoarthritic cartilage. 
Candidate  microRNA novel 7 (Fig. 4.20) is found within the single exon of small 
nucleolar RNA, H/ACA box 36A (SNORA36A) which is in turn transcribed from 
chromosome 2. SnoRNAs are thought to guide RNAs as part of their function, and 
SNORA36A specifically is thought to be involved in the pseudouridylation of U105 and 
U1244 residues of 18S (Kiss et al., 2004; Lestrade and Weber, 2006). Moreover, further 
research has been carried out which determines that snoRNAs could in fact act as 
precursors of microRNAs, with the precursors of other known microRNAs such as miR-
151, miR-140 and miR-605 possessing similar features to snoRNAs (Scott et al., 2009), 
or snoRNAs which function in a similar manner to microRNAs, for example the 
snoRNA ACA45 has been found to require cleavage by Dicer and is thought to have a 
role in gene silencing (Ender et al., 2008). We found comparable expression of 
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SNORA36A in cartilage from HOA and NOF (data not shown), suggesting it is not a 
marker of disease and follows the same expression pattern of candidate novel 7. 
Candidate microRNA novel 11 (Fig. 4.21) is found in the last intron of each respective 
transcript of cartilage acidic protein 1 (CRTAC1) on chromosome 10. CRTAC1 [also 
known as CEP-68 (chondrocyte expressed protein 68)] interestingly encodes a 
glycosylated extracellular matrix protein found in the deep zone of cartilage within the 
interterritorial matrix (Steck et al., 2007).The protein is on occasion used as a marker to 
distinguish chondrocytes from other cell types in culture and the gene has been found to 
be an effective marker of chondrogenesis (Steck et al., 2001). CRTAC1 is also thought 
to be involved in certain cell-cell or cell-matrix interactions containing both integrin 
binding and calcium binding domains (Steck et al., 2006). We found CRTAC1 to be up-
regulated in HOA cartilage compared to NOF (data not shown) in a similar manner to 
candidate novel 11, suggesting it could in addition be a marker of cartilage damage or 
disease. This is supported by Grgurevic et al who found CRTAC1 to be expressed in the 
plasma of patients with damaged cartilage. They posit that it could therefore be 
employed as a marker for cartilage damage and repair (Grgurevic et al., 2007). 
In combination with identifying the host gene of each candidate, the presence of each 
sequence was also examined within the multiple species’ genomes available within 
Ensembl to determine how conserved these candidates might be. The more species that 
a microRNA can be found in suggests that it is evolutionarily important and probably 
plays a vital role in common important biological pathways between those species. 
Candidate novel 11 (Fig. 4.24) appeared to be the most highly conserved, with the 
sequence found in partial form in a number of species, but in its exact form within 24 
different species in mammals which diverged approximately 94 million years ago. 
Candidate novel 7 (Fig. 4.23) was the second most highly conserved with the sequence 
found in partial form in a number of species, but in its exact form within 7 different 
species in mammals which diverged 65 million years ago. Candidate novel 2 (Fig. 4.22) 
sequence was found in partial form in a number of species, but the exact sequence was 
only found within 4 different species of mammals which diverged approximately 43 
million years ago. Although miR-140 was not analysed in this manner during this 
project, data available on miRBase (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 
2008; Kozomara and Griffiths-Jones, 2011) shows that the microRNA can be found in 
163 
 
its mature form in at least 28 different species which is comparable to candidate novel 
11 examined here. 
These data suggest that candidate microRNA novel 11 may be the most evolutionarily 
conserved out of the 3 candidates examined. The conservation of microRNAs, and 
genetic elements in general across species is an indication of how important they are. 
Specifically with microRNAs, conservation of their sequence ensures conservation of 
binding site and therefore conservation of any potential gene targets. Conservation 
implies these sequences have been maintained despite speciation, which suggests a vital 
role in aspects of the organisms’ function, survival or reproduction (Bejerano et al., 
2004). As many microRNAs have been found to be conserved between species, as well 
as suggesting a potential importance to function, this has provided an additional strategy 
of identification. The sequences of microRNAs found in one species can be hunted 
across the sequencing data of many more (Zhang et al., 2006a). 
Now that the candidate microRNAs have undergone significant functional analysis, we 
can assume from these data that novel 2, novel 7 and novel 11 are in fact microRNAs. 
In fact, since completion of this project each of the three candidate novel microRNAs 
has been published on miRBase (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 
2008; Kozomara and Griffiths-Jones, 2011). Candidate novel 2 is described in humans 
as hsa-miR-6509-5p, but has not been experimentally validated except for detection 
using Solexa sequencing (Li et al., 2012b). Candidate novel 7 is listed in humans as hsa-
miR-664b-3p (Friedlander et al., 2012), but again there is no experimental validation, 
with identification coming from a novel computational analysis of existing deep 
sequencing data. Candidate novel 11 has been published on miRBase in both mouse and 
rat as mmu-miR-3085-3p (Chiang et al., 2010) and rno-miR-3085 (Linsen et al., 2010) 
respectively with no experimental validation beyond identification from deep 
sequencing projects. However, miR-3085 has not yet been described in humans.  
The next step in this project was to investigate the function of the three chosen 
microRNAs: miR-6509-5p, miR-664b-3p and miR-3085-3p.  This would hopefully 
enable the understanding of their potential importance within cartilage and 
osteoarthritis. Target search analysis was carried out using bioinformatics and 
microarray analysis, followed by functional validation of a number of the subsequently 
identified targets.  
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Chapter 5 – Novel MicroRNA Target Search Analysis 
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5.1 Introduction 
Chapter 3 and 4 described the discovery and subsequent validation of a number of 
microRNAs from osteoarthritic cartilage tissue obtained from total joint replacement 
surgery. However, it’s not enough just to know these microRNAs exist, we need to 
know which genes they target in chondrocytes and why they have been evolutionarily 
conserved.  
Chapter 5 depicts this next step which is to analyse these candidates functionally to 
discover genetic targets that may play a role in osteoarthritis or cartilage development. 
The function of microRNAs is to bind to complementary targets within mRNA and 
suppress gene expression. In plants, it’s thought that microRNAs are able to directly 
bind and subsequently cleave a complementary target site of mRNA through the RISC 
complex (Tang et al., 2003).  In mammals, the microRNA is more likely to have less 
complementarity to their target and so inhibit translation of the mRNA rather than 
cleave it directly, this also results in the preservation of the target mRNA structure 
whilst still suppressing expression (Ambros, 2004).   
 
MicroRNAs bind to mRNA via specific sites at the 5’ end of the microRNA. These are 
known as seed sites which bind to corresponding complementary ‘target sites’ usually at 
the 3’ UTR of an mRNA sequence (Fig.1.7), these are the most conserved areas of a 
microRNA (Akbari Moqadam et al., 2013). Target sites have also been found within the 
5’ UTR as well as coding regions of the mRNA (Lee et al., 2009).  It is thought that 
microRNAs which bind at 3’UTRs cause a stronger or more efficient suppression of 
gene expression than if they were to bind to the 5’UTR, which could explain why 
targets in the 3’UTR are more prevalent (Moretti et al., 2010). A small number of 
microRNAs (including hsa-miR-1 and hsa-miR124) have been found which target both 
the 5’UTR and 3’UTR of the same gene, both resulting in down-regulation of gene 
expression (Lee et al., 2009).  
 
There are a number of seed sites of different sizes within the sequence of a microRNA 
which are thought to be responsible for binding to an mRNA target and they start at a 
number of known locations within the microRNA. The first is the 6mer, this is a site 
which is 6 nucleotides long which starts at the 2
nd
 nucleotide (from the 5’ end) and 
finishes at the 7
th
 (inclusive). The next is the 7merm8. This site is 7 nucleotides long 
beginning at the 2
nd
 nucleotide, and as the name suggests, ends at the 8
th
 nucleotide. 
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There is an additional site of the same length entitled 7merA1 however this site begins 
at the first nucleotide, finishing at the 7
th
. The final seed site is the 8mer, this site is 8 
nucleotides long beginning at the first nucleotide and ending at the 8
th
 (Mitra and 
Bandyopadhyay, 2011). 
 
It’s thought that although all 4 of these sites can result in binding sufficient to inhibit 
mRNA expression, the binding of the 8mer site results in a stronger down-regulation of 
the gene (Schnall-Levin et al., 2011). It is also theorised that in addition to the seed sites 
being the main locations of binding, the microRNA sequence can also bind to a mRNA 
sequence with its 3’ end, specifically an area known as the Watson-Crick complement 
which runs from the 12
th
 to the 17
th
 nucleotide of the microRNA (Mitra and 
Bandyopadhyay, 2011). 
 
The methods involved with miRNA function are multi-fold, depending on the organism 
in question. A number of microRNAs are produced in different cell types in different 
combinations and are thought to work co-operatively to regulate cell specific gene 
pathways. The target prediction algorithms show that a single microRNA can have 
hundreds of individual targets, and that genes can be targeted by multiple different 
microRNAs or even have multiple target sites for the same microRNA. It is thought that 
these microRNAs work co-operatively to down-regulate gene expression, and thus can 
result in a stronger suppression (Akbari Moqadam et al., 2013; Hon and Zhang, 2007). 
 
There are a number of algorithms available online which attempt to predict the targets 
of the majority of microRNAs described on miRBase (Griffiths-Jones et al., 2006; 
Griffiths-Jones et al., 2008; Kozomara and Griffiths-Jones, 2011). These include 
TargetScan (Friedman et al., 2009), miRanda (Betel et al., 2008), PITA (Kertesz et al., 
2007) and PicTar (Krek et al., 2005). However each database uses a different algorithm, 
and if results are compared they often do not overlap as can be seen in another online 
system which combines the results of a number of the databases: The microRNA body 
map (Mestdagh et al., 2011). One of the problems with using these online algorithms is 
that they all show high levels of false positive or false negative results (Mitra and 
Bandyopadhyay, 2011). 
 
Identifying the target of any microRNA can be extremely difficult, especially in 
mammals, as gene regulation can occur by a number of microRNA : mRNA 
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interactions. Gene regulation is not dependent upon exact seed site complementarity; 
mismatches within the binding can still result in gene suppression as well as matching 
between other areas of the microRNA and the mRNA target. This is one of the 
problems with using prediction algorithms which mainly look for targets with strict seed 
site matches. This means that all functional analysis must include an experimental 
analysis. Even exact seed site matches may not result in an observed functional down-
regulation. (Akbari Moqadam et al., 2013). 
 
Three promising novel microRNAs (identified as part of the cartilage miRNome and 
validated in chapter 4) were chosen to investigate their potential functional role within 
osteoarthritis and cartilage development. These were candidate novels 2, 7 and 11, now 
described as miR-6509-5p miR-664b-3p and miR-3085-3p respectively. This was 
carried out using primary chondrocytes in monolayer at passage one, obtained from 
total joint replacement of osteoarthritic knees from three patients. miR-6509-5p, miR-
664b-3p and miR-3085-3p were investigated using a gain- and loss-of-function method 
analysed with an Illumina Whole-Genome Expression BeadArrays Microarray 
encompassing over 47,000 genes, gene candidates, and splice variants. Qiagen 
microRNA mimics and inhibitors were designed for each microRNA and the genome 
array was analysed with R Studios (R Core Team, 2013) and Microsoft Excel.  
Whilst the genome array is significantly more quantitative than, for example, a deep 
sequencing project, there was a limit to the number of genes and splice variants 
examined, whereas a deep sequencing analysis would examine the entire DNA sequence 
available. 
The data obtained from the array were analysed and each gene was ranked based on its 
fold-change in expression from negative non-targeting siRNA controls when treated 
with a microRNA mimic or inhibitor. A positive gene target would theoretically be 
repressed with the microRNA mimic and increase in expression with the microRNA 
inhibitor.  
This experimental analysis was combined with a computational microRNA target 
search in the genes of the human genome using the R programming language (R Core 
Team, 2013) and the Biostrings package (Pages et al., 2012).  
To summarise, all genes measured by the array were assessed for their role as a target of 
one of the three newly discovered microRNAs by whether their expression levels 
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decreased with the microRNA mimic and increased with the microRNA inhibitor (when 
compared to a negative control) and whether they had at least one fully complementary 
target site. As previously explained, microRNAs can bind to a slightly mismatched 
target site on a gene and still cause an effect (although often not as extreme) and this 
analysis did not take into account any possible partial or ‘mismatched’ target sites. A 
more complex algorithm would be needed and there is still not enough data available to 
establish how many mismatches a microRNA can withstand and still successfully bind 
to a specific mRNA target. 
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5.2 Results 
5.2.1 Experimental microRNA target search analysis 
Primary chondrocytes from passage 1 isolated from osteoarthritic knee cartilage tissue 
were treated with either a microRNA mimic at 30nM (miR-6509-5p, miR-664b-3p and 
miR-3085-3p), inhibitor at 50nM (miR-6509-5p, miR-664b-3p and miR-3085-3p), or 
non-targeting controls for mimics and inhibitors at 30nM and 50nM respectively and 
incubated for 6 hours at 37°C 5% (v/v) CO2. RNA isolated from these samples was then 
sent to Source Bioscience to be analysed using a Whole-Genome Expression 
BeadArrays Microarray to measure the expression of over 47,000 genes, gene 
candidates and splice variants. 
Figure 5.1 shows the normalised untransformed data obtained from the array. Each 
point represents a gene, gene candidate, or splice variant and how it responded to both 
the microRNA mimics and inhibitors in comparison to non-targeting controls of the 
microRNAs (A) miR-6509-5p (B) miR-664b-3p and (C) miR-3085-3p. Figure 5.2 
shows the fold change in expression for each gene between a non-targeting control and 
the microRNA mimic and between the microRNA inhibitor and a non-targeting control 
of the microRNAs (A) miR-6509-5p (B) miR-664b-3p and (C) miR-3085-3p. The grey 
shading shows the area where genes are located if they are down-regulated by the 
microRNA mimic and up-regulated by the microRNA inhibitor. This indicates they are 
responding as expected for true microRNA targets. 
The gene which appeared to increase the most (by 31.6 fold) when treated with the 
microRNA miR-6509-5p mimic was IFIT2 (Interferon-Induced Protein with 
Tetratricopeptide Repeats 2) (Table 5.1). This gene is part of the type 1 interferon 
response group of genes known to be involved in the immune response and interferon 
signalling. It has also been found to bind to the eIF-3C initiation factor and therefore 
inhibit protein synthesis (Berchtold et al., 2008; Terenzi et al., 2006). The gene which 
decreased in expression the most (by 2.4 fold) when treated with the miR6509-5p 
mimic was HNRPA1P4 (Heterogeneous Nuclear Ribonucleoprotein A1 Pseudogene) 
(Table 5.2) and as yet has no described function. The gene which increased the most (by 
8.1 fold) when treated with the miR-6509-5p inhibitor was MX1 (Myxovirus Resistance 
1, Homolog of Murine Interferon Inducible Protein P78) (Table 5.3).  It encodes the 
protein MxA and is thought to be involved in the interferon-induced  antiviral response 
of cells (Gao et al., 2011; Tazi-Ahnini et al., 2000) and is thought to target the 
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nucleoprotein of MxA-sensitive RNA viruses (Haller and Kochs, 2011). The gene 
which appeared to show the largest decrease in expression (by 1.9 fold) when treated 
with the miR-6509-5p inhibitor was MT1H (Metallothionein 1H) (Table 5.4), this gene 
codes a protein known to bind heavy metals (Stennard et al., 1994). 
The gene which showed the highest expression in response to both the miR-664b-3p 
mimic and inhibitor was IFIT2 by 20.8 fold and 12.4 fold respectively (Tables 5.5. and 
5.7). The gene which appeared to decrease in expression the most (by 2.7 fold) in 
response to the miR-664b-3p inhibitor was CPA4 (Carboxypeptidase A4) (Table 5.8), 
this is considered a metalloprotease and has potential links to histone hyperacetylation. 
It is also known to be linked to the aggressiveness of prostate cancer (Pallares et al., 
2005; Tanco et al., 2010).  STT3A (Subunit of the Oligosaccharyltransferase Complex, 
Homolog A) appeared to decrease in expression the most (by 2.3 fold) in response to 
the miR-664b-3p mimic (Table 5.6). It produces a protein which is the catalytic subunit 
of OST (N-oligosaccharyl transferase) and is involved in substrate specificity (Kelleher 
et al., 2003). 
IFIT2 was also the most highly expressed gene (by 32.1 fold) when treated with the 
miR-3085-3p inhibitor (Table 5.11), whilst RPL14 (Ribosomal Protein L14) was the 
gene which appeared to decrease the most (by 2.5 fold) in response to the inhibitor 
(Table 5.12). RPL14 codes for a ribosomal protein (ribosomal protein L14) and is 
known to be involved in the RNA synthesis pathway (Uechi et al., 2001). The gene 
which showed the largest decrease in expression (by 2.2 fold) in response to the miR-
3085-3p mimic was CSTB (Cystatin B) (Table 5.10) which functions as a thiol 
proteinase inhibitor (Lalioti et al., 1997).  
The array also measured the expression of a small number of microRNAs within the 
treated samples, and microRNA-1974 appeared to be the gene most highly expressed 
(by 2 fold) when the samples were treated with the miR-3085-3p mimic (Table 5.9). 
However, this microRNA has since been removed from miRBase as a false microRNA. 
It has been found to map to the mitochondrial genome and appears to overlap a 
mitochondrial tRNA sequence (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008; 
Kozomara and Griffiths-Jones, 2011). To this end, the second most highly expressed 
gene in response to the miR-3085-3p mimic was CA2 (Carbonic Anhydrase 2) by 1.7 
fold (Table 5.9). This codes for a zinc containing enzyme and is involved in catalysing 
the reversible hydration of carbon dioxide (Becker et al., 2011). 
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Figure 5.3 shows the ideal gene target area defined in figure 5.2 and the fold change in 
expression of each gene. All genes represented in these graphs increase in expression in 
response to the inhibitors and decrease in response to the mimics of the microRNAs (A) 
miR-6509-5p, (B) miR-664b-3p and (C) miR-3085-3p. 
The gene which increased the most (by1.9 fold) in response to the miR-6509-5p 
inhibitor whilst still showing a fold change decrease (by 1.1 fold) in response to the 
miR-6509-5p mimic was OAZ2 (Ornithine Decarboxylase Antizyme 2). OAZ2’s 
functions include binding and destabilizing ornithine decarboxylase (Hayashi et al., 
1996; Ramos-Molina et al., 2013). LOC646688  [which corresponds to RPL4P2 
(Ribosomal Protein L4 Pseudogene)] was the gene which showed the largest decrease 
(by 2.1 fold) in response to the miR-6509-5p mimic whilst still showing a fold change 
increase (by 1.1 fold) in response to the miR-6509-5p inhibitor. RPL4P2 has as yet no 
known function. 
The gene which showed the largest fold change increase (by 9.2 fold) in response to the 
miR-664b-3p inhibitor whilst showing a decrease (by 1.5 fold) in expression in response 
to the miR-664b-3p mimic was LOC100132564 (a hypothetical protein) and is 
uncharacterised. The 2
nd
 most highly expressed gene (by 8 fold) in response to the miR-
664b-3p inhibitor but still showing a marginal decrease (by 1.01 fold) in expression in 
response to the mimic was LOC100008589 which is a ribosomal RNA and encodes part 
of a 28S rRNA. The gene to decrease in expression the most (by 2.3 fold)  in response 
to the miR-664b-3p mimic and still increase in expression (by 1.1 fold)  in response to 
the miR-664b-3p inhibitor was STT3A (Subunit of the Oligosaccharyltransferase 
Complex, Homolog A). STT3A produces a protein involved in complex substrate 
specificity (Kelleher et al., 2003). The gene which appeared to increase the most (by 14 
fold) when treated with the miR-3085-3p inhibitor but still decrease (by 1.1 fold) when 
treated by the miR-3085-3p mimic was RNU1G2 (also known as RNA, U1 Small 
Nuclear 4) which as yet has no described function. Finally, the gene which had the 
largest fold change decrease (by 2.1 fold)  in response to the miR-3085-3p mimic but 
still increased in expression (by 1.9 fold) with the miR-3085-3p inhibitor was ITGA5 
(Integrin alpha 5) which is a cell-surface receptor (Nagae et al., 2012; Takada et al., 
2007). 
The data obtained from the array suggested that, on the whole, the microRNA mimic 
siRNAs were more effective than the microRNA inhibitor siRNAs, especially when 
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looking at gene targets which responded to the siRNAs in a manner expected of 
microRNA targets (increased expression with inhibitor and decreased expression with 
mimic) . This lead to the observation of genes showing, for example, a very large down-
regulation when treated with the microRNA mimic but negligible increased expression 
in response to the microRNA inhibitor. To solve this problem, a series of cut off points 
were utilised in order to isolate genes which showed reasonable changes in expression 
to both the microRNA mimic and inhibitor siRNAs (Fig. 5.3). 
The fold-change cut-off points were situated at, firstly, the point exactly halfway 
between the zero change point (fold change of exactly 1) and the most highly down-
regulated gene (in response to the microRNA mimic) and the most up-regulated gene 
(in response to the microRNA inhibitor) and these lines were labelled in purple. No 
genes were found to be located beyond both of these lines, so new cut off points were 
created at both the 25% (red) and 12.5% (blue) from the zero change point. 
When these cut off points are taken into account 20 genes were found to be regulated in 
the correct manner by the miR-6509-5p mimic and inhibitor above the 25% cut off 
point and 452 genes were found to be regulated in the correct manner by the miR-6509-
5p mimic and inhibitor above the 12.5% cut off point [Fig. 5.3 (A)]. 
One gene was found to be regulated in the correct manner by the miR-664b-3p mimic 
and inhibitor above the 25% cut off point and 11 genes were found to be regulated in 
the correct manner by the miR-664b-3p mimic and inhibitor above the 12.5% cut off 
point [Fig. 5.3 (B)]. 
No genes were found to be regulated in the correct manner by the miR-3085-3p mimic 
and inhibitor above the 25% cut off point but 18 genes were found to be regulated in the 
correct manner by the miR-3085-3p mimic and inhibitor above the 12.5% cut off point 
[Fig. 5.3 (C)]. 
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Figure 5.1 Gene expression change in response to novel microRNA mimics and 
inhibitors. Untransformed data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. Figure shows the gene expression results of RNA isolated from cells treated 
with (A) miR-6509-5p mimic and inhibitor, (B) miR-664b-3p mimic and inhibitor and 
(C) miR-3085-3p mimic and inhibitor. The x-axis represents a change in expression in 
response to the microRNA mimic and the y-axis represents a change in expression in 
response to the microRNA inhibitor with down-regulation corresponding to a negative 
value, and up-regulation corresponding to a positive value. 
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Figure 5.2 Gene expression fold change in response to novel microRNA mimics and 
inhibitors. Fold change in gene expression of genome array. Data obtained from a 
Whole-Genome Expression BeadArrays Microarray measuring over 47,000 genes, gene 
candidates, and splice variants. The figure shows the fold change in gene expression of 
RNA isolated from cells treated with (A) miR-6509-5p mimic and inhibitor, (B) miR-
664b-3p mimic and inhibitor and (C) miR-3085-3p mimic and inhibitor. The x-axis 
represents a change in expression in response to the microRNA mimic and the y-axis 
represents a change in expression in response to the microRNA inhibitor. Down-
regulation corresponding to a negative value, and up-regulation corresponding to a 
positive value. The shaded areas show the area corresponding to genes which decrease 
in expression in response to the mimic and increase in expression in response to the 
inhibitor. 
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Gene Gene name Mimic fold change Inhibitor fold change
HNRPA1P4 Heterogeneous nuclear ribonucleoprotein A1 pseudogene 4 -2.355 -1.025
HNRPA1L-2 Heterogeneous nuclear ribonucleoprotein A1 pseudogene 10 -2.321 -1.179
ACO1 Aconitase 1, soluble -2.272 -1.034
ICMT Isoprenylcysteine carboxyl methyltransferase -1.936 -1.141
TXNDC12 Thioredoxin domain containing 12 -1.927 -1.051
DANCR Differentiation Antagonizing Non-Protein Coding RNA -1.889 1.048
SWI5 SWI5 Recombination Repair Homolog -1.836 1.100
ITGAE Integrin, alpha E -1.824 -1.022
FAP Fibroblast activation protein, alpha -1.815 1.182
RPS23 Ribosomal protein S23 -1.804 1.045
Gene Gene name Mimic fold change Inhibitor fold change
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 31.571 1.157
CCL5 Chemokine ligand 5 28.429 1.077
RSAD2 Radical S-adenosyl methionine domain containing 2 19.258 1.536
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 18.894 1.338
OASL 2'-5'-oligoadenylate synthetase-like 17.452 1.214
BST2 Bone marrow stromal cell antigen 2 14.054 1.227
IL18BP Interleukin 18 binding protein 12.567 1.277
IFI44L Interferon-induced protein 44-like 11.498 1.981
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 10.994 1.819
OAS2 2'-5'-oligoadenylate synthetase 2 9.487 1.642
 
 
 
 
 
Table 5.1 Top 10 genes from microarray with highest fold change increase in 
response to miR-6509-5p mimic compared to a non-targeting control. Gene 
expression fold change in response to miR-6509-5p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-6509-5p mimic and inhibitor. 
 
 
 
 
 
 
 
Table 5.2 Top 10 genes from microarray with highest fold change decrease in 
response to miR-6509-5p mimic compared to a non-targeting control. Gene 
expression fold change in response to miR-6509-5p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-6509-5p mimic and inhibitor. 
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Gene Gene name Mimic fold change Inhibitor fold change
MX1 Myxovirus resistance 1, interferon-inducible protein p78 8.103 2.110
GPR1 G protein-coupled receptor 1 1.230 2.031
IFI44L Interferon -induced protein 44-like 11.498 1.981
OAZ2 Ornithine decarboxylase antizyme 2 -1.102 1.897
IFIT1 Interferon -induced protein with tetratricopeptide repeats 1 10.994 1.819
PLIN5 Perilipin 5 -1.047 1.812
KIAA1751 KIAA1751 1.293 1.807
HERC6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 6.139 1.788
ISG15 ISG15 ubiquitin-like modifier 8.454 1.759
NBPF8 Neuroblastoma breakpoint family, member 8 -1.194 1.727
Gene Gene name Mimic fold change Inhibitor fold change
MT1H Metallothionein 1H 1.912 -2.603
MT1X Metallothionein 1X 1.408 -2.193
MT1F Metallothionein 1F 1.296 -2.193
MT1G Metallothionein 1G 2.533 -1.938
MT1M Metallothionein 1M 2.130 -1.903
MT1E Metallothionein 1E 1.653 -1.734
MEST Mesoderm specific transcript -1.380 -1.681
LOC148430 Ribosomal S2 Pseudogene -1.922 -1.634
BLOC1S1 Biogenesis of lysosomal organelles complex-1, subunit 1 1.024 -1.606
PIGP Phosphatidylinositol glycan anchor biosynthesis, class P -1.142 -1.581
 
 
 
 
 
Table 5.3 Top 10 genes from microarray with highest fold change increase in 
response to miR-6509-5p inhibitor compared to a non-targeting control. Gene 
expression fold change in response to miR-6509-5p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-6509-5p mimic and inhibitor. 
 
 
 
 
 
 
 
Table 5.4 Top 10 genes from microarray with highest fold change decrease in 
response to miR-6509-5p inhibitor compared to a non-targeting control. Gene 
expression fold change in response to miR-6509-5p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-6509-5p mimic and inhibitor. 
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Gene Gene name Mimic fold change Inhibitor fold change
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 20.811 12.407
RSAD2 Radical S-adenylsyl methionine domain containing 2 14.697 9.949
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 13.879 9.123
BST2 Bone marrow stromal cell antigen 2 10.497 2.798
IFI44L Interferon-induced protein 44-like 10.464 10.495
OASL 2'-5'-oligoadenylate synthetase-like 10.120 5.014
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 8.230 6.599
OAS1 2'-5'-oligoadenylate synthetase 1 8.141 3.741
ISG15 ISG15 ubiquitin-like modifier 7.769 5.176
CCL5 Chemokine ligand 5 7.646 1.609
Gene Gene name Mimic fold change Inhibitor fold change
STT3A Subunit of the oligosaccaryltransferase complex -2.339 1.079
CPD Carboxypeptidase D -2.262 -1.380
CALM1 Calmodulin 1 -1.937 1.015
MAMDC2 MAM domain containing 2 -1.933 -1.149
CD151 CD151 molecule -1.928 -1.198
PSAT1 Phosphoserine Aminotransferase -1.766 -1.131
PLAU Plasminogen activator, urokinase -1.669 -1.151
GSTM1 Glutothione S-transferase mu 1 -1.663 -1.067
LEPRE1 Leucine proline-enriched proteoglycan 1 -1.659 -1.404
TXNDC12 Thioredoxin domain containing 12 -1.653 1.301
 
 
 
 
 
Table 5.5 Top 10 genes from microarray with highest fold change increase in 
response to miR-664b-3p mimic compared to a non-targeting control. Gene 
expression fold change in response to miR-664b-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-664b-3p mimic and inhibitor. 
 
 
 
 
 
 
Table 5.6 Top 10 genes from microarray with highest fold change decrease in 
response to miR-664b-3p mimic compared to a non-targeting control. Gene 
expression fold change in response to miR-664b-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-664b-3p mimic and inhibitor. 
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Gene Gene name Mimic fold change Inhibitor fold change
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 20.811 12.407
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 11.133 11.841
IFI44L Interferon-induced protein 44-like 10.464 10.495
RSAD2 Radical S-adenylsyl methionine domain containing 2 14.697 9.949
MX1 Myxovirus resistance 1 6.936 7.385
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 8.230 6.599
HERC6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 5.488 6.189
OAS2 2'-5'-oligoadenylate synthetase 2 7.054 5.413
ISG15 ISG15 ubiquitin-like modfier 7.769 5.176
OASL 2'-5'-oligoadenylate synthetase-like 10.120 5.014
Gene Gene name Mimic fold change Inhibitor fold change
CPA4 Carboxypeptidase A4 1.138 -2.705
GLS Glutaminase -1.196 -2.609
RPS6KA2 Ribosomal protein S6 kinase, polypeptide 2 -1.040 -2.170
CA12 Carbonic anhydrase XII 1.201 -2.120
TFRC Transferrin receptor -1.145 -2.093
ACO1 Aconitase 1 -1.551 -2.089
ANGPTL5 Angiopoietin-like-5 -1.191 -2.076
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 -1.078 -2.064
IL7R Interleukin 7 receptor 1.060 -1.994
BLOC1S1 Biogenesis of lysosomal organelles complex-1, subunit 1 -1.298 -1.959
 
 
 
 
 
Table 5.7 Top 10 genes from microarray with highest fold change increase in 
response to miR-664b-3p inhibitor compared to a non-targeting control. Gene 
expression fold change in response to miR-664b-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-664b-3p mimic and inhibitor. 
 
 
 
 
 
 
Table 5.8 Top 10 genes from microarray with highest fold change decrease in 
response to miR-664b-3p inhibitor compared to a non-targeting control. Gene 
expression fold change in response to miR-664b-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-664b-3p mimic and inhibitor. 
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Gene Gene name Mimic fold change Inhibitor fold change
MIR1974 MicroRNA-1974 (dead entry) 1.999 2.550
CA2 Carbonic anhydrase II 1.735 -1.351
CPA4 Carboxypeptidase A4 1.734 -2.390
MT1G Metallothionein 1G 1.680 -1.656
SLC16A10 Solute carrier family 16, member 10 1.645 1.311
SNORA12 Small nucleolar RNA, H/ACA box 12 1.565 1.045
DESI2 Desumoylating Isopeptidase 2 1.560 -1.049
DAPK1 Death-associated protein kinase 1 1.546 -1.062
DICER1 Dicer 1, ribonuclease type III 1.537 1.058
ESM1 Endothelial cell-specific molecule 1 1.528 1.040
Gene Gene name Mimic fold change Inhibitor fold change
CSTB Cystatin B -2.169 -1.103
ITGA5 Integrin, alpha 5 -2.079 1.915
CYTL1 Cytokine-like 1 -1.876 1.531
CSPG4 Chondroitin sulphate proteoglycan 4 -1.739 1.771
PIN1 Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 -1.730 -1.384
MYADM Myeloid-associated differentiation marker -1.722 1.372
COPE Coatomer protein complex, subunit epsilon -1.683 1.006
CCND3 Cyclin D3 -1.660 1.208
HSPE1 Heat shock 10kDa protein 1 -1.649 -1.383
VPS26 Vacuolar protein sorting 26 homolog A -1.643 -1.107
 
 
 
 
 
 
Table 5.9 Top 10 genes from microarray with highest fold change increase in 
response to miR-3085-3p mimic compared to a non-targeting control. Gene 
expression fold change in response to miR-3085-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-3085-3p mimic and inhibitor. 
 
 
 
 
 
 
 
Table 5.10 Top 10 genes from microarray with highest fold change decrease in 
response to miR-3085-3p mimic compared to a non-targeting control. Gene 
expression fold change in response to miR-3085-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-3085-3p mimic and inhibitor. 
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Gene Gene name Mimic fold change Inhibitor fold change
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 1.129 32.110
RSAD2 Radical S-adenylsyl methionine domain containing 2 1.230 23.662
IFI44L Interferon-induced protein 44-like 1.125 20.085
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 1.140 20.071
RNVU1-18 RNA, Variant U1 small nuclear 18 1.025 15.509
RNU1-4 RNA, U1 small nuclear 4 -1.114 13.989
SNORD3D Small nucleolar RNA, C/D box 3D -1.068 13.174
RNU1-3 RNA, U1 small nuclear 3 1.063 11.897
RNU1-1 RNA, U1 small nuclear 1 -1.036 11.627
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 1.282 11.218
Gene Gene name Mimic fold change Inhibitor fold change
RPL14 Ribosomal protein L14 -1.018 -2.543
GLS Glutaminase 1.158 -2.521
ACO1 Aconitase 1 1.121 -2.504
MT1F Metallothionein1F 1.227 -2.431
CPA4 Carboxypeptidase A4 1.734 -2.390
RPL23A Ribosomal protein L23a -1.062 -2.267
RPS6KA2 Ribosomal protein S6 kinase, polypeptide 2 -1.068 -2.081
SUMF1 Sulfatase modifying factor 1 -1.013 -2.008
FABP4 Fatty acid binding protein 4, adipocyte -1.055 -1.972
BOLA3 BolA family member 3 1.120 -1.964
 
 
 
 
 
 
Table 5.11 Top 10 genes from microarray with highest fold change increase in 
response to miR-3085-3p inhibitor compared to a non-targeting control. Gene 
expression fold change in response to miR-3085-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-3085-3p mimic and inhibitor. 
 
 
 
 
 
 
 
Table 5.12 Top 10 genes from microarray with highest fold change decrease in 
response to miR-3085-3p inhibitor compared to a non-targeting control. Gene 
expression fold change in response to miR-3085-3p mimic and inhibitor. Fold change in 
gene expression of genome array. Data obtained from a Whole-Genome Expression 
BeadArrays Microarray measuring over 47,000 genes, gene candidates, and splice 
variants. The table shows the fold change in gene expression of RNA isolated from cells 
treated with miR-3085-3p mimic and inhibitor. 
 
 
 
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Candidate targets which responded as expected to microRNA mimic 
and inhibitor treatments. Genes which decrease in expression in response to the 
microRNA mimic and increase in expression in response to the inhibitor as expected for 
targets of the novel microRNAs (A) miR-6509-5p – 11871 genes, (B) miR-664b-3p – 
10800 genes and (C) miR-3085-3p – 10953 genes The x-axis represents the fold change 
down in gene expression in response to the mimic and the y-axis represents the fold 
change up in gene expression in response to the inhibitor. The purple line represents a 
fold change cut off point at 50% of the largest fold changes in response to both mimic 
and inhibitors. The red and blue lines represent the 25% and 12.5% cut off points 
respectively.  
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5.2.2 Bioinformatics microRNA target search analysis 
In combination with the functional array analysis to identify gene targets of the 3 
microRNAs miR-6509-5p, miR-664b-3p and miR-3085-3p, an in silico analysis was 
also carried out. In order to suppress the function of a gene, a microRNA must bind to a 
specific site within the mRNA, either exactly or partially. To this end, the R 
programming language was used with RStudios (R Core Team, 2013) and the 
Biostrings package (Pages et al.) to identify all possible target sites (6mer, 7merA1, 
7merm8 and 8mer) of each microRNA on the 3’UTR of each gene of the human 
genome as downloaded from the online database Ensembl (Flicek et al., 2014) using 
Biomart (Kasprzyk, 2011). 
Four potential seed sites from each microRNA were used to produce the target site 
sequences in the search. For miR-6509-5p, the 6mer seed site is TTAGGT, the 7merA1 
is ATTAGGT, the 7merm8 is TTAGGTA and the 8mer is ATTAGGTA. For miR-
664b-3p, the 6mer seed site is TCATTT, the 7merA1 is TTCATTT, the 7merm8 is 
TCATTTG and the 8mer is TTCATTTG. For miR-3085-3p, the 6mer seed site is 
CTGGCT, the 7merA1 is TCTGGCT, the 7merm8 is CTGGCTG and the 8mer is 
TCTGGCTG. The complementary sequences to these sites were used as search criteria 
using the R programming language with RStudios (R Core Team, 2013) and the 
Biostrings package (Pages et al., 2012).  
Tables 5.13, 5.14 and 5.15 show the top 20 genes identified as targets for each 
microRNA by this system, ranked firstly by the number of 8mer target sites, then by the 
total number of 7mer sites (including 7merA1 and 7merm8), and finally by the number 
of 6mer sites. 
Table 5.13 shows the top 20 out of 4655 genes which possessed at least one 6mer target 
site within their 3’UTR for miR-6509-5p. The top 5 are as follows: LNPEP (Leiomodin 
2) with 6 6mer sites, 8 7mer sites and 3 8mer sites. Next is KRAS (Karyopherin alpha 
8) with 5 6mers, 6 7mers and 2 8mers. This is followed by CCNT2 (Cyclin B3) with 4 
6mers, 6 7mers and 2 8mers. HELZ (Helicase with zinc finger) is in fourth place with 3 
6mers, 5 7mers and 2 8mers. Finally, there is LPP (Lon peptidase 2, peroxisomal) with 
3 6mers, 5 7mers and 2 8mers. 
Table 5.14 shows the top 20 out of 9690 genes which possessed at least one 6mer target 
site within their 3’UTR for miR-664b-3p. The top 5 are as follows: ERAP2 
(Endoplasmic reticulum aminopeptidase 2) with 6 6mer sites, 8 7mer sites and 4 8mer 
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sites. This is followed by AFF2 (AF4/FMR2 family member 2 with 15 6mers, 14 7mers 
and 3 8mers. Next is by APC (Adenomatous polyposis coli) with 10 6mers, 10 7mers 
and 3 8mers. MLL3 (Membrane bound O-acyltransferase domain containing 2) is in 
fourth place with 12 6mers, 9 7mers and 3 8mers. Finally, there is ATAD1 (ATPase 
family, AAA domain containing 1) with 7 6mers, 9 7mers and 3 8mers. 
Table 5.15 shows the top 20 out of 8930 genes which possessed at least one 6mer target 
site within their 3’UTR for miR-3085-3p. The top 5 are as follows: TG (Thyroglobulin) 
with 8 6mer sites, 10 7mer sites and 4 8mer sites. Next is TANC2 (Tetratricopeptide 
repeat, ankyrin) with 12 6mers, 11 7mers and 3 8mers. This is followed by LMX1B 
(LIM homeobox transcription factor 1, beta) with 11 6mers, 11 7mers and 3 8mers. 
GFER (Growth factor, augmenter of liver regeneration) is in fourth place with 9 6mers, 
9 7mers and 3 8mers. Finally, there is PTPN18 (Protein tyrosine phosphatase, non-
receptor type 18) with 6 6mers, 8 7mers and 3 8mers. 
.  
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6mer All 7mers 8mer Ensemble gene ID Gene Gene name
6 8 3 ENSG00000113441 LNPEP leiomodin 2 (cardiac)
5 6 2 ENSG00000133703 KRAS karyopherin alpha 3 (importin alpha 4)
4 6 2 ENSG00000082258 CCNT2 cyclin B3
3 5 2 ENSG00000198265 HELZ helicase with zinc finger
3 5 2 ENSG00000145012 LPP lon peptidase 2, peroxisomal
3 5 2 ENSG00000146373 RNF217 ring finger protein 217
4 4 2 ENSG00000196632 WNK3 WNK lysine deficient protein kinase 3
3 4 2 ENSG00000081014 AP4E1 adaptor-related protein complex 4, epsilon 1 subunit
3 4 2 ENSG00000163545 NUAK2 NUAK family, SNF1-like kinase, 2
3 4 2 ENSG00000120948 TARDBP TAR DNA binding protein
2 4 2 ENSG00000135932 CAB39 chromosome 9 open reading frame 72
2 4 2 ENSG00000241644 INMT indolethylamine N-methyltransferase
2 4 2 ENSG00000131626 PPFIA1 protein tyrosine phosphatase, receptor type, f polypeptide, interacting protein, alpha 1
2 4 2 ENSG00000170234 PWWP2A PWWP domain containing 2A
2 4 2 ENSG00000154114 TBCEL tubulin folding cofactor E-like
2 4 2 ENSG00000118965 WDR35 WD repeat domain 35
6 5 1 ENSG00000163428 LRRC58 LIM domain containing preferred translocation partner in lipoma
5 5 1 ENSG00000149212 SESN3 sestrin 3
5 5 1 ENSG00000117500 TMED5 transmembrane emp24 protein transport domain containing 5
5 5 1 ENSG00000169905 TOR1AIP2 torsin A interacting protein 2
Target sites Target information
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.13 Computational gene target search of miR-6509-5p using RStudios. All 4 
target sites; 6mer, 7merm8, 7merA1 and 8mer were identified within the 3’UTR of all 
genes within the human genome as described on Ensembl, downloaded using Biomart. 
Target search was carried out with the R programming Biostrings package, and the top 
20 genes of 4655 with target sites (ranked by size and number of target sites) is shown. 
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6mer All 7mers 8mer Ensemble gene ID Gene Gene name
6 8 4 ENSG00000164308 ERAP2 endoplasmic reticulum aminopeptidase 2
15 14 3 ENSG00000155966 AFF2 AF4/FMR2 family, member 2
10 10 3 ENSG00000134982 APC adenomatous polyposis coli
12 9 3 ENSG00000055609 MLL3 membrane bound O-acyltransferase domain containing 2
7 9 3 ENSG00000138138 ATAD1 ATPase family, AAA domain containing 1
7 9 3 ENSG00000144824 PHLDB2 pleckstrin homology-like domain, family B, member 2
3 6 3 ENSG00000196166 C8orf86 chromosome 8 open reading frame 86
3 6 3 ENSG00000040199 PHLPP2 PH domain and leucine rich repeat protein phosphatase 2
15 12 2 ENSG00000168807 SNTB2 syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, basic component 2)
13 12 2 ENSG00000104290 FZD3 frizzled family receptor 3
10 10 2 ENSG00000166450 PRTG protogenin
10 9 2 ENSG00000172795 DCP2 decapping mRNA 2
8 9 2 ENSG00000133739 LRRCC1 lysine (K)-specific methyltransferase 2C
12 8 2 ENSG00000152495 CAMK4 calcium/calmodulin-dependent protein kinase IV
11 8 2 ENSG00000010244 ZNF207 zinc finger protein 207
10 8 2 ENSG00000169213 RAB3B RAB3B, member RAS oncogene family
9 8 2 ENSG00000154429 CCSAP centriole, cilia and spindle-associated protein
8 8 2 ENSG00000036530 CYP46A1 cytochrome P450, family 46, subfamily A, polypeptide 1
8 8 2 ENSG00000143797 MBOAT2 leucine rich repeat and coiled-coil centrosomal protein 1
8 8 2 ENSG00000147862 NFIB nuclear factor I/B
Target sites Target information
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.14 Computational gene target search of miR-664b-3p using RStudios. All 4 
target sites; 6mer, 7merm8, 7merA1 and 8mer were identified within the 3’UTR of all 
genes within the human genome as described on Ensembl, downloaded using Biomart. 
Target search was carried out with the R programming Biostrings package, and the top 
20 genes of 9690 with target sites (ranked by size and number of target sites) is shown. 
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6mer All 7mers 8mer Ensemble gene ID Gene Gene name
8 10 4 ENSG00000042832 TG Thyroglobulin
12 11 3 ENSG00000170921 TANC2 Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2
11 11 3 ENSG00000136944 LMX1B LIM homeobox transcription factor 1, beta
9 9 3 ENSG00000127554 GFER Growth factor, augmenter of liver regeneration
6 8 3 ENSG00000072135 PTPN18 Protein tyrosine phosphatase, non-receptor type 18
6 7 3 ENSG00000156639 ZFAND3 Zinc finger, AN1-type domain 3
5 6 3 ENSG00000110888 CAPRIN2 Caprin family member 2
3 6 3 ENSG00000073331 ALPK1 Alpha-kinase 1
10 8 2 ENSG00000114735 HEMK1 HemK methyltransferase family member 1
10 8 2 ENSG00000130052 STARD8 StAR-related lipid transfer (START) domain containing 8
8 8 2 ENSG00000164742 ADCY1 adenylate cyclase 1
6 8 2 ENSG00000100106 TRIOBP TRIO and F-actin binding protein
11 7 2 ENSG00000196092 PAX5 Paired box 5
9 7 2 ENSG00000136279 DBNL Drebrin-like
9 7 2 ENSG00000174437 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twich 2
8 7 2 ENSG00000072501 SMC1A Structural maintenance of chromosomes 1A
7 7 2 ENSG00000142765 SYTL1 Synaptotagmin-like 1
7 7 2 ENSG00000169118 CSNK1G1 Casein kinase 1, gamma 1
7 7 2 ENSG00000090905 TNRC6A Trinucleotide repeat containing 6A
6 7 2 ENSG00000123643 SLC36A1 Solute carrier family 36 (proton/amino acid symporter)
Target informationTarget sites
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.15 Computational gene target search of miR-3085-3p using RStudios. All 4 
target sites; 6mer, 7merm8, 7merA1 and 8mer were identified within the 3’UTR of all 
genes within the human genome as described on ensembl, downloaded using Biomart. 
Target search was carried out with the R programming Biostrings package, and the top 
20 genes of 8930 genes with target sites (ranked by size and number of target sites) is 
shown. 
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5.2.3 MicroRNA target search analysis combining array data and bioinformatics 
In order to utilise both methods of gene target identification of the three chosen 
microRNAs: miR-6509-5p, miR-664b-3p and miR-3085-3p, the results of the two 
methods were combined (as shown in figure 5.4). All genes identified by the array 
analysis to show expression changes in the expected fashion of increasing when treated 
with the microRNA inhibitor and decreasing when treated with the mimic were cross-
referenced with the list of human genes determined to have at least one target site. The 
resulting genes are presented in figure 5.5 for microRNAs (A) miR-6509-5p, (B) miR-
664b-3p and (C) miR-3085-3p. 
A system of fold-change cut off points were also utilised at the 50%, 25% and 12% 
marks, in an attempt to triage the possible targets to a number suitable for further 
experimental analysis. 
Table 5.16 shows the 23 genes (ranked by size and number of target sites) which fall 
above the 25% cut off point for miR-6509-5p. All these genes increase in expression 
when treated with the microRNA inhibitor and decrease in expression when treated with 
the mimic in comparison to non-targeting controls.  
Table 5.17 shows the 53 genes (ranked by size and number of target sites) which fall 
above the 12.5% cut off point for miR-664b-3p. The cut off of 12.5% was used as there 
were only 4 genes which were found to be above the 25% point. All these genes 
increase in expression when treated with the microRNA inhibitor and decrease in 
expression when treated with the mimic in comparison to non-targeting controls.  
Table 5.18 shows the 21 genes (ranked by size and number of target sites) which fall 
above the 12.5% cut off point for miR-3085-3p. The cut off of 12.5% was used as there 
was only 1 gene which was found to be above the 25% point. All of the genes increase 
in expression when treated with the microRNA inhibitor and decrease in expression 
when treated with the mimic in comparison to non-targeting controls.  
The gene for each microRNA which appeared to have the largest number of target sites 
within the subset of genes which increased with the inhibitor and decreased with the 
mimic were for miR-6509-5p; LRRC58 (Leucine rich repeat containing 58) with 6 
6mers, 5 7mers and 1 8mer. SNTB2 (Syntrophin, beta 2) was the top gene for miR-
664b-3p with 15 6mers, 12 7mers and 2 8mers. Finally the gene for miR-3085-3p was 
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ITPRIPL2 (Inositol 1, 4, 5-triphosphate receptor interacting protein-like 2) with 7 
6mers, 5 7mers and 1 8mer. 
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Figure 5.4 Venn diagram of computational analysis combined with gain- and loss-
of-function studies to identify microRNA gene targets. The process undertaken to 
identify potential novel microRNA targets using data from both the computational 
analysis with RStudios and the whole genome microarray with microRNA mimics and 
inhibitors. Targets are considered promising if they contain at least one complementary 
target site, increase in expression when treated with the microRNA inhibitor, and 
decrease in expression when treated with the microRNA mimic.  
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Figure 5.5 Candidate targets which responded as expected to mimic and inhibitor 
treatments which also have at least one target site. Genes which decrease in 
expression in response to the microRNA mimic, and increase in expression in response 
to the inhibitor as expected for targets of the three microRNAs and which also contain 
at least 1 6mer target site, (A) miR-6509-5p – 1782 genes, (B) miR-664b-3p – 3245 
genes and (C) miR-3085 - 3091 genes The x-axis represents the fold change down in 
gene expression in response to the mimic and the y-axis represents the fold change up in 
gene expression in response to the inhibitor. The purple line represents a fold change cut 
off point at 50% of the largest fold changes in response to both mimic and inhibitors. 
The red and blue lines represent the 25% and 12.5% cut off points respectively.  
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Mimic fold Inhibitor fold
change down change up 6mer All 7mers 8mer
LRRC58  leucine rich repeat containing 58 1.292 1.171 6 5 1
RASSF6  Ras association (RalGDS/AF-6) domain family member 6, transcript variant 1 1.250 1.230 2 2 1
DCBLD2  discoidin, CUB and LCCL domain containing 2 1.207 1.350 2 2 1
PDGFD  platelet derived growth factor D, transcript variant 1 1.188 1.254 4 2 0
PLEKHA1  pleckstrin homology domain containing,family A(phosphoinositide binding specific)member 1,variant 1 1.410 1.200 2 2 0
KCNK2  potassium channel, subfamily K, member 2, transcript variant 3 1.322 1.252 2 2 0
PEG3  paternally expressed 3 1.199 1.178 2 1 0
GHR  growth hormone receptor 1.188 1.169 2 1 0
SFRP4  secreted frizzled-related protein 4 1.659 1.303 1 1 0
STEAP4  STEAP family member 4 1.486 1.161 1 1 0
CA5B  carbonic anhydrase VB, mitochondrial, nuclear gene encoding mitochondrial protein 1.457 1.209 1 1 0
TROVE2  TROVE domain family, member 2, transcript variant 1 1.311 1.294 1 1 0
HERPUD2  HERPUD family member 2 1.234 1.195 1 1 0
AZIN1  antizyme inhibitor 1, transcript variant 1 1.220 1.339 1 1 0
RBM3  RNA binding motif (RNP1, RRM) protein 3 1.201 1.409 1 1 0
TGFBR3  transforming growth factor, beta receptor III 1.197 1.219 1 1 0
ENAH  enabled homolog (Drosophila), transcript variant 2 1.676 1.158 1 0 0
SLC2A3  solute carrier family 2 (facilitated glucose transporter), member 3 1.250 1.190 1 0 0
PDE5A  phosphodiesterase 5A, cGMP-specific, transcript variant 3 1.235 1.236 1 0 0
TTC3  tetratricopeptide repeat domain 3, transcript variant 1 1.222 1.160 1 0 0
HSPA12A  heat shock 70kDa protein 12A 1.217 1.238 1 0 0
RTN3  reticulon 3, transcript variant 1 1.212 1.163 1 0 0
SHROOM4  shroom family member 4 1.181 1.290 1 0 0
N2 target sites
Gene Gene name
 
 
 
 
 
 
 
 
 
 
Table 5.16 Table of the candidate gene targets of miR-6509-5p represented in 
figure 5.5 (A) above the 25% cut off point. The ID and full name of all the gene 
targets of miR-6509-5p above the 25% cut off point which increase in expression when 
treated with the microRNA inhibitor and decrease in expression when treated with the 
microRNA mimic. 
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Mimic fold Inhibitor fold
change down change up 6mer All 7mers 8mer
SNTB2  syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, basic component 2) 1.275 2.885 15 12 2
NFIB  nuclear factor I/B 1.241 1.502 8 8 2
DENND4C  DENN/MADD domain containing 4C 1.206 1.727 7 7 2
PVRL3  poliovirus receptor-related 3 1.497 2.163 5 6 2
HIPK2  homeodomain interacting protein kinase 2 1.236 2.581 6 5 2
MBTD1  mbt domain containing 1 1.232 1.393 5 4 2
BZW1 PREDICTED:  basic leucine zipper and W2 domains 1 1.364 1.529 4 4 2
GPM6B  glycoprotein M6B,  transcript variant 1, . 1.444 1.317 9 7 1
KLF5  Kruppel-like factor 5 (intestinal) 1.187 1.515 5 4 1
ABCA5 ATP-binding cassette, sub-family A, member 5,  transcript variant 2 1.188 1.303 3 3 1
LRRFIP1  leucine rich repeat (in FLII) interacting protein 1 1.293 1.895 3 3 1
ARL5A  ADP-ribosylation factor-like 5A, transcript variant 3 1.207 1.402 2 3 1
RIOK3  RIO kinase 3 (yeast), transcript variant 1 1.190 1.487 2 3 1
VCAN  versican 1.316 1.666 6 4 0
SYAP1  synapse associated protein 1, SAP47 homolog (Drosophila) 1.219 1.493 5 4 0
FAM129A  family with sequence similarity 129, member A, transcript variant 2 1.370 1.595 4 3 0
NTAN1  N-terminal asparagine amidase 1.606 1.369 4 3 0
RAB27A  RAB27A, member RAS oncogene family, transcript variant 1 1.338 1.485 3 3 0
TIMP3  TIMP metallopeptidase inhibitor 3 1.382 2.671 3 3 0
PCYOX1  prenylcysteine oxidase 1 1.413 1.580 4 2 0
ZMAT3  zinc finger, matrin type 3, transcript variant 2 1.258 1.730 4 2 0
FBXL3  F-box and leucine-rich repeat protein 3 1.171 1.403 3 2 0
DAB2  disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 1.192 1.619 2 2 0
RBPMS2  RNA binding protein with multiple splicing 2 1.182 1.379 2 2 0
ALDH1A3  aldehyde dehydrogenase 1 family, member A3 1.191 1.442 3 1 0
CHRNA5  cholinergic receptor, nicotinic, alpha 5 1.236 1.522 2 1 0
DENR  density-regulated protein 1.259 1.771 2 1 0
ERRFI1  ERBB receptor feedback inhibitor 1 1.288 1.463 2 1 0
FKBP14  FK506 binding protein 14, 22 kDa 1.279 1.943 2 1 0
LRRC1  leucine rich repeat containing 1 1.186 1.310 2 1 0
MEF2D  myocyte enhancer factor 2D 1.246 2.165 2 1 0
PRPF40A  PRP40 pre- processing factor 40 homolog A (S. cerevisiae) 1.183 1.593 2 1 0
SYNJ2BP  synaptojanin 2 binding protein 1.185 1.457 2 1 0
AGFG2  ArfGAP with FG repeats 2 1.171 1.503 1 1 0
CILP  cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 1.273 1.392 1 1 0
GADD45A  growth arrest and DNA-damage-inducible, alpha 1.255 1.424 1 1 0
KRCC1  lysine-rich coiled-coil 1 1.319 1.793 1 1 0
LEO1  Leo1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) 1.205 1.474 1 1 0
SF3B1  splicing factor 3b, subunit 1, 155kDa, transcript variant 1 1.212 1.438 1 1 0
ZNF483  zinc finger protein 483, transcript variant 2 1.258 1.842 1 1 0
CRCP  CGRP receptor component,  transcript variant 1, . 1.185 2.159 2 0 0
IGF2BP2  insulin-like growth factor 2  binding protein 2,  transcript variant 1, . 1.194 1.485 2 0 0
SLC4A5  solute carrier family 4, sodium bicarbonate cotransporter, member 5,  transcript variant c 1.206 1.361 2 0 0
SOX4  SRY (sex determining region Y)-box 4 1.188 1.784 2 0 0
FGD5  FYVE, RhoGEF and PH domain containing 5 1.176 1.411 1 0 0
IVNS1ABP  influenza virus NS1A binding protein 1.294 2.009 1 0 0
MYO3B  myosin IIIB 1.171 1.404 1 0 0
PPA2  pyrophosphatase (inorganic) 2,  nuclear gene encoding mitochondrial protein,  variant 2 1.188 1.569 1 0 0
RHOBTB3  Rho-related BTB domain containing 3 1.185 1.893 1 0 0
SSPN  sarcospan (Kras oncogene-associated gene) 1.230 1.450 1 0 0
ZNF394  zinc finger protein 394 1.171 1.858 1 0 0
ZNF577  zinc finger protein 577 1.280 1.404 1 0 0
ZNF69  zinc finger protein 69 1.213 1.848 1 0 0
Gene
N7 target sites
Gene name
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.17 Table of the candidate gene targets of miR-664b-3p represented in 
figure 5.5 (B) above the 12.5% cut off point. The ID and full name of all the gene 
targets of miR-664b-3p above the 12.5% cut off point which increase in expression 
when treated with the microRNA inhibitor and decrease in expression when treated with 
the microRNA mimic. 
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Mimic fold Inhibitor fold
change up change up 6mer All 7mers 8mer
ITPRIPL2 inositol 1,4,5-triphosphate receptor interacting protein-like 2 1.325 2.097 7 5 1
IL18BP interleukin 18 binding protein, transcript variant A 1.153 4.593 1 2 1
PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7), variant 2 1.326 1.872 1 2 1
PODXL podocalyxin-like, transcript variant 1 1.191 2.932 4 3 0
MYD88 myeloid differentiation primary response gene (88) 1.166 1.991 3 2 0
APOL3 apolipoprotein L, 3, transcript variant beta/a 1.177 2.383 2 2 0
TGFBR3 transforming growth factor, beta receptor III 1.321 3.342 2 2 0
TMEM140 transmembrane protein 140 1.165 2.975 2 2 0
KLF6 Kruppel-like factor 6 1.164 4.717 2 1 0
MSX1 msh homeobox 1 1.185 3.340 2 1 0
CD248 CD248 molecule, endosialin 1.217 2.032 1 1 0
CSNK1E casein kinase 1, epsilon, transcript variant 1 1.179 2.217 1 1 0
LY6E lymphocyte antigen 6 complex, locus E 1.205 2.313 1 1 0
FKBP14 FK506 binding protein 14, 22 kDa 1.142 2.142 3 0 0
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 2.079 1.915 2 0 0
DDIT4L DNA-damage-inducible transcript 4-like 1.373 2.092 1 0 0
MXD1 MAX dimerization protein 1 1.158 2.445 1 0 0
PLIN5 perilipin 5 1.437 2.332 1 0 0
SCIN scinderin 1.170 3.279 1 0 0
TSC22D1 TSC22 domain family, member 1, transcript variant 2 1.257 1.907 1 0 0
TSC22D3 TSC22 domain family, member 3, transcript variant 1 1.425 2.052 1 0 0
Gene
N11 target sites
Gene name
 
 
 
 
 
 
 
 
 
 
Table 5.18 Table of the candidate gene targets of miR-3085-3p represented in 
figure 5.5 (C) above the 12.5% cut off point. The ID and full name of all the gene 
targets of miR-3085-3p above the 12.5% cut off point which increase in expression 
when treated with the microRNA inhibitor and decrease in expression when treated with 
the microRNA mimic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
change down 
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5.2.4 Experimental validation of microRNA targets 
In order to validate a number of targets of miR-6509-5p, miR-664b-3p and miR-3085-
3p experimentally, a shortlist of candidates was created (Table 5.19). These genes were 
among those which showed the appropriate response to the siRNAs (decreased 
expression with the microRNA mimic and increased expression with the inhibitor) as 
well as having at least one target site which would exactly match one of the 
microRNAs’ seed sites. These genes were also chosen based upon their function. 
Potential targets of miR-6509-5p included PDGFD (Platelet derived growth factor D), 
SFRP4 (Secreted frizzled-related protein 4), CA5B (Carbonic anhydrase VB), RBM3 
(RNA binding motif protein 3) and TGFβR3 (Transforming growth factor, beta receptor 
III).  
Targets of miR-664b-3p chosen were TIMP3 (tissue inhibitor of metalloproteinases 3), 
GPM6B (Glycoprotein M6B), VCAN (Versican), and CILP (Cartilage intermediate 
layer protein).  
Possible targets of miR-3085-3p were TGFβR3 (Transforming growth factor, beta 
receptor III), MYD88 [Myeloid differentiation primary response gene (88)], CSNK1E 
(Casein kinase 1, epsilon) and ITGA5 (Integrin, alpha 5). 
To narrow this selection down even further, the expression of each gene was measured 
by qRT-PCR in the original RNA samples sent for the array analysis to determine if 
they followed the same rate of regulation as the array data showed. Figure 5.6 shows the 
qRT-PCR results for the genes theorised to be miR-6509-5p targets. 
PDGFD (A) appeared to decrease in expression in response to the miR-6509-5p mimic 
but showed a similar expression between the miR-6509-5p inhibitor and non-targeting 
control. SFRP4 (B) also showed a decrease in expression from non-targeting control to 
the microRNA mimic, but again remained the same in expression between the 
microRNA inhibitor and control. CA5B (C) decreased in expression significantly (p ≤ 
0.01) with the microRNA mimic compared to the control. Expression of the gene 
appeared to decrease slightly between the microRNA inhibitor and the control, however 
there are large error bars. RBM3 (D) decreased in expression from the control to the 
microRNA mimic which approached statistical significance at p = 0.0642, however 
expression also decreased from control to microRNA inhibitor. Finally the expression 
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of TGFβR3 (E) decreased in response to the microRNA mimic but also appeared to 
decrease when treated with the inhibitor. 
Figure 5.7 shows the qRT-PCR results for the genes predicted to be targets of miR-
664b-3p. GPM6B (A) shows a slight decrease in expression between the control and 
microRNA mimic and remains fairly stable in expression between the control and 
microRNA inhibitor if error bars are taken into account. VCAN (B) decreases slightly 
when treated with the microRNA mimic, and increases when treated with the 
microRNA inhibitor with a p value approaching significance (p=0.0829). TIMP3 (C) 
increases significantly when treated with the microRNA inhibitor (p ≤0.001) but 
remained stable between the control and microRNA mimic. Finally CILP (D) increases 
in expression between the control and microRNA inhibitor in a manner approaching 
significance (p =0.0533) and decreases when treated with the microRNA mimic. 
Figure 5.8 shows the qRT-PCR results for the genes predicted to be targets of miR-
3085-3p. MYD88 (A) shows an increase in expression when treated with the microRNA 
inhibitor, but similar expression rates between the microRNA mimic and control. 
TGFβR3 (B) increases in expression in response to the microRNA inhibitor, however 
there is no obvious effect when treated with the microRNA mimic. The expression of 
CSNK1E (C) increases slightly when treated with both the microRNA inhibitor and 
mimic and finally ITGA5 (D) shows a significant decrease with the microRNA mimic (p 
≤0.01) and a slight increase when treated with the microRNA inhibitor. 
Constructs of the 3’UTRs of SFRP4, TIMP3, CILP, MYD88 and ITGA5 were 
successfully sub-cloned into the pmirGLO vector. Constructs of the 3’UTRs of RBM3, 
TGFβR3 and VCAN were also attempted but proved unsuccessful. The transformed 
vectors were transfected into DF-1 fibroblast cells and treated with the corresponding 
novel microRNA mimic. This then underwent a luciferase assay to determine if the 
microRNA mimic was actually binding the target sequence within the target gene 
(Figure 5.9). SFRP4 (A) showed a decrease in relative light units produced when the 
transfected cells were treated with the miR-6509-5p mimic compared to a control, 
however the decrease was not significant and there was also a decrease in relative light 
units when cells were treated with a mimic for miR-29b. TIMP3 (B) showed a 
significant decrease (p ≤0.001) in relative light units when transfected cells were treated 
with the miR-664b-3p mimic compared to a non-targeting control. There was also a 
significant difference (p ≤0.05) in relative light units between cells treated with miR-
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664b-3p and miR-29b mimics, with miR-664b-3p causing a significant decrease. CILP 
(C) showed the same relative light units when cells were treated with both a control and 
the miR-664b-3p mimic, with a decrease in relative light units actually being seen with 
cells treated with the miR-29b mimic (p ≤0.01). The expression of relative light units 
for cells transfected with the MYD88 (D) construct remained stable between the 
control, miR-3085-3p mimic and the miR-29b mimic. Finally ITGA5 (E) showed a 
statistically significant decrease in relative light units emitted by cells treated with the 
miR-3085-3p mimic compared to both the control and the miR-29b mimic (p ≤0.001). 
Two subsequent constructs of ITGA5 were created with a mutation in one of the two 
target sites within the 3’UTR of the gene, and a further construct of ITGA5 with 
mutations in both target sites. These were used as further controls within the luciferase 
assay. 
Figure 5.10 shows a significant decrease in emitted light units when cells transfected 
with the original ITGA5 construct were treated with the miR-3085-3p mimic (p ≤0.001) 
at 50nM compared to the non-targeting control at 50nM [as seen in figure 5.9 (E)]. 
When cells transfected with any of the three mutated constructs (two with mutations in 
only one seed site, one with mutations in both seed sites) were treated with the miR-
3085-3p mimic, there was no statistical significance of emitted light units compared to 
treatments with the non-targeting control. 
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Table 5.19 List of candidate targets of miR-6509-5p, miR-664b-3p and miR-3085-
3p to experimentally validate. Candidate targets of the three microRNAs chosen to 
experimentally validate due to their expression pattern, target site content, and known or 
predicted function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mimic fold Inhibitor fold
change up change up 6mer All 7mers 8mer
ENSG00000170962 PDGFD Platelet derived growth factor 1.188 1.254 4 2 0
ENSG00000106483 SFRP4 Secreted frizzled related protein 4 1.659 1.303 1 1 0
ENSG00000169239 CA5B Carbonic anhydrase VB, mitochondrial 1.457 1.209 1 1 0
ENSG00000102317 RBM3 RNA binding motif protein 3 1.201 1.409 1 1 0
ENSG00000069702 TGFBR3 Transforming growth factor beta receptor 3 1.197 1.219 1 1 0
ENSG00000046653 GPM6B Glycoprotein m6b 1.444 1.317 9 7 1
ENSG00000038427 VCAN Versican 1.316 1.666 6 4 0
ENSG00000100234 TIMP3 Tissue inhibitors of metalloproteinases 3 1.382 2.671 3 3 0
ENSG00000138615 CILP Cartilage intermediate layer protein 1.273 1.392 1 1 0
ENSG00000172936 MYD88 Myeloid differentiation factor 88 1.166 1.991 3 2 0
ENSG00000069702 TGFBR3 Transforming growth factor beta receptor 3 1.321 3.342 2 2 0
ENSG00000213923 CSNK1E Casein kinase 1-epsilon 1.179 2.217 1 1 0
ENSG00000161638 ITGA5 Alpha 5 Integrin 2.079 1.915 2 0 0
Novel microRNA
miR-6509-5p
miR-664b-3p
miR-3085-3p
Ensembl gene ID Gene Gene name
N11 target sites
change down 
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Figure 5.6 Expression of candidate targets of miR-6509-5p in original array 
samples by qRT-PCR. Expression of (A) PDGFD, (B) SFRP4, (C) CA5B, (D) RBM3 
and (E) TGFβR3 were obtained by qRT-PCR from RNA of primary chondrocytes 
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treated with miR-6509-5p mimic and inhibitor, and non-targeting controls. Data were 
normalised to 18S RNA expression. Data are shown as mean +/- S.E.M, n = 3. (** = p 
≤0.01 analyzed by a Student’s t test). 
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Figure 5.7 Expression of candidate targets of miR-664b-3p in original array 
samples by qRT-PCR. Expression of (A) GPM6B, (B) VCAN, (C) TIMP3 and (D) 
CILP were obtained by qRT-PCR from RNA of primary chondrocytes treated with 
miR-664b-3p mimic and inhibitor, and non-targeting controls. Data were normalised to 
18S RNA expression. Data are shown as mean +/- S.E.M., n = 3. (*** = p ≤0.001 
analyzed by a Student’s t test). 
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Figure 5.8 Expression of candidate targets of miR-3085-3p in original array 
samples by qRT-PCR. Expression of (A) MYD88, (B) TGFRβR3, (C) CSNK1E and 
(D) ITGA5 were obtained by qRT-PCR from RNA of primary chondrocytes treated with 
miR-3085-3p mimic and inhibitor, and non-targeting controls. Data were normalised to 
18S RNA expression. Data are shown as mean +/- S.E.M., n = 3. (** = p ≤0.01 analyzed 
by a Student’s t test). 
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Figure 5.9 Luciferase assays of cloned 3’UTR constructs of target genes in 
pmirGLO vector transfected into DF-1 cells and treated with microRNA mimics. 
100ng of cloned DNA construct with 50nM of either microRNA mimic, inhibitor or a 
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non-targeting control siRNAs were transfected with 25% (v/v) Lipofectamine 2000 into 
DF1 cells for 24 hours at 37°C, 5% (v/v) CO2.   Expression of firefly luciferase activity 
of (A) SFRP4 treated with miR-6509-5p mimic, (B) TIMP3 treated with miR-664b-3p 
mimic, (C) CILP treated with miR-664b-3p mimic, (D) MYD88 treated with miR-3085-
3p mimic and (E) ITGA5 treated with miR-3085-3p mimic were obtained by firefly 
luciferase assay of the transfected DF-1 cells. Firefly luciferase relative light units were 
normalised to Renilla relative light units. Data are mean +/- S.E.M., n = 3. (* = p ≤0.01, 
** = p ≤0.01 and *** = p ≤0.001 analyzed by a Student’s t test). 
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Figure 5.10 Luciferase assay of cloned 3’UTRconstructs of wild type ITGA5 and 
mutated ITGA5 constructs in pmirGLO vector transfected into DF-1 cells and 
treated with the miR-3085-3p mimic or a scrambled non-targeting control. 100ng 
of cloned DNA construct with either 50nM of either microRNA mimic or non-targeting 
control siRNAs were transfected with 25% (v/v) Lipofectamine 2000 into DF1 cells for 
24hours at 37°C, 5% (v/v) CO2. Expression of firefly luciferase activity when DF-1 
cells were transfected with either an ITGA5 wild type (WT) construct, an ITGA5 
construct with a mutation in one of two microRNA target sites (MUT 1, MUT 2), and 
an ITGA5 construct with a mutation in each microRNA target site (MUT 1+2). Firefly 
luciferase relative light units were normalised to Renilla relative light units. Data are 
mean +/- S.E.M., n = 3. (*** = p ≤0.001 analyzed by a Student’s t test). 
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5.3 Discussion 
In order to capitalise upon the discovery of new microRNAs in osteoarthritic cartilage, 
the functions of these microRNAs were also explored. A number of techniques were 
used to identify possible targets of each of miR-6509-5p, miR-664b-3p and miR-3085-
3p. 
A functional analysis using the gain- and loss-of-function theory was carried out. This 
involved using custom-designed siRNAs of each microRNA. Both mimics and 
inhibitors of each microRNA were created and used to treat primary chondrocyte cells 
for a period of 48 hours, a non-targeting control for each of the mimics and inhibitors 
was also used. The resultant extracted RNA was sent for microarray analysis to measure 
the expression of over 47000 genes, gene candidates and splice variants when treated 
with the siRNAs compared to the non-targeting controls. 
If a gene is a target of one of the microRNAs, then its expression should decrease when 
cells were treated with the mimic as this would introduce additional synthesised 
microRNA into the system which would increase suppression of the gene in question. 
When treated with the inhibitor the expression of the gene should increase, as the 
inhibitor would bind the existing microRNA within the system, reducing the amount of 
microRNA which is able to repress the same gene, resulting in an increase in gene 
expression. If a gene both decreases when treated with the mimic and increases when 
treated with the inhibitor, it is considered a potential target. This form of functional 
analysis is widely used to determine mRNA targets of microRNAs for example Cxcl12 
[Chemokine (C-X-C Motif) Ligand 12] was validated as a target of miR-140 in this 
manner. (Nicolas et al., 2008). 
However, the baseline level of microRNA already present in a cell can play a role in 
how effective the aforementioned methodology is. We found that the largest fold 
changes seen in the array were generally in response to the mimic siRNAs (Fig 5.2) 
however, the inhibitor of miR-3085-3p also seemed quite effective. The expression of 
each of the three microRNAs was measured in RNA obtained from siRNA treated cells 
prior to analysis by array. These data showed, for each microRNA, a dramatic increase 
in expression when treated with mimic compared to a non-targeting control, ranging 
from 40 to over 100 fold increases. In contrast, the expression of the microRNAs after 
treatment with a siRNA inhibitor, although decreased, showed much lower fold changes 
(data not shown). Overall, baseline expression of each microRNA within the primary 
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chondrocyte cells was relatively low, this is supported by the initial deep sequencing 
data in chapter 3 of primary chondrocytes and the subsequent northern blot validation 
using SW1353 RNA in chapter 4, meaning that the mimic siRNAs were more likely to 
have a larger effect than the siRNA inhibitors within the cells due to baseline levels 
initially being quite low. 
We already know that for a microRNA to suppress the expression of a gene it must bind 
to a specific sequence usually found within the 3’UTR of the gene in question (Akbari 
Moqadam et al., 2013). This binding can be either partial or complete between the target 
site and a location on the microRNA known as the seed site.  
For a candidate target discovered from the microarray to be a true target, there must be a 
form of binding site as well, otherwise this could represent a false positive result or 
indicate a downstream target. The potential seed sites of all 3 microRNAs were assessed 
and the exact target sequences they would bind to were hunted for amongst all the 
3’UTRs of the genes within the human genome as downloaded from Ensembl.org 
(Flicek et al., 2014). 
Four potential seed sites from each microRNA were used to produce the target sites 
sequences in the search: 6mer, 7merA1, 7merm8 and 8mer. The complementary 
sequences to these sites were used as search criteria using the R programming language 
with RStudios (R Core Team, 2013) and the Biostrings package (Pages et al., 2012). 
Unfortunately, the R code did not account for any partial target matches so it is likely 
that a number of potential gene targets were missed. It is still not known how many 
mismatches between a microRNA seed site and mRNA is acceptable to still function to 
repress the gene, meaning there are few gold standard negative gene : microRNA 
binding matches to work with to develop a perfect search algorithm (Akbari Moqadam 
et al., 2013). So to that end it was considered more productive in this project to simply 
look at exact microRNA seed site to mRNA target site matches. 
There are existing online algorithms which are able to search for potential gene targets 
of microRNAs based upon their structure in addition to their seed site sequence, 
however, these only function with existing, described microRNAs currently available 
on miRBase (Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008; Kozomara and 
Griffiths-Jones, 2011). There is another algorithm which is able to assess target binding 
of any microRNA sequence, whether or not it is present on the miRBase database, and 
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this is RNAhybrid (Kruger and Rehmsmeier, 2006). However this algorithm has a much 
lower throughput compared to the R programming assessment which was used. 
A large number of genes were found to have a least one 6mer target site within their 
3’UTR for each of the three microRNAs. 4,655 genes had target site/s for miR-6509-5p, 
9,690 genes had target site/s for miR-664b-3p and 8,930 genes had target sites for miR-
3085-3p. The top 20 of each are presented in table 5.13, table 5.14 and table 5.15. These 
potential targets were ranked based on the size and number of their target sites. 8mer 
target sites are thought to cause a more significant repression than shorter matches 
(Schnall-Levin et al., 2011), so the target genes were ranked firstly based on their 
number of 8mer matches, followed by the total number of 7mer matches and then their 
6mer matches. 
Out of the 47,000 genes, gene candidates and splice variants tested (shown in Fig.5.2), 
those that decreased in expression with the microRNA mimic and increased in 
expression with the microRNA inhibitor compared to non-targeting controls included 
11,871 for miR-6509-5p, 10,800 for miR-664b-3p and 10,953 for miR-3085 (Fig. 5.3). 
All of those genes were then cross-referenced with all of the genes discovered to have 
target sites with the computational analysis. This resulted in 1782 potential targets of 
miR-6509-5p, 3245 potential targets of miR-664b-3p and 3091 potential targets of miR-
3085-3p (shown in Fig. 5.5).   
Interestingly, when examining the array data without the addition of the computational 
target site analysis, a number of interferon-induced genes were found to be up-regulated 
when treated with the miR-6509-5p mimic and inhibitor, the miR-664b-3p mimic and 
inhibitor and the miR-3085 inhibitor suggesting an interferon response in the primary 
chondrocytes to the siRNAs. They were found to be within the top 10 genes showing 
regulation in this manner and included IFIT1 (Interferon-induced protein with 
tetratricopeptide repeats 1), IFIT2 (Interferon-induced protein with tetratricopeptide 
repeats 2), IFIT3 (Interferon-induced protein with tetratricopeptide repeats 3) and 
IFI44L (Interferon-induced protein 44-like). Interferon-induced genes are closely linked 
to the immune response to viral infection and IFIT1/2/3 are thought to target the 
FLUAV (influenza A virus), HPV (human papillomavirus), MHV (mouse hepatitis 
virus), RVFV (Rift Valley fever virus), SINV (Sindbis virus), VSV (vesicular stomatitis 
virus) and WNV (West Nile virus) viruses (Schoggins and Rice, 2011). The mechanism 
by which the IFIT genes respond to viral threats involves the formation of a 
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multiprotein complex which is able to sequester viral RNAs containing 5’ triphosphates 
(Pichlmair et al., 2011; Schoggins and Rice, 2011) The IFIT genes are also induced by 
double stranded RNA and lipopolysaccharides in addition to interferons (Fensterl and 
Sen, 2011).  
The induction seen from the array could therefore be the result of flooding the system 
with double stranded RNA in the form of synthesised microRNA mimics. However this 
does not account for the increased interferon presence when cells were treated with 
microRNA inhibitors as these were synthesised as single stranded RNA molecules. 
Research has shown a common problem of siRNA technology in causing off target 
effects, especially in the form of an immune response. For example, it has been found 
that synthesised siRNAs can activate RIG-1 (retinoic acid-induced gene 1) and Toll-like 
receptors which are sensors of foreign RNA and can trigger an innate immune response, 
of which interferons play a role (Olejniczak et al., 2011). Aagaard et al also discuss the 
common problem of off-target effects from the therapeutic use of siRNAs (Aagaard and 
Rossi, 2007).  
Although it was initially thought that short RNA sequences would not induce such a 
strong interferon response as the long dsRNA, it was found that specific siRNA 
sequences could activate an immune response through Toll-like receptors, resulting in 
the up-regulation of interferon-induced genes (Hornung et al., 2005; Marques and 
Williams, 2005). Further research from Reynolds et al also show that synthesised 
siRNAs can cause an immune response in transfected cells, and that although shorter 
siRNAs are thought to cause the smallest off target effects, this length threshold can 
differ greatly between cell types (Reynolds et al., 2006). Therefore it can be concluded 
that the apparent up-regulation in the array of many genes known to be interferon 
inducible is most likely a product of the off-targeting effects which siRNAs can cause, 
rather than a biologically relevant response to the microRNA mimics and inhibitors 
used in this project.  
The large number of potential targets which responded appropriately to the microRNA 
siRNAs (showing repression in response to mimics and de-repression in response to 
inhibitors) in addition to possessing target sites for each microRNA in question were 
triaged further with the introduction of fold-change cut off points based upon their 
expression in response to both the microRNA mimics and inhibitors. This ensured that 
genes were chosen which had more of a balanced response to both the mimics and 
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inhibitors. The baseline expression of each microRNA was relatively low meaning the 
mimic of each microRNA would show a higher response than the inhibitor. The cut off 
points were set at 50%, 25% and 12.5% of the largest fold-change of each mimic and 
inhibitor (Fig. 5.5). 
The triaged pool consisted of 23 genes for miR-6509-5p, 53 genes for miR-664b-3p, 
and 21 genes for miR-3085-3p. The three genes which contained the most microRNA 
target sites of miR-6509-5p, miR-664b-3p and miR-3085-3p and also increased in 
expression with the microRNA inhibitor and decreased in expression with the 
microRNA mimic were LRRC58, SNTB2 and ITPRIPL2 respectively. 
LRRC58 is known to selectively interact with protein complexes (Kobe and 
Deisenhofer, 1994). SNTB2 codes for a protein which binds and organises the 
subcellular localisation of specific membrane proteins (Lumeng et al., 1999). Finally, 
ITPRIPL2 is known to be a protein coding gene linked to the lncRNA class, however its 
exact function has not been elucidated. ITPRIP is a paralog of ITPRIPL2 and is known 
to enhance the inhibition of ITPR (Inositol 1, 4, 5-trisphosphate receptor) calcium 
release (Mignery and Sudhof, 1990; van Rossum et al., 2006). 
A number of the genes within these chosen subsets with known functions linked to 
cartilage, osteoarthritis, chondrogenesis or bone development were validated further 
using qRT-PCR which gives a greater sensitivity than microarray (Git et al., 2010).  
The chosen targets of miR-6509-5p included PDGFD (Platelet derived growth factor D) 
which functions as a mitogenic factor for MSC derived cells as well as being involved 
in the development of kidneys, eyes and brain (Reigstad et al., 2005), SFRP4 (Secreted 
frizzled-related protein 4) which is a modulator of WNT signalling mediated by frizzled 
membrane receptors (Jones and Jomary, 2002). Also a target, was CA5B (Carbonic 
anhydrase VB) which is a member of the zinc metalloenzyme family and is involved in 
adipocyte development and metabolism. It is also known to be expressed in human 
articular cartilage (Schultz et al., 2011). RBM3 (RNA binding motif protein 3) was a 
third potential target and is a cold inducible protein which appears to inhibit microRNA 
function (Pilotte et al., 2011) and is thought to play a role in innate immune responses 
(Matsuda et al., 2011). Finally there is TGFβR3 (Transforming growth factor, beta 
receptor III) which may be involved in the inhibition of TGFβ signalling (Moren et al., 
1992; Santibanez et al., 2011). 
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Targets of miR-664b-3p chosen were TIMP3 (tissue inhibitor of metalloproteinases 3) 
which is known to inhibit the MMP function of many MMPs (both membrane bound 
and transmembrane) including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, 
MMP-14 and MMP-15 (Kashiwagi, Tortorella et al. 2001; Visse and Nagase 
2003)(Apte et al., 1996). GPM6B (Glycoprotein M6B) was also chosen and is thought 
to be involved in osteoblast function and the development of bone (Drabek et al., 2011). 
VCAN (Versican) was the third gene chosen and encodes chondroitin sulphate 
proteoglycan which in turn is a cartilage ECM component (Sotoodehnejadnematalahi 
and Burke, 2013). Finally CILP (Cartilage intermediate layer protein) was the last 
chosen, which has a role in cartilage scaffolding and is also known to play a role in a 
number of cartilage diseases (Lorenzo et al., 1998; Wang et al., 2012). 
The selected targets of miR-3085-3p were TGFβR3 (Transforming growth factor, beta 
receptor III) and MYD88 [Myeloid differentiation primary response gene (88)] which is 
involved in the IL1 pathway as well as the activation of NFκB (Medzhitov et al., 1998). 
CSNK1E (Casein kinase 1, epsilon) was another and is part of the WNT pathway and 
responsible for phosphorylating both itself and other proteins including DVL1 
(Dishevelled segment polarity protein 1) and a number of proteins involved in the 
regulation of circadian rhythm: PER1 (Period circadian clock 1) and PER2 (Period 
circadian clock 2). Through this it is thought to play a role in the negative regulation of 
circadian rhythms (Hino et al., 2003; Wager-Smith and Kay, 2000). The final selected 
target of miR-3085-3p is ITGA5 (Integrin Alpha 5). This gene codes an integrin, which 
functions as a transmembrane link between the actin microfilaments of the cell 
cytoskeleton and extracellular factors such as the ECM (Takada et al., 2007). ITGA5 
encodes integrin alpha 5 which is a fibronectin receptor as well as an adhesion molecule 
(Nagae et al., 2012).  
Figures 5.6, 5.7 and 5.8 show the expression of these genes measured in the original 
RNA samples (isolated from cells treated with microRNA mimics, inhibitors and non-
targeting controls) sent to array.  
The genes which showed the same pattern of expression with qRT-PCR as in the array 
(SFRP4, TIMP3, CILP, MYD88, ITGA5, RBM3, TGFβR3 and VCAN) were selected 
for further experimental validation by a luciferase reporter assay. Sites within each 
gene’s 3’UTR which contained the microRNA target site/s were sub-cloned into 
pmirGLO plasmid vectors with a firefly luciferase component. Constructs of SFRP4, 
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TIMP3, CILP, MYD88 and ITGA5 were successfully sub-cloned and the constructs 
were transfected into DF-1 chicken fibroblast cells. DF-1 cells are a commonly used cell 
line for transfections, and were chosen in this instance, due to unsuccessful transfection 
attempts into both SW1353 chondrosarcoma cells and primary chondrocytes. DF-1 
cells, originating from chicken, should also not contain the human microRNAs under 
investigation at a baseline level, ruling out any non-specific effects. 
The transfected cells were then treated with the relevant microRNA mimic. The 
emission of relative light units were measured and if they decreased when cells were 
treated with a microRNA mimic compared to the non-targeting control then it suggests 
that the microRNA was binding to the target site within the construct, decreasing the 
translation of luciferase.  
Out of the 5 genes successfully cloned, 2 showed a statistically significant decrease in 
light units emitted when transfected cells were treated with the microRNA mimics 
compared to non-targeting controls suggesting a successful binding of microRNA to 
mRNA target. These were ITGA5 and TIMP3 (Fig. 5.9).  
TIMP3 is known to inhibit the function of ADAMTS4, ADAMTS5 and 
TACE/ADAM17 (tumor necrosis factor-α converting enzyme) expression (Amour et 
al., 1998; Brew and Nagase, 2010; Kashiwagi et al., 2001; Visse and Nagase, 2003). In 
addition to lung and cardiac deficiencies, (Fedak et al., 2004; Leco et al., 2001) the 
TIMP3 null mouse shows an increase in collagen and aggrecan degradation similar to 
that seen during osteoarthritis. Showing that TIMP3 plays an important role in 
metalloproteinase balance in cartilage homeostasis (Sahebjam et al., 2007). Mahmoodi 
et al have also shown an increased inflammatory response in TIMP3
-/-
 mice induced 
through arthritis by intra-articular injection, with an increased level of TNF-α detected. 
The research suggests that TIMP3 plays a role in combating TNF-α induced 
inflammation in inflammatory arthritis by the targeting of ADAM17 (Mahmoodi et al., 
2005). In addition to its role in arthritis, mutations in TIMP3 have also been linked to 
other diseases such as Sorby’s fundus dystrophy which is a degenerative eye disease 
(Weber et al., 1994). 
TIMP3 is also known to inhibit many MMPs, a number of which are involved in the 
progression of osteoarthritis, specifically MMP1, 8 and 13 which are known to be up-
regulated in osteoarthritic cartilage compared to normal (Billinghurst et al., 1997; 
Kevorkian et al., 2004). It has also been found that the degradation of collagen by 
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MMPs can be reduced by the introduction of inhibitors of these collagenases (Dahlberg 
et al., 2000; Poole et al., 2002). This suggests that TIMP-3 could be a useful target of 
miR-664b-3p to study further, and that miR-664b-3p could play an interesting role 
within the progression of osteoarthritis. 
Additionally, mutant constructs of ITGA5 were also created to see if the effect of the 
microRNA mimic seen with the original construct could be prevented (Fig. 5.10). 
Mutant constructs of TIMP3 were also attempted but sub-cloning proved unsuccessful. 
Two constructs of ITGA5 contained mutations in one of the two target sites present, 
whilst the third contained two mutated target sites. The luciferase assay shows the 
emission of light units significantly decreasing in cells transfected with the original 
construct and the miR-3085-3p mimic compared to a non-targeting control showing a 
decrease in luciferase translation meaning that the miR-3085-3p mimic was indeed 
binding to the sub-cloned target site. In comparison, the light units emitted in cells 
transfected with each of the three mutated constructs showed no significant change 
when treated with the miR-3085-3p mimic compared to the non-targeting control, 
showing that luciferase translation was unaffected due to the abrogation of microRNA : 
mRNA binding. 
ITGA5 codes an integrin, which functions as a transmembrane link between the actin 
microfilaments of the cell cytoskeleton and extracellular factors such as the ECM 
(Takada et al., 2007). ITGA5 encodes integrin alpha 5 which is a fibronectin receptor as 
well as an adhesion molecule (Nagae et al., 2012). The integrin alpha 5 chain undergoes 
post-translational cleavage resulting in disulphide-linked light and heavy chains which 
are able to bind with integrin beta 1 and form the known integrin alpha5beta1 receptor 
which binds to fibronectin and fibrinogen (Nagae et al., 2012).  Fibronectin is a 
glycoprotein found in the ECM of normal articular cartilage and is thought to play a role 
in the organisation of the ECM. It has been found to increase in expression in 
osteoarthritic cartilage due to increased production by chondrocytes, and this is thought 
to result in a potential role in the changing phenotype of chondrocytes during 
osteoarthritis (Chevalier, 1993). 
Integrin alpha 5 beta 1 is also known to mediate chondrocyte attachment via COMP 
(cartilage oligomeric matrix protein) (Chen et al., 2005).  Knockout mice of α5 show a 
lethal phenotype with aberrant brain and intestine development and function, whilst β1 
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knock out mice shows a severe phenotype with defects within the vascular 
system.(Schaffner et al., 2013).  
In addition, it has been found that Integrin alpha5beta1 has a role as a mechanoreceptor 
in both normal and OA chondrocytes. Millward-Sadler et al discovered that when 
subjected to pressure-induced strain, OA chondrocytes responded differently to their 
non-OA counterparts, with the cell membranes showing a depolarisation or 
hyperpolarisation response respectively. Though use of alpha 5 antibodies, Millward-
Sadler and colleagues have determined that alpha5beta1 plays a vital role in this 
mechanotransduction event (Millward-Sadler et al., 2000). 
Integrin alpha 5 beta 1 is obviously multifunctional and important in the cellular 
connections to ECM components. Using miR-3085-3p to manipulate gene expression 
could result in an impact upon both osteoarthritis progression and mechanotransduction 
pathways in the disease, but is also likely to affect other vital functions, unless the affect 
can be directed specifically to cartilage tissue. 
Species conservation of microRNAs is a common method used to identify ‘novel’ 
microRNAs between species, with the often correct theory that the same microRNAs 
are often found within the genome of related species (Zhang et al., 2006a). The same 
process can be used when identifying targets of microRNAs which are found within 
multiple species. If a microRNA is conserved, then it is likely that its seed site is also 
conserved and it will bind to a common gene or homologue. For example, ITGA5 was 
found to be a target of miR-3085-3p. ITGA5 transcripts can be found in 50 species’ 
genomes in addition to humans (Ensembl.org). Out of those 51 species, the 3’UTR 
sequence was only available for 17. And of those, 9 species (Chimpanzee, Dog, Ferret, 
Gorilla, Human, Marmoset, Mouse, Orangutan and Rat) were found to contain 6mer 
target sites for miR-3085-3p (data not shown) similar to that seen in humans, in addition 
to those species’ genomes containing the miR-3085-3p sequence itself. 
There are many experimental methods available to validate gene targets of microRNAs, 
including qRT-PCR, luciferase reporter assays and western blotting. QRT-PCR 
examines the co-expression of the microRNA and target mRNA, whilst western blots 
describe effects at the protein level. Reporter assays in turn show direct miRNA: mRNA 
interactions (Kuhn et al., 2008; Thomson et al., 2011). There are of course certain 
drawbacks with all experimental validation methodology, with successful sub-cloning 
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vital for reporter assays, and effective antibodies and primer probe sets necessary for 
western blotting and qRT-PCR respectively.  
Targets which are regulated at the mRNA level can be detected by microarray, qRT-
PCR and luciferase reporter assays and it is thought that the majority of microRNA 
targets can be detected by changes at the mRNA level due to the destabilisation caused 
by the microRNA: mRNA interaction (Guo et al., 2010). This suggests that the main 
mechanism of gene suppression by microRNAs is through mRNA destabilisation rather 
than affecting the efficiency of translation, in turn meaning that experimental validation 
looking at mRNA changes would be more efficient than examining protein regulation 
by western blot. Guo et al compared ribosome profiling with mRNA detection and 
discovered that over 84% of the protein reduction observed could be accounted for by a 
corresponding mRNA expression decrease (Guo et al., 2010; van Rooij, 2011). 
However recent data has shown that there are microRNA targets which can only be 
detected at the protein level such as Smad3 as a miR-140 target (Pais et al., 2010), this 
suggests that proteome analysis would be necessary in cases where a change in mRNA 
levels of a likely candidate target is not detected. 
Methods of functional analysis of microRNAs more specific to cartilage and 
chondrocyte biology include the use of chondrogenesis assays such as cartilage disc 
models. Human mesenchymal stem cells can be induced through chondrogenesis to 
form cartilage discs with expression of known cartilage matrix genes (Murdoch et al., 
2007). Dr. Barter from Newcastle University has shown an inhibition of Dicer within 
the chondrocytes of these discs results in malformation of the disc (Dr Matt Barter, 
Newcastle University, Personal Communication), showing that the microRNA 
population is vital for aspects of cartilage development. The general effect of one or 
multiple microRNAs can be assessed in the same way via overexpression or inhibition 
within these cartilage discs to determine if the microRNAs play a role in chondrocyte 
and cartilage formation. 
Additional methods of experimental target validation include utilising the interaction 
between a microRNA and its target via the Ago (Argonaute) protein complex. Pull-
down methods can be employed to detect the mRNA targets bound to these complexes 
alongside the microRNA (Beitzinger et al., 2007). Further techniques involve the use of 
in vivo experimentation; however there are many known issues with the delivery system 
of in vivo applications. For example, siRNAs are degraded easily by enzymes and 
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RNAses within the blood and tissue, and it has been found that accumulation of the 
siRNA in the area of interest can be problematically low, due mainly to poor delivery 
methods.  
There have been a number of approaches to address these problems, including the use of 
electroporation and use of a carrier for the siRNA, such as liposomal bubbles (Higuchi 
et al., 2010). MicroRNAs have also been successfully injected into knee joints using an 
atelocollagen complex as a carrier. Atelocollagen consists of a purified type 1 collagen. 
Nagata et al used a microRNA-atelocollagen complex to effectively deliver miR-15a to 
the knee joints of mice (Nagata et al., 2009). This substance appears to be very effective 
in siRNA delivery and has also been used in the delivery of siRNAs to various cancer 
tissues (Mu et al., 2009). 
This microRNA project has utilised a number of functional and target analysis 
methodologies to examine candidate targets of the three microRNAs validated in 
chapter 4. These combined data have determined miR-3085-3p to have at least one fully 
experimentally validated target which is known to play a role in osteoarthritis: ITGA5, 
with TIMP3 being a highly likely target of miR-664b-3p. This means that the two 
microRNAs may be able to influence aspects of osteoarthritis if correctly manipulated, 
although obviously not all of their potential targets have, as yet, been investigated which 
could result in unforeseen consequences if they were to be used therapeutically.  
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Chapter 6 – General Discussion and Future Directions 
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6.1 – MicroRNA profiling 
This project has addressed the hypothesis that cartilage contains as yet unidentified 
microRNAs which may contribute to skeletal development or osteoarthritis.  
Osteoarthritis is a debilitating disease affecting over 8 million people in the UK today, a 
number which is thought to increase to over 17 million by the year 2030 (Arthritis-Care, 
2012). It is most common in the elderly but is also associated with risk factors such as 
obesity and mechanical injury (Attur et al., 2010). It is disease which encompasses the 
entire joint, including the progressive degradation of cartilage (Martel-Pelletier et al., 
2008) and is the focus of much research. 
MicroRNAs are small RNA molecules which effect gene expression. Initially thought to 
be merely fine tuners of gene regulation, extensive publications have demonstrated that 
microRNAs are also vital to survival (shown by the embryonic lethal Dicer knockout 
mouse model (Bernstein et al., 2003)) and play important roles in a large range of 
diseases and developmental processes, in addition to their continued minor regulation of 
a number of genes. Previous research has already shown a role for microRNAs in 
cartilage development and pathology, such as miR-140 and miR-455, two microRNAs 
known to be cartilage specific with roles in development, and altered expression in 
osteoarthritis (Miyaki et al., 2009; Miyaki et al., 2010; Swingler et al., 2012). 
This project used a targeted approach first to identify the existing miRNome of 
osteoarthritic cartilage in as great a detail as possible, there has been little previous 
exploration into identifying the entire microRNA population of cartilage with only one 
recent study by Sun et al discovering 286 known microRNAs and 86 novel microRNAs, 
however this was in rat cartilage rather than human (Sun et al., 2011b). A next 
generation deep sequencing approach of primary chondrocytes extracted immediately 
from the osteoarthritic cartilage of three patients was utilised on the Illumina platform. 
To enable the most accurate detection rate, newly developed HD adapters were also 
used to reduce sequence bias (Sorefan et al., 2012). 
Chapter 3 describes the results from the sequencing analysis. 990 microRNAs described 
on miRBase were discovered, along with 1621 novel microRNA candidates. These 
sequences were ascribed microRNA status by Dr H. Pais (School of Computing, UEA) 
using the MiRCat software package (Moxon et al., 2008). Ideally, if the theme of this 
project were to be extended and awarded further funding, the deep sequencing would be 
replicated on further OA patients. It is already known that samples often show wide 
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variation between patients, potentially due to undefined subtypes (Bierma-Zeinstra and 
Verhagen, 2011). One way to control for this would be to carry out multiple replicates, 
allowing for the detection of the microRNA population to be compared between 
multiple patients to discover the most common miRNome for osteoarthritis. Subtypes of 
osteoarthritis could also be investigated to find a common miRNome and enable 
stratifying of patients. Using additional patients would also reinforce and verify the 
discovery of novel microRNAs, if the same candidate is detected in multiple patients it 
suggests that it is a genuine detection and not a false positive created by the presence of 
a degraded longer sequence which fulfils the criteria of a microRNA.  Deep sequencing 
analysis could also be carried out on primary chondrocytes from non-OA control 
cartilage samples, to allow comparison of the miRNome between diseased and normal 
tissues. 
However, carrying out next generation sequencing on so many multiple samples does 
incur greater cost. This could however be negated, as sequencing technologies improve, 
especially in microRNA detection, and become cheaper. One example of this is 
nanopore sequencing. This method works by the passing of a single stranded DNA 
polymer through a protein nanopore. The nucleotide bases are identified as they pass 
through the pore. The technology is also able to detect specific microRNAs; the current 
passing through the nuclear pore is measured, with changes in the current signifying a 
probe-bound microRNA passing through the pore (Schneider and Dekker, 2012). 
The large number of new sequences discovered in this project made validation of all in 
the timeframe impossible. To this end, a smaller pool of promising candidates were 
chosen to investigate further based on a number of criteria. 
Triaging from the initial pool of 1621 candidate novel microRNAs to 16 was based on, 
first of all, whether they were present in all three patients, as presence in more than one 
patient increases the chance that the candidate was real. Secondly, the presence of the 
complementary strand of the candidate microRNA within the expression profile was 
also used as a positive selection. Both strands of a microRNA are more commonly 
being found to be expressed and functional as opposed to having just one dominant 
strand (Winter et al., 2009). 
Finally, the candidates were cross-referenced with other sequencing projects obtained 
by Professor Tamas Dalmay’s lab (School of Biological Sciences, UEA) to see if they 
appeared in other tissues or cell lines, this would provide support to their microRNA 
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status if they were detected elsewhere, and suggest that they were not just artefacts of a 
specific experiment. The two cell lines compared were DLD-1 wild type and DLD-1 
dicer knockdown. In addition to just comparing presence of the sequences between the 
projects, Dicer is an enzyme known to be vital to microRNA synthesis. If the 
candidate’s expression was down-regulated in the Dicer knock down cell line compared 
to the wild type, then this added credibility to the candidacy, suggesting that the 
sequence was processed by the Dicer enzyme. However, this factor was only included 
in combination with the previously mentioned criteria, and a candidate was not 
discarded if it fulfilled the others but did not appear to be Dicer dependent, this is due to 
the growing idea that not all microRNAs are dependent upon Dicer for their synthesis 
(Cheloufi et al., 2010). 
Future work could focus on the validation of additional candidate microRNAs, using 
data obtained from subsequent sequencing analyses of primary chondrocytes, to 
determine the most likely true candidates. In addition, new techniques adopted in the lab 
since the initial sequencing experiment include a more efficient method of cartilage 
crushing , this could provide cleaner RNA for use in future sequencing, and could be 
used in addition to primary chondrocytes to provide a fuller overview of microRNA 
expression in osteoarthritis and cartilage. 
Within microRNA research, over 30,000 microRNAs have been discovered across all 
species, however in comparison only a small number have been experimentally 
validated and further investigated functionally. If this is also combined with the 
knowledge that each microRNA could have hundreds of possible targets (Brennecke et 
al., 2005; Hendrickson et al., 2009); then there is still a wealth of untapped information 
regarding microRNA biology. The next direction of general microRNA research will 
most likely focus more heavily in fully understanding the existing microRNAs in 
physiology and pathophysiology in addition to the discovery of new microRNAs as 
detection methods are increasingly improved. This could be addressed with a more 
systems biology based approach (Watanabe and Kanai, 2011). MicroRNA biology is 
complex, and to truly understand the role of microRNAs within a specific tissue or 
disease, then a broader look must be taken to incorporate the entirety of miRNA-mRNA 
interactions within the system as a whole. This would require a combination of both 
transcriptomic and proteomic analysis of target mRNAs and microRNAs, in addition to 
a computational analysis of the targets and biological pathways. 
220 
 
6.2 – MicroRNA validation 
Chapter 4 is focussed on the validation of the select few candidate novel microRNAs 
described in chapter 3. 16 candidates were examined and designated the temporary IDs 
of Novel 1 – 16. Since the initial sequencing analysis and microRNA validation portion 
of this PhD, the miRBase database has been updated 3 times and 6 of the 16 candidate 
novel microRNAs have been subsequently identified by other research groups and 
added to the database. 
Candidate novel 2 is described as hsa-miR-6509-5p (Joyce et al., 2011), candidate novel 
7 is known as hsa-miR-664b-3p (Friedlander et al., 2012), candidate novel 8 is a 
truncated form of hsa-miR-1277-5p (Morin et al., 2008). Candidate novel 10 is 
described as hsa-miR-487a-5p in humans (Fu et al., 2005) and a similar sequence can be 
found as oar-miR-487a-5p in sheep (Caiment et al., 2010). Candidate novel 11, 
although still not annotated in humans can be found in mouse and rat as mmu-miR-
3085-3p and rno-miR-3085 respectively (Chiang et al., 2010; Linsen et al., 2010). 
Finally candidate novel 12 can be found in humans as hsa-miR-539-3p (Sewer et al., 
2005), with marginally altered sequences found in mouse, rat and sheep as mmu-miR-
539-3p, rno-miR-539-3p and oar-miR-539-3p respectively (Caiment et al., 2010; 
Landgraf et al., 2007; Sewer et al., 2005). Additionally, candidate novel 15 was present 
in miRBase V.19 but has since been removed and annotated as a fragment of tRNA. 
Although these microRNAs have now been described on miRBase, none have been 
experimentally validated, with identification coming only from sequencing data or 
bioinformatics analysis. 
The literature identifying candidate novels 8, 10 and 12 as microRNAs were published 
before the version of miRBase (V.17) used during the initial data analysis; however 
those microRNAs were not identified as existing microRNAs by the bioinformatics 
analysis carried out for this project. This could be due to an error within the data 
analysis, or potentially the data from the literature referenced was not added to the 
miRBase database until after V.17 and hence not available for inclusion in the initial 
results. 
Validation of the novel candidates encompassed a myriad of techniques, including 
northern blotting using RNA obtained from the chondrosarcoma cell line SW1353, to 
establish the size of these sequences and ascertain if the candidate microRNAs detected 
during the deep sequencing were, in fact, fragments of larger sequences and hence not 
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microRNAs. QRT-PCR was also used to detect the candidate microRNAs in a number 
of tissues and cell types, and microRNA expression was also measured in 
chondrogenesis and de-differentiation models as well as a Dicer knockout cell line. In 
situ hybridisation was also utilised to localise a candidate microRNA to a specific 
location within mouse embryo. Through this, candidate novels 2, 7 and 11 (miR-6509-
5p, miR-664b-3p and miR-3085-3p respectively) were assigned microRNA status. 
Due to time constraints, only miR-3085-3p was investigated with in situ hybridisation, 
and only one age of embryo was used [a developmental stage where a known cartilage 
selective microRNA is readily detected (Tuddenham et al., 2006)]. Further 
experimentation could involve all three candidate microRNAs at the same time point to 
verify results, but also use a range of developmental stages of embryo. In situ 
hybridisation could also be carried out on human cartilage samples (both osteoarthritic 
and control) as well as sections of embryo in addition to whole mount. This would 
allow for a more precise localisation of the microRNA in mouse embryo tissue, and 
identify whether a similar pattern of expression can be seen within human cartilage.    
With additional time, a larger number of the 1621 candidate novel microRNAs could be 
investigated to establish their true microRNA identity before inclusion in miRBase. 
This would then provide a more accurate map of the miRNome of osteoarthritic 
cartilage. 
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6.3 – MicroRNA functional analysis 
Chapter 5 continued the analysis of the three validated microRNAs in the form of 
functional analysis. This utilised a computational search with RStudios, searching for 
complementary target sites of the three microRNAs in the 3’UTRs of the genes of the 
human genome, including all exacting matches of 6mers, 7merm8s, 7merA1s and 
8mers. A genome analysis was also carried out on primary chondrocytes treated with 
siRNAs of the candidate microRNAs, and the results correlated with the computational 
analysis. A gene was considered a potential target if it contained one or more of the four 
target sites, if its expression decreased in response to treatment with a microRNA mimic 
and if expression increased in response to microRNA inhibition. 
This combined analysis produced a large number of potential targets; 1782 for miR-
6509-5p, 3245 for miR-664b-3p and 3091 for miR-3085-3p. Fold change cut off points 
addressing gene expression were introduced to triage the results down to a manageable 
number and a selection for each microRNA were analysed by sub-cloning and luciferase 
assays. The most likely target obtained from this assessment was ITGA5 (a fibronectin 
receptor (Nagae et al., 2012), a target for miR-3085-3p. 
Further study would allow for a more in depth functional analysis of each of the three 
candidates such as exploring the remaining targets from the computational and genome 
array analysis, and utilising additional techniques such as western blotting to determine 
if protein expression of the targets of interest are affected when the microRNA is 
inhibited or enhanced. The interaction between a microRNA and its target via the Ago 
protein complex can also be utilised in functional analysis. Pull-down methods can be 
employed to detect the mRNA targets bound to these complexes alongside the 
microRNA (Beitzinger et al., 2007).  
Additionally, a computational search for the microRNA targets could be carried out 
within the 5’UTR of genes plus the coding region, as research has increasingly shown 
that microRNAs can bind at more than just the 3’UTR (Lee et al., 2009). This would 
give a larger pool of targets to compare with the genome array data. It is also known, 
that a microRNA: mRNA binding does not have to be an exact complementary match. 
Further analysis could take this into account, searching for variations in the target 
sequence which may still function. 
The expression of the microRNA candidates was measured in a mesenchymal stem cell 
chondrogenesis assay as part of the validation process described in chapter 4. This could 
223 
 
be taken further in future functional studies. Each candidate microRNA could be 
inhibited or overexpressed, and the cartilage disc produced as the end point of the assay 
could be analysed for functional or physical changes which would suggest a substantial 
role of the microRNA in cartilage development. In addition, the candidate microRNAs 
could be investigated as to whether they play a role in determining cell fate from 
mesenchymal stem cells, resulting in the formation of chondrocytes, osteocytes or 
adipocytes. It has already been shown that microRNAs can play an important role in 
cell fate determination. For example, Cordes et al found that both miR-145 and miR-
143 are heavily  involved in the differentiation of smooth muscle cells from multipotent 
murine cardiac progenitors (Cordes et al., 2009). 
A more long term goal to address the functional qualities of the candidate microRNAs, 
specifically miR-3085-3p which was found to be more cartilage specific than the other 
two, would to be to create a miR-3085-3p transgenic mouse and analyse the phenotype. 
Conditional cartilage and skeletal knockouts could also be carried out to determine if 
there is a detrimental effect to cartilage development in vivo. 
Finally, all experiments involved either primary chondrocytes or cartilage obtained from 
end stage patients. Future experiments should, if possible, examine a range of 
osteoarthritic grades, and subtypes (of which there is yet no exact number) (Bierma-
Zeinstra and Verhagen, 2011) . This could provide a pattern of microRNA expression 
across osteoarthritis progression. 
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6.4 – Final summary 
The hypothesis of this PhD that cartilage contains as yet unidentified microRNAs which 
may contribute to skeletal development or osteoarthritis, has been proven, with a 
significant miRNome with multiple novel microRNAs discovered in primary 
chondrocytes obtained from osteoarthritic cartilage samples. A number of the candidate 
microRNAs have been investigated and identified as true microRNAs, however there 
are many more left to analyse.  
So, whilst the project has substantially addressed its original guidelines, there are much 
data left to progress this area of study forward. We already know microRNAs to be very 
useful in terms of understanding disease and their use (particularly circulating 
microRNAs) as biomarkers (Weiland et al., 2012). Over 100 microRNAs have been 
identified as biomarkers of disease so far, including miR-155, miR-133a, and miR-202 
which have been identified as biomarkers for early pancreatic neoplasia, coronary artery 
disease and early stage breast cancer respectively (Fichtlscherer et al., 2010; Habbe et 
al., 2009; Schrauder et al., 2012; Weiland et al., 2012). MicroRNAs have also been 
implicated as biomarkers of arthritic diseases. For example, recently, Beyer et al found 
let-7e to be a probable biomarker of osteoarthritis at the knee and hip (Beyer et al., 
2014). 
The data from this project will therefore contribute to the growing field of microRNA 
biology in regards to osteoarthritis, and will hopefully aid in the battle against this 
increasingly common disease. 
 
 
 
 
 
 
 
 
225 
 
Appendices 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
226 
 
Appendix 1- qRT-PCR primers and probe sequences 
Gene 
Symbol 
Gene name Primer/probe Sequence 
18S 
18S Ribosomal 
RNA 
Forward primer: 
Reverse primer: 
Probe: 
5’-GCCGCTAGAGGTGAAATTCTTG-3’ 
5’-CATTCTTGGCAAATGCTTTCG-3’ 
5’-FAM-ACCGGCGCAAGACGGA-TAMRA-3’ 
ACAN Aggrecan 
Forward primer: 
Reverse primer: 
Probe: 
5’-CCGCTACGACGCCATCTG-3’ 
5’-CCCCCACTCCAAAGAAGTTTT-3’ 
5’-FAM-
TACACAGGTGAAGACTTTGTGGACATCCCA-
TAMRA-3’ 
CA5B 
Carbonic 
anhydrase VB 
Forward primer: 
Reverse primer: 
Probe: 
5’-ACACCGTGGACAGCAAATG-3’ 
5’-CAAATCTGACTGCGTTCCAA-3’ 
Probe #3 (Roche Universal probe 
library) 
CILP 
Cartilage 
intermediate 
layer protein 
Forward primer: 
Reverse primer: 
Probe: 
5’-ATATAAGGCCGGCACTGGA-3’ 
5’-GGTCCCCTGGGAAGTTTCT-3’ 
Probe #15 (Roche Universal probe 
library) 
COL1A1 Type I collagen 
Forward primer: 
Reverse primer: 
Probe: 
5’-GGGATTCCCTGGACCTAAAG-3’ 
5’-GGAACACCTCGCTCTCCA-3’ 
Probe #67 (Roche Universal probe 
library) 
COL2A1 Type II collagen 
Forward primer: 
Reverse primer: 
Probe: 
5’-GTGAACCTGGTGTCTCTGGTC-3’ 
5’-TTTCCAGGTTTTCCAGCTTC-3’ 
Probe #9 (Roche Universal probe 
library) 
COL3A1 Type III collagen 
Forward primer: 
Reverse primer: 
Probe: 
5’-CTGGACCCCAGGGTCTTC-3’ 
5’-CATCTGATCCAGGGTTTCCA-3’ 
Probe #20 (Roche Universal probe 
library) 
COL9A1 Type IX collagen 
Forward primer: 
Reverse primer: 
Probe: 
5’-AGATAATCCTCAAGTTTCTGTTCCA-3’ 
5’-GCAGCTCATGGCAAGTTTCT-3’ 
Probe #89 (Roche Universal probe 
library) 
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Appendix 1 - qRT-PCR primers and probe sequences 
Gene 
Symbol 
Gene name Primer/probe Sequence 
COL10A1 Type X collagen 
Forward primer: 
Reverse primer: 
Probe: 
5’-CACCTTCTGCACTGCTCATC-3’ 
5’-GGCAGCATATTCTCAGATGGA-3’ 
Probe #6 (Roche Universal probe 
library) 
COL11A1 Type XI collagen 
Forward primer: 
Reverse primer: 
Probe: 
5’-TGCTCAAGCTCAGGAACCTC-3’ 
5’-CCTCTGTTACACTTTCAGCCTCTT-3’ 
Probe #38 (Roche Universal probe 
library) 
COL27A1 Type XXVII collagen 
Forward primer: 
Reverse primer: 
Probe: 
5’-GGTCCTATCCAATTGCAACAA-3’ 
5’-AGCCGGTCTGGATAGCTGTA-3’ 
Probe #43 (Roche Universal probe 
library) 
CRTAC1 
Cartilage acidic 
protein 1 
Forward primer: 
Reverse primer: 
Probe: 
5’-GGAGTGTGGCCAAGGATTC-3’ 
5’-GATGCATTCATTGGTGTCCA-3’ 
Probe #18 (Roche Universal probe 
library) 
CSNK1E 
Casein kinase 1 
epsilon 
Forward primer: 
Reverse primer: 
Probe: 
5’-TCCATCAACACGCACCTG-3’ 
5’-GGAGCCCAGGTTGAAGTACA-3’ 
Probe #80 (Roche Universal probe 
library) 
DICER1 Dicer1 
Forward primer: 
Reverse primer: 
Probe: 
5’-TCCGATGGTTCTCGAAGG-3’ 
5’-GCAAAGCAGGGCTTTTCAT-3’ 
Probe #47 (Roche Universal probe 
library) 
GPM6B Glycoprotein M6B 
Forward primer: 
Reverse primer: 
Probe: 
5’-AGTACCATCCCGTGCCAAC-3’ 
5’-CTCCCAGACACTTGATGCAG-3’ 
Probe #64 (Roche Universal probe 
library) 
ITGA5 Integrin alpha 5 
Forward primer: 
Reverse primer: 
Probe: 
5’-CCCATTGAATTTGACAGCAA-3’ 
5’-TGCAAGGACTTGTACTCCACA-3’ 
Probe #55 (Roche Universal probe 
library) 
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Appendix 1 - qRT-PCR primers and probe sequences 
Gene 
Symbol 
Gene name Primer/probe Sequence 
Hsa-miR-
140-5p 
Hsa-miR-140 
Forward primer: 
Reverse primer: 
Probe: 
Sequence not known 
Sequence not known 
Sequence not known 
Hsa-miR-
455-5p 
Hsa-miR-455 
Forward primer: 
Reverse primer: 
Probe: 
Sequence not known 
Sequence not known 
Sequence not known 
MMP1 
Matrix 
metalloproteina
se-1 
Forward primer: 
Reverse primer: 
Probe: 
5’-AAGATGAAAGGTGGACCAACAATT-3’ 
5’-CCAAGAGAATGGCCGAGTTC-3’ 
5’-FAM-
CAGAGAGTACAACTTACATCGTGTTGCGGCTC-
TAMRA-3’ 
MMP13 
Matrix 
metalloproteina
se-2 
Forward primer: 
Reverse primer: 
Probe: 
5’-AAATTATGGAGGAGATGCCCATT-3’ 
5’-TCCTTGGAGTGGTCAAGACCTAA-3’ 
5’-FAM-
CTACAACTTGTTTCTTGTTGCTGCGCATGA-
TAMRA-3’ 
MYD88 
Myeloid 
differentiation 
primary 
response gene 
88 
Forward primer: 
Reverse primer: 
Probe: 
5’-GGACCCAGCATTGAGGAG-3’ 
5’-ACAGCGGCCACCTGTAAA-3’ 
Probe #18 (Roche Universal probe library) 
PDGFD 
Platelet derived 
growth factor D 
Forward primer: 
Reverse primer: 
Probe: 
5’-CCATGACCGGAAGTCAAAAG-3’ 
5’-ATTCCTGGGAGTGCAACTGT 
Probe #85 (Roche Universal probe library) 
RBM3 
RNA binding 
motif protein 3 
Forward primer: 
Reverse primer: 
Probe: 
5’-GAGAGCCATGAACGGAGAGT-3’ 
5’-CCTCTAGAGTAGCTGCGACCA-3’ 
Probe #10 (Roche Universal probe library) 
MYD88 
Myeloid 
differentiation 
primary 
response gene 
88 
Forward primer: 
Reverse primer: 
Probe: 
5’-GGACCCAGCATTGAGGAG-3’ 
5’-ACAGCGGCCACCTGTAAA-3’ 
Probe #18 (Roche Universal probe library) 
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Appendix 1 - qRT-PCR primers and probe sequences 
Gene 
Symbol 
Gene name Primer/probe Sequence 
PDGFD 
Platelet derived 
growth factor D 
Forward primer: 
Reverse primer: 
Probe: 
5’-CCATGACCGGAAGTCAAAAG-3’ 
5’-ATTCCTGGGAGTGCAACTGT-3’ 
Probe #85 (Roche Universal probe 
library) 
RBM3 
RNA binding 
motif protein 3 
Forward primer: 
Reverse primer: 
Probe: 
5’-GAGAGCCATGAACGGAGAGT-3’ 
5’-CCTCTAGAGTAGCTGCGACCA-3’ 
Probe #10 (Roche Universal probe 
library) 
SFRP4 
Secreted frizzled-
related protein 4 
Forward primer: 
Reverse primer: 
Probe: 
5’-GCCTGAAGCCATCGTCAC-3’ 
5’-CCATCATGTCTGGTGTGATGT-3’ 
Probe #88 (Roche Universal probe 
library) 
SNORA36A 
Small nucleolar 
RNA, H/ACA box 
36A 
Forward primer: 
Reverse primer: 
Probe: 
Sequence not known 
Sequence not known 
Sequence not known 
TGFβR3 
Transforming 
growth factor, 
beta receptor III 
Forward primer: 
Reverse primer: 
Probe: 
5’-GATTTCATCTTCGGCTTGAAA-3’ 
5’-GCTCAGGAGGAATAGTGTGGA-3’ 
Probe #82 (Roche Universal probe 
library) 
TIMP3 
TIMP 
metallopeptidase 
inhibitor 3 
Forward primer: 
Reverse primer: 
Probe: 
5’-GTGCAACTTCGTGGAGAGGT-3’ 
5’-AGCAGGACTTGATCTTGCAGT-3’ 
Probe #14 (Roche Universal probe 
library) 
VCAN Versican 
Forward primer: 
Reverse primer: 
Probe: 
5’-GCACCTGTGTGCCAGGATA-3’ 
5’-CAGGGATTAGAGTGACATTCATCA-3’ 
Probe #54 (Roche Universal probe 
library) 
WDR91 
WD repeat-
containing 91 
Forward primer: 
Reverse primer: 
Probe: 
5’-CTGGGGGACTCGGAACTT-3’ 
5’-AGGAAGCCCACACGAGGT-3’ 
Probe #14 (Roche Universal probe 
library) 
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Appendix 2 - Oligonucleotide sequences of northern blot probes for 
candidate novel and known microRNAs 
 
MicroRNA ID Probe sequence Positive control sequence 
Hsa-miR-140-
3p 
5’-CCGTGGTTCTACCCTGTGGTA-3’ 5’-TACCACAGGGTAGAACCACGG-3’ 
Hsa-miR-140-
5p 
5’-CTACCATAGGGTAAAACCACTG-3’ 5’-CAGTGGTTTTACCCTATGGTAG-3’ 
Novel 1 5’-GCTCTACACGTTCAGAGAAACTT-3’ 5’-AAGTTTCTCTGAACGTGTAGAGC-3’ 
Novel 2 5’-GTTCCACTGCCACTACCTAAT-3’ 5’-ATTAGGTAGTGGCAGTGGAAC-3’ 
Novel 3 5’-ACCAGGGACCTTTAGATCTTCAG-3’ 5’-CTGAAGATCTAAAGGTCCCTGGT-3’ 
Novel 4 5’-CCACTGAGCTACACCCCC-3’ 5’- GGGGGTGTAGCTCAGTGG-3’ 
Novel 5 5’-ACTCGGATCGCTGGATTCA-3’ 5’-TGAATCCAGCGATCCGAGT-3’ 
Novel 6 5’-TCCTCTAGATAGTCAAGTTCGA-3’ 5’-TCGAACTTGACTATCTAGAGGA-3’ 
Novel 7 5’-TGTAGGCTGGGAGGCAAATGAA-3’ 5’-TTCATTTGCCTCCCAGCCTACA-3’ 
Novel 8 5’-ATACGTACATATATATATATA-3’ 5’-TATATATATATATGTACGTAT-3’ 
Novel 9 5’-CAGATCGCAACTCCCAGGCATC-3’ 5’-GATGCCTGGGAGTTGCGATCTG-3’ 
Novel 10 5’-CGAACACAGCAGGGATAACCAC-3’ 5’-GTGGTTATCCCTGCTGTGTTCG-3’ 
Novel 11 5’-GAGGGGGCCATAGCAGCCAGA-3’ 5’-TCTGGCTGCTATGGCCCCCTC-3’ 
Novel 12 5’-AAAGAAATTGTCCTTGTATGAT-3’ 5’-ATCATACAAGGACAATTTCTTT-3’ 
Novel 13 5’- GCCAGATAGTCTTCAGTCCAGCT-3’ 5’-AGCTGGACTGAAGACTATCTGGC-3’ 
Novel 14 5’- TCCGACACCGAGAGGGCAGGCG-3’ 5’-CGCCTGCCCTCTCGGTGTCGGA-3’ 
Novel 15 5’- GGGATTCGAACCCAGGATCTCC-3’ 5’-GGAGATCCTGGGTTCGAATCCC-3’ 
Novel 16 5’- TCAACCAACACCTTTTCTGGGGTC-3’ 5’-GACCCCAGAAAAGGTGTTGGTTGA-3’ 
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Appendix 3 – Primer sequences for subcloning. DNA sequences of 
forward and reverse primers used for PCR analysis. 
Gene 
symbol 
Novel 
micro-
RNA 
Primer Sequence 
SFRP4 2 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACGACTTCCGACTTCCTTAC-3’ 
5’-GTACGTCGACGTCAGTGAAGAAACCACC-3’  
TGFβR
3 
2 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACCAGAAGGGTATCAGAGTGG-3’ 
5’-GTACGTCGACCAGACAATCTGCCTTGGAG -3’ 
RBM3 2 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACGTGGTGTACGCCTGTAATC-3’ 
5’-GTACGTCGACCACAAAGATGAGTTCAGTGC-3’ 
CILP 7 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACGTGGTACTTCACCCTCTTC-3’ 
5’-GTACGTCGACCCAGGAGATGTTCTTTCC-3’ 
TIMP3 
– 1 
7 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACGCCATGCCAGAAAGAATG-3’ 
5’-GTACGTCGACCTCTCTTGTAGTTCCTTC-3’ 
TIMP3 
– 2 
7 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACGTAGCTGAGACACTTCTG-3’ 
5’-GTACGTCGACCATCTTGGGGTAGTCCAG-3’ 
VCAN 7 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACCAGCCAAAGTCCTAACTTC-3’ 
5’-GTACGTCGACGTCATCTTCAGCAGTCAC-3’ 
ITGA5 11 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACCAGACTCCCATTCCTGAAG-3’ 
5’-GTACGTCGACCTAGTTCTGGTCAGTGGG-3’ 
MYD88 11 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACCTGCCTCCTCCTTTCGTTG-3’ 
5’-GTACGTCGACGCATCCATTCCCTCCCAAG-3’ 
TGFβR
3 
11 
Forward primer: 
Reverse primer: 
5’-GTACGTCGACCAAAGTGCAACATAGGGAAG-3’ 
5’-GTACGTCGACGCTTAGAAAGCCTCAAAGC-3’ 
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Appendix 4 – Selected candidate novel microRNAs identified from 
next generation sequencing 
Nove
l ID 
Sequence Size 
Average 
reads Complementary Presence in  
Down 
regulation 
per 10 
million strand detected DLD 
in Dicer knock 
out 
1 AAGTTTCTCTGAACGTGTAGAGC 23 48.4 Yes Yes Yes 
2 ATTAGGTAGTGGCAGTGGAAC 21 0.5 Yes Yes Yes 
3 CTGAAGATCTAAAGGTCCCTGGT 23 328.9 No Yes No 
4 GGGGGTGTAGCTCAGTGG 18 180.0 No No No 
5 TGAATCCAGCGATCCGAGT 19 83.5 No No No 
6 TCGAACTTGACTATCTAGAGGA 22 57.1 Yes Yes No 
7 TTCATTTGCCTCCCAGCCTACA 22 14.5 Yes Yes No 
8 TATATATATATATGTACGTAT 21 44.4 Yes No No 
9 GATGCCTGGGAGTTGCGATCTG 22 18.5 Yes No No 
10 GTGGTTATCCCTGCTGTGTTCG 22 18.3 Yes No No 
11 TCTGGCTGCTATGGCCCCCTC 21 11.9 Yes No No 
12 ATCATACAAGGACAATTTCTTT 22 6.3 Yes No No 
13 AGCTGGACTGAAGACTATCTGGC 23 2.3 Yes No No 
14 CGCCTGCCCTCTCGGTGTCGGA 22 0.5 No Yes Yes 
15 GGAGATCCTGGGTTCGAATCCC 22 16.9 No No No 
16 GACCCCAGAAAAGGTGTTGGTTGA 24 4.6 No No No 
  GGATTTTTGGAGCAGGGAGAT 21 58.6 No No No 
  GGGGGCGGCGGCGGGGGG 18 28.2 No Yes No 
  GGCGCGCGCGCGCGCGCGT 19 23.9 No Yes No 
  GGAGATCCTGGGTTCGAATCC 21 22.7 No No No 
  GGCGCGCGGCGGCGGCGGCGGC 22 15.1 No No No 
  GGGATGTATTCGTACTGTCTGATG 24 13.3 No No No 
  GGCGGAGGGGCCGCGGGCCGG 21 11.0 No Yes No 
  GGCGCGCGGCGGCGGCGGC 19 6.4 No No No 
  GGCGCGCGGCGGCGGCGGCG 20 5.2 No No No 
  ATTCGTGTGGACATTTTGGAGA 22 4.0 No Yes No 
  GAGAGAGAGAGATCGGAA 18 4.0 No No No 
  CTCCCACTGCTTCACTTGACTAGT 24 3.5 No Yes No 
  AGCTTTGCGCAGTGGCAG 18 3.3 No No No 
  GCGCGCGGCGGCGGCGGCGGC 21 3.3 No Yes No 
  GGAGGGCGGCGGCGGCGGCGG 21 2.8 No No No 
  TCAGCCGTGTCTGTTCTCTGG 21 2.7 No No No 
  CCTCACCACCCCTTCTGCCTGC 22 2.5 No No No 
  TACAGATGCAGATTCTCTGACT 22 2.1 No No No 
  AAAAGTTATTGTGGTTTTTGCT 22 2.1 No Yes No 
  CCCCGCCCCGCGCCCTCT 18 2.1 No No No 
  GAGAGAGAGAGAGATCGGAA 20 2.1 No Yes No 
  GGGGGGCTGATTCTGCTCAGAT 22 2.0 No No No 
  TCACCACCCCTTCTGCCTGCA 21 1.9 No No No 
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Appendix 4 – Selected candidate novel microRNAs identified from 
next generation sequencing 
Novel 
ID 
Sequence Size 
Average 
reads Complementary Presence in  Down regulation 
per 10 
million strand detected DLD 
in Dicer knock 
out 
  TTATGCCTGTGACTGCTGTAG 21 1.6 No No No 
  CAGGGCCTGGAACTCCAATGGGA 23 1.5 No No No 
  ATTTGCAGTAACAGGTGTGAGC 22 1.4 No No No 
  TGAGGCCGAGAAGGCAACCGCGA 23 1.4 No Yes No 
  TCAGGACACTTCTGAACTTGGA 22 1.2 No Yes No 
  TGAGGCTGTAACTGAGAGAAAG 22 1.2 No No No 
  AGCAATGTGTGATTAGGAAAAG 22 1.2 No Yes No 
  GGGCGGCGGCGGCGGCGGTGGCGG 24 1.0 No No No 
  GAAAGTAATGGTGGGTTTTGCC 22 1.0 No Yes No 
  GGGGGGGCTTCCTCCAGGA 19 1.0 No No No 
  GGGAGCGGCGGGGGCGGCGCG 21 0.8 No No No 
  GGGGGCGGGCGCCGGGGGC 19 0.8 No No No 
  GGTGGTGGCGGTGGCGGCGGCGGG 24 0.8 No No No 
  AGAGTCGAGAGTGGGAGAAGAG 22 0.7 Yes No No 
  GGCGGTGGTGGCGGTGGCGGC 21 0.7 No No No 
  TTGCCTGCCCTCTTCCTCCAG 21 0.7 No No No 
  TCTCGTCCCGGCCCTGCCCGCT 22 0.6 No No No 
  TCCGTCGGTTCTCAGGAGGTGG 22 0.6 No Yes No 
  CAGCAATTACTTTTGCACCACT 22 0.5 No No No 
  TTGAGGGGAGAATGAGGTGGAGA 23 0.5 No No No 
  TCACTTCCTGTTCTGTGGCCTGT 23 0.5 No Yes No 
 
Table A4.1 - Candidate novel microRNAs identified from next generation sequencing 
in all three patients. 61 candidate novel microRNAs were found in all three patients 
out of the initial 1621 sequences identified. The complementary strands of 11 of the 
60 candidates were detected, 10 of which are found within the triaged 16 candidate 
novels. 20 sequences were also detected in a sequencing project examining cells of the 
DLD cell line. Of those 20, 3 appeared down-regulated in a sequencing project of a 
DICER knockout DLD cell line. The triaged 16 contained 6 candidate sequences found in 
DLD cells, including the 3 candidates down-regulated in response to a DICER down-
regulation. Also included in the chosen 16 candidates were the 3 candidate novels 
which were the most highly expressed out of the 60 sequences: candidate novel 3, 4 
and 5. 
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Appendix 5 - Read number of most highly expressed 100 known 
microRNAs 
MicroRNA 
Reads per 10 million reads 
Patient 1 Patient 2 Patient 3 Average 
hsa-mir-140-3p 4325532 3958193 3762965 4015563 
hsa-mir-10b 166734 361833 457263 328610 
hsa-mir-101 142849 311361 207423 220545 
hsa-mir-140-5p 230886 247074 179621 219194 
hsa-mir-26a 182911 164578 94932 147474 
hsa-let-7b 67707 131882 100569 100053 
hsa-mir-320a 86270 87063 82286 85206 
hsa-mir-23b 58259 107486 85430 83725 
hsa-let-7a 58306 96245 62147 72233 
hsa-mir-23a 45619 84229 78874 69574 
hsa-mir-27b 49403 79242 57848 62164 
hsa-mir-125b 58044 62879 64987 61970 
hsa-mir-27a 47965 67599 50943 55502 
hsa-mir-100 24277 50548 78862 51229 
hsa-mir-21 38211 53157 53220 48196 
hsa-mir-24 40517 48748 37715 42327 
hsa-let-7c 34793 59699 31642 42045 
hsa-let-7f 29436 52644 31836 37972 
hsa-mir-30d 39840 35425 28376 34547 
hsa-mir-99b 24049 32075 44565 33563 
hsa-mir-99a 23137 45767 30967 33290 
hsa-mir-320b 31751 34899 33120 33256 
hsa-mir-29b 26830 33086 37982 32633 
hsa-mir-30e* 26966 35790 29143 30633 
hsa-mir-148a 21373 34813 24745 26977 
hsa-mir-30a* 23331 29949 25798 26359 
hsa-mir-26b 27819 30071 16929 24940 
hsa-mir-25 18824 27408 26089 24107 
hsa-mir-210 23653 23873 23280 23602 
hsa-mir-374a 22407 30470 16745 23208 
hsa-mir-16 23150 22767 12525 19481 
hsa-let-7g 15091 24578 15963 18544 
hsa-mir-152 14799 22524 18061 18461 
hsa-mir-92a 17882 15808 20769 18153 
hsa-mir-3074-5p 16660 20482 16703 17949 
hsa-let-7i 15521 19965 13244 16243 
hsa-mir-125a-5p 16673 11126 13974 13924 
hsa-mir-22 14600 13361 10632 12864 
hsa-mir-19b 8960 15632 12615 12402 
hsa-mir-379 2806 16592 12003 10467 
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Appendix 5 -  Read number of most highly expressed 100 known 
microRNAs 
MicroRNA 
Reads per 10 million reads 
Patient 1 Patient 2 Patient 3 Average 
hsa-mir-195 14893 9995 6218 10369 
hsa-mir-29a 9303 11650 9516 10156 
hsa-mir-155 6192 9589 11278 9020 
hsa-mir-199a-3p 5504 11024 9640 8723 
hsa-mir-199b-3p 5504 11024 9640 8723 
hsa-mir-221 5352 10621 8910 8294 
hsa-mir-146b-5p 4084 13371 5549 7668 
hsa-mir-199a-5p 5408 8999 8189 7532 
hsa-mir-30b 3938 9466 8688 7364 
hsa-mir-222 5122 9203 7454 7259 
hsa-mir-196a 4407 10558 5694 6886 
hsa-mir-29c 5594 8104 6921 6873 
hsa-mir-30a 6090 8592 5690 6791 
hsa-mir-320c 5055 6780 6715 6183 
hsa-mir-191 5287 7341 5769 6132 
hsa-mir-93 4555 6328 6664 5849 
hsa-mir-15a 5924 6662 3942 5509 
hsa-mir-30c 4139 6520 5444 5368 
hsa-mir-103a 4881 6024 4403 5103 
hsa-mir-103b 4881 6024 4403 5103 
hsa-mir-107 4448 5339 3941 4576 
hsa-mir-196b 4572 5395 3744 4570 
hsa-mir-30e 3909 5721 4001 4543 
hsa-mir-106b 3170 5127 4598 4298 
hsa-mir-92b 4143 3493 3981 3872 
hsa-mir-28-3p 2804 4183 4575 3854 
hsa-mir-365 4319 3619 3231 3723 
hsa-mir-19a 2616 4348 3380 3448 
hsa-mir-199b-5p 1317 4624 2861 2934 
hsa-mir-455-3p 3652 3183 1906 2914 
hsa-mir-455-5p 1682 3871 2489 2681 
hsa-let-7e 3083 2891 2051 2675 
hsa-mir-320d 1866 2957 3123 2649 
hsa-mir-574-3p 2787 2205 2590 2527 
hsa-mir-574-5p 1244 3069 3176 2496 
hsa-mir-193b 1972 3095 2128 2398 
hsa-mir-130a 1890 2973 2331 2398 
hsa-mir-497 2009 2640 2181 2277 
hsa-let-7d 2335 2256 1875 2155 
hsa-mir-186 2048 2552 1688 2096 
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Appendix 5 -  Read number of most highly expressed 100 known 
microRNAs 
MicroRNA 
Reads per 10 million reads 
Patient 1 Patient 2 Patient 3 Average 
hsa-mir-532-5p 1368 2418 1831 1872 
hsa-mir-143 1513 1613 2367 1831 
hsa-mir-20a 1790 2027 1638 1818 
hsa-mir-374b 1510 2216 1506 1744 
hsa-mir-374c 1499 2215 1503 1739 
hsa-mir-151-3p 1336 2134 1399 1623 
hsa-mir-425 1043 2088 1670 1600 
hsa-mir-151-5p 1710 1786 1120 1538 
hsa-mir-664 1514 1611 1482 1535 
hsa-mir-214 2002 1314 1237 1518 
hsa-mir-193a-3p 1006 1680 1755 1480 
hsa-mir-374b* 1176 1691 1243 1370 
hsa-mir-342-3p 1395 1180 1207 1261 
hsa-mir-34a 1505 937 1242 1228 
hsa-mir-423-3p 969 1570 1008 1182 
hsa-mir-361-5p 1219 1223 1026 1156 
hsa-mir-98 1040 1383 884 1102 
hsa-mir-17 1228 1141 911 1093 
hsa-mir-106a 1225 1141 911 1092 
hsa-mir-378 644 1240 1367 1083 
 
Table A5.1 - Read number of most highly expressed 100 known microRNAs shown 
in read number per 10
 
million reads were obtained by deep sequencing (analysed with 
miRCat and miRBase software) of cDNA transcribed from RNA obtained from 
chondrocytes of 3 patients isolated immediately after digestion. 
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Appendix 6 - Assessment of candidate novel microRNA using 
northern blots 
 
 
 
 
 
 
 
 
 
 
Figure A6.1 - Assessment of candidate novel microRNA using northern blots. 
Expression of candidate novel microRNAs (A) novel 1, novel 3, novel 4, novel 5, novel 
6, novel 8 was measured by northern blot using 10µg SW1353 total RNA or 2µg of 
RNA enriched for small RNAs. MiR-140-3p was used as a size control and the small 
RNA U6 was used as a standard reference for the northern blot. 
 
 
 
 
 
 
 
U6 
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Appendix 6 - Assessment of candidate novel microRNA using 
northern blots 
 
 
 
 
 
 
 
 
 
 
Figure A6.2 - Assessment of candidate novel microRNA using northern blots. 
Expression of candidate novel microRNAs (B) novel 9, novel 10, novel 12, novel 13, 
novel 14, novel 15 and novel 16 was measured by northern blot using 10µg SW1353 
total RNA or 2µg of RNA enriched for small RNAs. MiR-140-3p was used as a size 
control and the small RNA U6 was used as a standard reference for the northern blot. 
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Appendix 7 - Candidate microRNA response to lack of Dicer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7.1 - Candidate novel microRNA expression in DLD-1 parental and DLD-1 
Dicer null cell lines. Expression of candidate microRNA (A) novel 1, (B) novel 3,  (C) 
novel 4, (D) novel 5, (E) novel 6 and (F) novel 8 were obtained by qRT-PCR from RNA 
240 
 
purified from DLD-1 wild type (parental) and DLD-1 Dicer null cell lines. Data were 
normalised to U6 RNA expression. Data shows mean +/- SEM, n = 6. (*, p ≤0.05 
analyzed by a Student T test). 
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Appendix 7 - Candidate microRNA response to lack of Dicer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7.2 - Candidate novel microRNA expression in DLD-1 parental and DLD-
1 Dicer null cell lines. Expression of candidate microRNA (A) novel 9, (B) novel 10,  
(C) novel 14, (D) novel 15 and (E) novel 16 were obtained by qRT-PCR from RNA 
purified from DLD-1 wild type (parental) and DLD-1 Dicer null cell lines. Candidate 
Novel 14 Novel 15 
Novel 16 
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novels 12 and 13 were not detected in the DLD cell lines. Data were normalised to U6 
RNA expression. Data shows mean +/- SEM, n = 6. (**, p ≤0.005 analyzed by a Student 
T test). 
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Appendix 8 – Candidate novel microRNA expression in osteoarthritic 
cartilage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A8.1 - Candidate novel microRNA expression in HOA and NOF cartilage 
tissue. Expression levels of candidate microRNAs (A) novel 1, (B) novel 3 and (C) 
novel 5, (D) novel 6, (E) novel 8 and (F) novel 9 were obtained by qRT-PCR from RNA 
isolated from: osteoarthritic hip cartilage tissue (HOA) and neck of femur fracture 
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cartilage (NOF). Candidate novel 4 was undetectable. Data were normalised to U6 RNA 
expression. Data shows mean +/- SEM, n = 6 (analyzed by a Students T test, no 
significance was seen). 
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Appendix 8 – Candidate novel microRNA expression in osteoarthritic 
cartilage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A8.2 - Candidate novel microRNA expression in HOA and NOF cartilage 
tissue. Expression levels of candidate microRNAs (A) novel 10, (B) novel 12 and (C) 
novel 13, (D) novel 14, (E) novel 15 and (F) novel 16 were obtained by qRT-PCR from 
RNA isolated from: osteoarthritic hip cartilage tissue (HOA) and neck of femur fracture 
Novel 14 
Novel 15 Novel 16 
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cartilage (NOF). Data were normalised to U6 RNA expression. Data shows mean +/- 
SEM, n = 6 (analyzed by a Students T test, no significance was seen). 
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Appendix 9 - Candidate novel microRNA expression across a human 
tissue panel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A9.1 Candidate novel microRNA expression across a human tissue panel. 
Expression levels of candidate microRNAs (A) novel 1, (B) novel 3, (C) novel 4, (D) 
novel 5 and (E) novel 6 were obtained by qRT-PCR from RNA isolated from 23 human 
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tissues including adipose, bladder, brain, cervix, colon, oesophagus, heart, kidney, liver, 
lung, ovary, placenta, prostate, small intestine, skeletal muscle, spleen, testes, thymus, 
thyroid, trachea, osteoarthritic knee cartilage tissue (KOA), and neck of femur fracture 
cartilage (NOF). Data were normalised to U6 RNA expression. RNA of cartilage 
samples was from 3 patients. RNA from all remaining tissues was from a pool of 3 
patients with n= 3 technical replicates. 
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Appendix 9 - Candidate novel microRNA expression across a human 
tissue panel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A9.2 - Candidate novel microRNA expression across a human tissue panel. 
Expression levels of candidate microRNAs (A) novel 8, (B) novel 9, (C) novel 10, (D) 
Novel 14 
Novel 15 
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novel 14 and (E) novel 15 were obtained by qRT-PCR from RNA isolated from 23 
human tissues including adipose, bladder, brain, cervix, colon, oesophagus, heart, 
kidney, liver, lung, ovary, placenta, prostate, small intestine, skeletal muscle, spleen, 
testes, thymus, thyroid, trachea, osteoarthritic knee cartilage tissue (KOA), and neck of 
femur fracture cartilage (NOF). Candidate novels 12, 13 and 18 were undetectable. Data 
were normalised to U6 RNA expression. RNA of cartilage samples was from 3 patients. 
RNA from all remaining tissues was from a pool of 3 patients with n= 3 technical 
replicates. 
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Appendix 10 – Computational target search of miR-6509-5p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
6 8 3 ENSG00000113441 LNPEP leucyl/cystinyl aminopeptidase 
5 6 2 ENSG00000133703 KRAS Kirsten rat sarcoma viral oncogene homolog 
4 6 2 ENSG00000082258 CCNT2 cyclin T2 
3 5 2 ENSG00000145012 LPP 
LIM domain containing preferred translocation 
partner in lipoma 
3 5 2 ENSG00000146373 RNF217 ring finger protein 217 
3 5 2 ENSG00000198265 HELZ helicase with zinc finger 
4 4 2 ENSG00000196632 WNK3 WNK lysine deficient protein kinase 3 
3 4 2 ENSG00000081014 AP4E1 
adaptor-related protein complex 4, epsilon 1 
subunit 
3 4 2 ENSG00000120948 TARDBP TAR DNA binding protein 
3 4 2 ENSG00000163545 NUAK2 NUAK family, SNF1-like kinase, 2 
2 4 2 ENSG00000118965 WDR35 WD repeat domain 35 
2 4 2 ENSG00000131626 PPFIA1 
protein tyrosine phosphatase, receptor type, f 
polypeptide, interacting protein, alpha 1 
2 4 2 ENSG00000135932 CAB39 calcium binding protein 39 
2 4 2 ENSG00000154114 TBCEL tubulin folding cofactor E-like 
2 4 2 ENSG00000170234 
PWWP2
A 
PWWP domain containing 2A 
2 4 2 ENSG00000241644 INMT indolethylamine N-methyltransferase 
6 5 1 ENSG00000163428 LRRC58 leucine rich repeat containing 58 
5 5 1 ENSG00000117500 TMED5 
transmembrane emp24 protein transport 
domain containing 5 
5 5 1 ENSG00000149212 SESN3 sestrin 3 
5 5 1 ENSG00000169905 
TOR1AI
P2 
torsin A interacting protein 2 
4 5 1 ENSG00000158528 
PPP1R9
A 
protein phosphatase 1, regulatory subunit 9A 
4 5 1 ENSG00000172469 MANEA mannosidase, endo-alpha 
5 4 1 ENSG00000046889 PREX2 
phosphatidylinositol-3,4,5-trisphosphate-
dependent Rac exchange factor 2 
5 4 1 ENSG00000071537 SEL1L sel-1 suppressor of lin-12-like 
5 4 1 ENSG00000204406 MBD5 methyl-CpG binding domain protein 5 
5 4 1 ENSG00000205189 ZBTB10 zinc finger and BTB domain containing 10 
4 4 1 ENSG00000060982 BCAT1 branched chain amino-acid transaminase 1 
4 4 1 ENSG00000070367 EXOC5 exocyst complex component 5 
4 4 1 ENSG00000149187 CELF1 CUGBP, Elav-like family member 1 
4 4 1 ENSG00000149948 HMGA2 high mobility group AT-hook 2 
3 4 1 ENSG00000097046 CDC7 cell division cycle 
3 4 1 ENSG00000122042 UBL3 ubiquitin-like 3 
3 4 1 ENSG00000133103 COG6 component of oligomeric golgi complex 6 
3 4 1 ENSG00000143322 ABL2 c-abl oncogene 2, non-receptor tyrosine kinase 
3 4 1 ENSG00000154429 CCSAP centriole, cilia and spindle-associated protein 
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Appendix 10 – Computational target search of miR-6509-5p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
3 4 1 ENSG00000164022 AIMP1 
aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1 
3 4 1 ENSG00000198010 DLGAP2 
discs, large (Drosophila) homolog-associated 
protein 2 
6 3 1 ENSG00000055609 MLL3 lysine (K)-specific methyltransferase 2C 
5 3 1 ENSG00000172765 TMCC1 transmembrane and coiled-coil domain family 1 
4 3 1 ENSG00000052723 SIKE1 suppressor of IKBKE 1 
4 3 1 ENSG00000082175 PGR progesterone receptor 
4 3 1 ENSG00000101639 CEP192 centrosomal protein 192kDa 
4 3 1 ENSG00000102271 KLHL4 kelch-like family member 4 
4 3 1 ENSG00000135913 USP37 ubiquitin specific peptidase 37 
4 3 1 ENSG00000151338 MIPOL1 mirror-image polydactyly 1 
3 3 1 ENSG00000072364 AFF4 AF4/FMR2 family, member 4 
3 3 1 ENSG00000106692 FKTN fukutin 
3 3 1 ENSG00000109158 GABRA4 
gamma-aminobutyric acid (GABA) A receptor, 
alpha 4 
3 3 1 ENSG00000112874 NUDT12 
nudix (nucleoside diphosphate linked moiety X)-
type motif 12 
3 3 1 ENSG00000115137 
DNAJC2
7 
DnaJ (Hsp40) homolog, subfamily C, member 27 
3 3 1 ENSG00000119729 RHOQ ras homolog family member Q 
3 3 1 ENSG00000120137 PANK3 pantothenate kinase 3 
3 3 1 ENSG00000124783 SSR1 signal sequence receptor, alpha 
3 3 1 ENSG00000128989 ARPP19 cAMP-regulated phosphoprotein, 19kDa 
3 3 1 ENSG00000133104 SPG20 spastic paraplegia 20 (Troyer syndrome) 
3 3 1 ENSG00000134352 IL6ST 
interleukin 6 signal transducer (gp130, 
oncostatin M receptor) 
3 3 1 ENSG00000139173 
TMEM1
17 
transmembrane protein 117 
3 3 1 ENSG00000145335 SNCA 
synuclein, alpha (non A4 component of amyloid 
precursor) 
3 3 1 ENSG00000163904 SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 
3 3 1 ENSG00000168152 THAP9 THAP domain containing 9 
3 3 1 ENSG00000175414 ARL10 ADP-ribosylation factor-like 10 
3 3 1 ENSG00000178295 GEN1 GEN1 Holliday junction 5' flap endonuclease 
3 3 1 ENSG00000185518 SV2B synaptic vesicle glycoprotein 2B 
3 3 1 ENSG00000185760 KCNQ5 
potassium voltage-gated channel, KQT-like 
subfamily, member 5 
3 3 1 ENSG00000213281 NRAS neuroblastoma RAS viral (v-ras) 
3 3 1 ENSG00000257127 CLLU1 chronic lymphocytic leukemia up-regulated 1 
2 3 1 ENSG00000003989 SLC7A2 solute carrier family 7, member 2 
2 3 1 ENSG00000006576 PHTF2 putative homeodomain transcription factor 2 
2 3 1 ENSG00000079387 SENP1 SUMO1/sentrin specific peptidase 1 
2 3 1 ENSG00000084110 HAL histidine ammonia-lyase 
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Appendix 10 – Computational target search of miR-6509-5p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
2 3 1 ENSG00000089916 
GPATCH
2L 
G patch domain containing 2-like 
2 3 1 ENSG00000101938 CHRDL1 chordin-like 1 
2 3 1 ENSG00000110987 BCL7A B-cell CLL/lymphoma 7A 
2 3 1 ENSG00000112246 SIM1 
single-minded family bHLH transcription factor 
1 
2 3 1 ENSG00000113319 
RASGRF
2 
Ras protein-specific guanine nucleotide-
releasing factor 2 
2 3 1 ENSG00000120217 CD274 CD274 molecule 
2 3 1 ENSG00000120963 ZNF706 zinc finger protein 706 
2 3 1 ENSG00000123728 RAP2C RAP2C, member of RAS oncogene family 
2 3 1 ENSG00000133704 IPO8 importin 8 
2 3 1 ENSG00000145545 SRD5A1 steroid-5-alpha-reductase, alpha polypeptide 1 
2 3 1 ENSG00000145833 DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 
2 3 1 ENSG00000146776 
ATXN7L
1 
ataxin 7-like 1 
2 3 1 ENSG00000150637 CD226 CD226 molecule 
2 3 1 ENSG00000152495 CAMK4 
calcium/calmodulin-dependent protein kinase 
IV 
2 3 1 ENSG00000157106 SMG1 
SMG1 phosphatidylinositol 3-kinase-related 
kinase 
2 3 1 ENSG00000162981 FAM84A family with sequence similarity 84, member A 
2 3 1 ENSG00000162994 CLHC1 clathrin heavy chain linker domain containing 1 
2 3 1 ENSG00000163492 
CCDC14
1 
coiled-coil domain containing 141 
2 3 1 ENSG00000164284 GRPEL2 GrpE-like 2, mitochondrial 
2 3 1 ENSG00000165192 ASB11 ankyrin repeat and SOCS box containing 11 
2 3 1 ENSG00000171466 ZNF562 zinc finger protein 562 
2 3 1 ENSG00000172575 
RASGRP
1 
RAS guanyl releasing protein 1 
2 3 1 ENSG00000186591 UBE2H ubiquitin-conjugating enzyme E2H 
2 3 1 ENSG00000186834 HEXIM1 hexamethylene bis-acetamide inducible 1 
2 3 1 ENSG00000188419 CHM choroideremia (Rab escort protein 1) 
2 3 1 ENSG00000188906 LRRK2 leucine-rich repeat kinase 2 
2 3 1 ENSG00000198814 GK glycerol kinase 
2 3 1 ENSG00000205835 GMNC geminin coiled-coil domain containing 
2 3 1 ENSG00000258588 
TRIM6-
TRIM34 
TRIM6-TRIM34 readthrough 
2 3 1 ENSG00000258659 TRIM34 tripartite motif containing 34 
 
Table A10.1 - Computational gene target search of miR-6509-5p using RStudios. 
All 4 target sites; 6mer, 7merm8, 7merA1 and 8mer were identified within the 3’UTR 
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of all genes within the human genome as described on Ensembl, downloaded using 
Biomart. Target search was carried out with the R programming Biostrings package, 
and the top 100 genes of 4655 with target sites (ranked by size and number of target 
sites) is shown. 
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Appendix 11 – Computational target search of miR-664b-3p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
6 8 4 ENSG00000164308 ERAP2 endoplasmic reticulum aminopeptidase 2 
15 14 3 ENSG00000155966 AFF2 AF4/FMR2 family, member 2 
10 10 3 ENSG00000134982 APC adenomatous polyposis coli 
12 9 3 ENSG00000055609 MLL3 
membrane bound O-acyltransferase domain 
containing 2 
7 9 3 ENSG00000138138 ATAD1 ATPase family, AAA domain containing 1 
7 9 3 ENSG00000144824 PHLDB2 
pleckstrin homology-like domain, family B, 
member 2 
3 6 3 ENSG00000196166 C8orf86 chromosome 8 open reading frame 86 
3 6 3 ENSG00000040199 PHLPP2 
PH domain and leucine rich repeat protein 
phosphatase 2 
15 12 2 ENSG00000168807 SNTB2 
syntrophin, beta 2 (dystrophin-associated 
protein A1, 59kDa, basic component 2) 
13 12 2 ENSG00000104290 FZD3 frizzled family receptor 3 
10 10 2 ENSG00000166450 PRTG protogenin 
10 9 2 ENSG00000172795 DCP2 decapping mRNA 2 
8 9 2 ENSG00000133739 LRRCC1 lysine (K)-specific methyltransferase 2C 
12 8 2 ENSG00000152495 CAMK4 
calcium/calmodulin-dependent protein 
kinase IV 
11 8 2 ENSG00000010244 ZNF207 zinc finger protein 207 
10 8 2 ENSG00000169213 RAB3B RAB3B, member RAS oncogene family 
9 8 2 ENSG00000154429 CCSAP 
centriole, cilia and spindle-associated 
protein 
8 8 2 ENSG00000036530 CYP46A1 
cytochrome P450, family 46, subfamily A, 
polypeptide 1 
8 8 2 ENSG00000143797 MBOAT2 
leucine rich repeat and coiled-coil 
centrosomal protein 1 
8 8 2 ENSG00000147862 NFIB nuclear factor I/B [Source:HGNC 
8 8 2 ENSG00000051382 PIK3CB 
phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit beta 
6 8 2 ENSG00000196865 NHLRC2 NHL repeat containing 2 
14 7 2 ENSG00000143190 POU2F1 POU class 2 homeobox 1 
10 7 2 ENSG00000082438 COBLL1 cordon-bleu WH2 repeat protein-like 1 
7 7 2 ENSG00000137145 DENND4C DENN/MADD domain containing 4C 
5 7 2 ENSG00000157538 DSCR3 Down syndrome critical region gene 3 
5 7 2 ENSG00000185231 MC2R 
melanocortin 2 receptor 
(adrenocorticotropic hormone) 
9 6 2 ENSG00000198087 CD2AP CD2-associated protein 
8 6 2 ENSG00000143079 CTTNBP2NL CTTNBP2 N-terminal like 
7 6 2 ENSG00000248905 FMN1 formin 1 
6 6 2 ENSG00000144959 NCEH1 neutral cholesterol ester hydrolase 1 
5 6 2 ENSG00000102531 FNDC3A fibronectin type III domain containing 3A 
5 6 2 ENSG00000145626 UGT3A1 
UDP glycosyltransferase 3 family, 
polypeptide A1 
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Appendix 11 – Computational target search of miR-664b-3p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
5 6 2 ENSG00000147488 ST18 
suppression of tumorigenicity 18 (breast 
carcinoma) (zinc finger protein) 
5 6 2 ENSG00000177707 PVRL3 poliovirus receptor-related 3 
5 6 2 ENSG00000182168 UNC5C unc-5 homolog C 
4 6 2 ENSG00000116985 BMP8B bone morphogenetic protein 8b 
4 6 2 ENSG00000118689 FOXO3 forkhead box O3 
8 5 2 ENSG00000124209 RAB22A RAB22A, member RAS oncogene family 
7 5 2 ENSG00000064933 PMS1 PMS1 postmeiotic segregation increased 1 
7 5 2 ENSG00000112701 SENP6 SUMO1/sentrin specific peptidase 6 
7 5 2 ENSG00000161048 NAPEPLD 
N-acyl phosphatidylethanolamine 
phospholipase D 
7 5 2 ENSG00000163762 TM4SF18 transmembrane 4 L six family member 18 
7 5 2 ENSG00000170522 ELOVL6 ELOVL fatty acid elongase 6 
6 5 2 ENSG00000064393 HIPK2 homeodomain interacting protein kinase 2 
6 5 2 ENSG00000113273 ARSB arylsulfatase B 
5 5 2 ENSG00000047932 GOPC 
golgi-associated PDZ and coiled-coil motif 
containing 
5 5 2 ENSG00000073803 MAP3K13 
mitogen-activated protein kinase kinase 
kinase 13 
5 5 2 ENSG00000170160 CCDC144A coiled-coil domain containing 144A 
5 5 2 ENSG00000266302 CCDC144A Coiled-coil domain-containing protein 144A 
4 5 2 ENSG00000122145 TBX22 T-box 22 
4 5 2 ENSG00000132849 INADL InaD-like 
4 5 2 ENSG00000145349 CAMK2D 
calcium/calmodulin-dependent protein 
kinase II delta 
4 5 2 ENSG00000164307 ERAP1 endoplasmic reticulum aminopeptidase 1 
4 5 2 ENSG00000171435 KSR2 kinase suppressor of ras 2 
4 5 2 ENSG00000187699 C2orf88 chromosome 2 open reading frame 88 
4 5 2 ENSG00000196715 VKORC1L1 
vitamin K epoxide reductase complex, 
subunit 1-like 1 
4 5 2 ENSG00000204186 ZDBF2 zinc finger, DBF-type containing 2 
3 5 2 ENSG00000054796 SPO11 
SPO11 meiotic protein covalently bound to 
DSB 
3 5 2 ENSG00000054965 FAM168A 
family with sequence similarity 168, member 
A 
3 5 2 ENSG00000065243 PKN2 protein kinase N2 
3 5 2 ENSG00000070190 DAPP1 
dual adaptor of phosphotyrosine and 3-
phosphoinositides 
3 5 2 ENSG00000084093 REST RE1-silencing transcription factor 
3 5 2 ENSG00000112276 BVES blood vessel epicardial substance 
3 5 2 ENSG00000120868 APAF1 apoptotic peptidase activating factor 1 
3 5 2 ENSG00000125827 TMX4 
thioredoxin-related transmembrane protein 
4 
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Appendix 11 – Computational target search of miR-664b-3p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
3 5 2 ENSG00000131042 LILRB2 
leukocyte immunoglobulin-like receptor, 
subfamily B, member 2 
3 5 2 ENSG00000145757 SPATA9 spermatogenesis associated 9 
3 5 2 ENSG00000149260 CAPN5 calpain 5 
3 5 2 ENSG00000196935 SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 
3 5 2 ENSG00000234631 AL162407.1 CDNA FLJ20147 fis, Uncharacterized protein 
8 4 2 ENSG00000134852 CLOCK clock circadian regulator 
5 4 2 ENSG00000011258 MBTD1 mbt domain containing 1 
4 4 2 ENSG00000009694 TENM1 teneurin transmembrane protein 1 
4 4 2 ENSG00000082153 BZW1 basic leucine zipper and W2 domains 1 
4 4 2 ENSG00000119729 RHOQ ras homolog family member Q 
4 4 2 ENSG00000134376 CRB1 crumbs homolog 1 
4 4 2 ENSG00000149948 HMGA2 high mobility group AT-hook 2 
4 4 2 ENSG00000178217 SH2D4B SH2 domain containing 4B 
3 4 2 ENSG00000038945 MSR1 macrophage scavenger receptor 1 
3 4 2 ENSG00000127993 RBM48 RNA binding motif protein 48 
3 4 2 ENSG00000134910 STT3A 
STT3A, subunit of the 
oligosaccharyltransferase complex 
3 4 2 ENSG00000144597 EAF1 ELL associated factor 1 
3 4 2 ENSG00000145740 SLC30A5 
solute carrier family 30 (zinc transporter), 
member 5 
3 4 2 ENSG00000186417 GLDN gliomedin 
3 4 2 ENSG00000196932 TMEM26 transmembrane protein 26 
3 4 2 ENSG00000197170 PSMD12 
proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 12 
2 4 2 ENSG00000100027 YPEL1 yippee-like 1 
2 4 2 ENSG00000103550 C16orf88 lysine-rich nucleolar protein 1 
2 4 2 ENSG00000109684 CLNK 
cytokine-dependent hematopoietic cell 
linker 
2 4 2 ENSG00000116678 LEPR leptin receptor 
2 4 2 ENSG00000120686 UFM1 ubiquitin-fold modifier 1 
2 4 2 ENSG00000147224 PRPS1 phosphoribosyl pyrophosphate synthetase 1 
2 4 2 ENSG00000152457 DCLRE1C DNA cross-link repair 1C 
2 4 2 ENSG00000152578 GRIA4 glutamate receptor, ionotropic, AMPA 4 
2 4 2 ENSG00000162511 LAPTM5 lysosomal protein transmembrane 5 
2 4 2 ENSG00000169504 CLIC4 chloride intracellular channel 4 
2 4 2 ENSG00000170921 TANC2 
tetratricopeptide repeat, ankyrin repeat and 
coiled-coil containing 2 
2 4 2 ENSG00000182712 CMC4 C-x(9)-C motif containing 4 
2 4 2 ENSG00000214827 MTCP1 mature T-cell proliferation 1 
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Table A11.1 - Computational gene target search of miR-664b-3p using RStudios. 
All 4 target sites; 6mer, 7merm8, 7merA1 and 8mer were identified within the 3’UTR 
of all genes within the human genome as described on Ensembl, downloaded using 
Biomart. Target search was carried out with the R programming Biostrings package, 
and the top 100 genes of 9690 with target sites (ranked by size and number of target 
sites) is shown. 
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Appendix 12 – Computational target search of miR-3085-3p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
8 10 4 ENSG00000042832 TG thyroglobulin 
12 11 3 ENSG00000170921 TANC2 
tetratricopeptide repeat, ankyrin repeat and 
coiled-coil containing 2 
11 11 3 ENSG00000136944 LMX1B LIM homeobox transcription factor 1, beta 
9 9 3 ENSG00000127554 GFER 
growth factor, augmenter of liver 
regeneration 
6 8 3 ENSG00000072135 PTPN18 
protein tyrosine phosphatase, non-receptor 
type 18 
6 7 3 ENSG00000156639 ZFAND3 zinc finger, AN1-type domain 3 
5 6 3 ENSG00000110888 CAPRIN2 caprin family member 2 
3 6 3 ENSG00000073331 ALPK1 alpha-kinase 1 
10 8 2 ENSG00000130052 STARD8 
StAR-related lipid transfer (START) domain 
containing 8 
9 8 2 ENSG00000114735 HEMK1 HemK methyltransferase family member 1 
8 8 2 ENSG00000164742 ADCY1 adenylate cyclase 1 (brain) 
6 8 2 ENSG00000100106 TRIOBP TRIO and F-actin binding protein 
11 7 2 ENSG00000196092 PAX5 paired box 5 
9 7 2 ENSG00000136279 DBNL drebrin-like 
9 7 2 ENSG00000174437 ATP2A2 
ATPase, Ca++ transporting, cardiac muscle, 
slow twitch 2 
8 7 2 ENSG00000072501 SMC1A structural maintenance of chromosomes 1A 
7 7 2 ENSG00000090905 TNRC6A trinucleotide repeat containing 6A 
7 7 2 ENSG00000142765 SYTL1 synaptotagmin-like 1 
7 7 2 ENSG00000169118 CSNK1G1 casein kinase 1, gamma 1 
6 7 2 ENSG00000119720 NRDE2 
NRDE-2, necessary for RNA interference, 
domain containing 
6 7 2 ENSG00000123643 SLC36A1 
solute carrier family 36 (proton/amino acid 
symporter), member 1 
6 7 2 ENSG00000258388 EGFL8 PPT2-EGFL8 readthrough 
8 6 2 ENSG00000092847 EIF2C1 argonaute RISC catalytic component 1 
6 6 2 ENSG00000078900 TP73 tumor protein p73 
6 6 2 ENSG00000213901 SLC23A3 solute carrier family 23, member 3 
5 6 2 ENSG00000141736 ERBB2 
v-erb-b2 avian erythroblastic leukemia viral 
oncogene homolog 2 
5 6 2 ENSG00000160218 TRAPPC10 trafficking protein particle complex 10 
5 6 2 ENSG00000185838 GNB1L 
guanine nucleotide binding protein (G 
protein), beta polypeptide 1-like 
5 6 2 ENSG00000212719 C17orf51 chromosome 17 open reading frame 51 
4 6 2 ENSG00000134160 TRPM1 
transient receptor potential cation channel, 
subfamily M, member 1 
4 6 2 ENSG00000136051 KIAA1033 KIAA1033 
4 6 2 ENSG00000138092 CENPO centromere protein O 
4 6 2 ENSG00000143217 PVRL4 poliovirus receptor-related 4 
4 6 2 ENSG00000157570 TSPAN18 tetraspanin 18 
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Appendix 12 – Computational target search of miR-3085-3p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
4 6 2 ENSG00000204220 PFDN6 prefoldin subunit 6 
7 5 2 ENSG00000153404 PLEKHG4B 
pleckstrin homology domain containing, 
family G member 4B 
6 5 2 ENSG00000137070 IL11RA interleukin 11 receptor, alpha 
6 5 2 ENSG00000164061 BSN bassoon presynaptic cytomatrix protein 
6 5 2 ENSG00000169057 MECP2 
methyl CpG binding protein 2 (Rett 
syndrome) 
5 5 2 ENSG00000102786 INTS6 integrator complex subunit 6 
5 5 2 ENSG00000111331 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 
5 5 2 ENSG00000121671 CRY2 cryptochrome 2 (photolyase-like) 
5 5 2 ENSG00000134516 DOCK2 dedicator of cytokinesis 2 
4 5 2 ENSG00000003400 CASP10 
caspase 10, apoptosis-related cysteine 
peptidase 
4 5 2 ENSG00000137135 ARHGEF39 
Rho guanine nucleotide exchange factor 
(GEF) 39 
4 5 2 ENSG00000163820 FYCO1 FYVE and coiled-coil domain containing 1 
3 5 2 ENSG00000081059 TCF7 transcription factor 7 
3 5 2 ENSG00000113494 PRLR prolactin receptor 
3 5 2 ENSG00000154975 CA10 carbonic anhydrase X 
3 5 2 ENSG00000155229 MMS19 
MMS19 nucleotide excision repair homolog 
(S. cerevisiae) 
3 5 2 ENSG00000166912 MTMR10 myotubularin related protein 10 
3 5 2 ENSG00000173210 ABLIM3 actin binding LIM protein family, member 3 
3 5 2 ENSG00000179409 GEMIN4 gem (nuclear organelle) associated protein 4 
3 5 2 ENSG00000225697 SLC26A6 
solute carrier family 26 (anion exchanger), 
member 6 
5 4 2 ENSG00000106246 PTCD1 pentatricopeptide repeat domain 1 
5 4 2 ENSG00000111752 PHC1 polyhomeotic homolog 1 
5 4 2 ENSG00000120645 IQSEC3 IQ motif and Sec7 domain 3 
5 4 2 ENSG00000152104 PTPN14 
protein tyrosine phosphatase, non-receptor 
type 14 
5 4 2 ENSG00000196209 SIRPB2 signal-regulatory protein beta 2 
4 4 2 ENSG00000158786 PLA2G2F phospholipase A2, group IIF 
4 4 2 ENSG00000175662 TOM1L2 target of myb1-like 2 (chicken) 
4 4 2 ENSG00000185163 DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 
3 4 2 ENSG00000079387 SENP1 SUMO1/sentrin specific peptidase 1 
3 4 2 ENSG00000126822 PLEKHG3 
pleckstrin homology domain containing, 
family G member 3 
3 4 2 ENSG00000144583 MARCH4 
membrane-associated ring finger (C3HC4) 4, 
E3 ubiquitin protein ligase 
3 4 2 ENSG00000161904 LEMD2 LEM domain containing 2 
3 4 2 ENSG00000162510 MATN1 matrilin 1, cartilage matrix protein 
3 4 2 ENSG00000182040 USH1G Usher syndrome 1G (autosomal recessive) 
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Appendix 12 – Computational target search of miR-3085-3p 
Target sites Target information 
6mer 
All 
7mers 
8mer Ensemble gene ID Gene Gene name 
3 4 2 ENSG00000196922 ZNF252P zinc finger protein 252, pseudogene 
2 4 2 ENSG00000023902 PLEKHO1 
pleckstrin homology domain containing, 
family O member 1 
2 4 2 ENSG00000053108 FSTL4 follistatin-like 4 
2 4 2 ENSG00000054392 HHAT hedgehog acyltransferase 
2 4 2 ENSG00000073417 PDE8A phosphodiesterase 8A 
2 4 2 ENSG00000103222 ABCC1 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 1 
2 4 2 ENSG00000106609 TMEM248 transmembrane protein 248 
2 4 2 ENSG00000107331 ABCA2 
ATP-binding cassette, sub-family A (ABC1), 
member 2 
2 4 2 ENSG00000115594 IL1R1 interleukin 1 receptor, type I 
2 4 2 ENSG00000131373 HACL1 2-hydroxyacyl-CoA lyase 1 
2 4 2 ENSG00000136878 USP20 ubiquitin specific peptidase 20 
2 4 2 ENSG00000141141 DDX52 DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 
2 4 2 ENSG00000157227 MMP14 
matrix metallopeptidase 14 (membrane-
inserted) 
2 4 2 ENSG00000173698 GPR64 G protein-coupled receptor 64 
2 4 2 ENSG00000183837 PNMA3 paraneoplastic Ma antigen 3 
2 4 2 ENSG00000187987 ZSCAN23 zinc finger and SCAN domain containing 23 
2 4 2 ENSG00000214022 REPIN1 replication initiator 1 
2 4 2 ENSG00000254806 
SYS1-
DBNDD2 
SYS1-DBNDD2 readthrough 
15 15 1 ENSG00000072840 EVC Ellis van Creveld syndrome 
11 10 1 ENSG00000149187 CELF1 CUGBP, Elav-like family member 1 
14 9 1 ENSG00000167291 TBC1D16 TBC1 domain family, member 16 
11 8 1 ENSG00000149639 SOGA1 
suppressor of glucose, autophagy associated 
1 
9 8 1 ENSG00000146067 FAM193B 
family with sequence similarity 193, member 
B 
10 7 1 ENSG00000115461 IGFBP5 insulin-like growth factor binding protein 5 
7 7 1 ENSG00000122863 CHST3 
carbohydrate (chondroitin 6) 
sulfotransferase 3 
7 7 1 ENSG00000153885 KCTD15 
potassium channel tetramerization domain 
containing 15 
9 6 1 ENSG00000164627 KIF6 kinesin family member 6 
9 6 1 ENSG00000170006 TMEM154 transmembrane protein 154 
9 6 1 ENSG00000181873 IBA57 
IBA57, iron-sulfur cluster assembly homolog 
(S. cerevisiae) 
9 6 1 ENSG00000220256 
AC093802.
1 
Uncharacterized protein 
8 6 1 ENSG00000133454 MYO18B Myosin XVIIIB 
8 6 1 ENSG00000131389 SLC6A6 Solute carrier family 6 
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Table A12.1 - Computational gene target search of microRNA miR-3085-3p using 
RStudios. All 4 target sites; 6mer, 7merm8, 7merA1 and 8mer were identified within 
the 3’UTR of all genes within the human genome as described on ensembl, downloaded 
using Biomart. Target search was carried out with the R programming Biostrings 
package, and the top 100 genes of 8930 genes with target sites (ranked by size and 
number of target sites) is shown. 
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